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Hepatitis C virus (HCV) infection is a major global healthcare problem infecting 180 million 
people worldwide. Infection persists in 80% of patients and is thought to result from a 
failure to sustain an immune response to HCV. Current treatment with ribavirn and PEG-
IFNα leads to a sustained viral clearance in 40-80% of patients. Despite its use for many 
years, the exact mechanisms of actions of ribavirin are poorly understood. These current 
treatments are poorly tolerated by many and therefore newer and more effective 
treatments are being investigated. 
 
This thesis investigated how current and novel treatments were able to modulate the 
immune response looking at effects on the innate immune response including dendritic 
cells and NK cells and their ability to stimulate T cells and the adaptive immune response.  
 
The aim of the work described in chapter 3 was to investigate the immunomodulatory 
effects of ribavirin on dendritic cell (DC) function. The results obtained suggest that 
ribavirin is able to modulate cytokine production from dendritic cells in response to 
maturation stimuli, in particular suppressing the production of IFNα from pDCS from both 
CHC and NHD patients but also TNFα, IL8 and IL10. In MoDCs from NHDs, ribavirin 
decreased CD40L-induced TNFα production but had no effect on other cytokines tested 
or on DC phenotype. These findings explain possible reasons behind the failure of 
monotherapy and dependence on co-administration of IFNα in treatment regimens. 
 
The aim of the work in chapters 4 and 5 was to investigate the immunomodulatory effects 
of two novel treatments, a novel helminth protein, rOv-ASP-1 and a TLR7 agonist, SM-
360320.  
   
 rOv-ASP-1 showed evidence of DC phenotypic maturation, based on up-regulation of 
phenotypic markers (CD40, HLA-DR, CD83 and CD86) and enhanced pro-inflammatory 
cytokine production (IL-6, IL-8 and TNFα). It was also shown to stimulate proliferation of 
allogeneic CD4
+ T cells suggesting that the protein is able to enhance the 
accessory/antigen presentation by DCs. These findings suggest that this novel protein 
may be used as an effective immuno-stimulant to boost antigen specific responses or as a 
vaccine adjuvant. 
 
SM-360320 was shown to enhance viral clearance and immune modulation with induction 
of 2’5’OAS gene expression, inhibition of replication of HCV replicons in Huh 7 cells, 
enhanced secretion of anti-viral and pro-inflammatory cytokines, up-regulation of NK cell 
activation. These findings suggest that SM-360320 might provide complementary and 
additional mechanisms of action to current HCV therapies making it a promising novel 
treatment. 
 
Further investigation of these compounds is therefore warranted due to their potential 
widespread application in treating infectious diseases and immune mediated conditions
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1.1    The Liver - Structure 
 
 
The liver is the largest gland in the body. It weighs between 1200-1600g depending on 
size and sex.  It is situated in the right upper quadrant of the abdominal cavity against the 
diaphragm.  
 
1.1.1 Macroscopic  Structure: 
The liver is covered by the visceral peritoneum of Glisson’s capsule, which thickens into  
ligaments connecting it to the diaphragm and abdominal wall - the falciform ligament 
superiorly, (which also separates the right and left lobes), the coronary, the right and left 
triangular and the round ligament (derived from the umbilical vein)(1). 
 
It is divided by fissures into four lobes- the right (largest), left, quadrate and caudate. But it 
is divided functionally into 8 segments following the distribution of the portal pedicles and 
divisions of the right, middle and left hepatic veins. 
 
Blood Flow: 
The liver has a dual blood supply: 
Hepatic Portal Vein –  
Formed form the confluence of the splenic vein and superior mesenteric vein. It drains 
venous blood into the liver from the entire GI tract and supplies 75% of the liver’s blood. 
The normal portal pressure is 5-8mmHg. 
Hepatic Artery –  
Originates from the celiac trunk as the common hepatic artery and supplies oxygenated 
blood to the liver. It supplies 25% of the total blood flow to the liver. Both vessels enter the 
liver via the hilum (porta hepatis). The blood from these vessels is distributed to the 
segments and passes into the sinusoids via the portal tracts. 
Hepatic Vein – 
The venous drainage from the liver is from the three hepatic veins. Short veins within 
lobes of the liver unite to form hepatic veins which join to the inferior vena cava. 
    1 Figure 1   Surface anatomy of the liver as viewed from superior aspect (a) and  






    2 1.1.2 Microscopic  Structure 
 
The basic architecture of the liver has classically been described as a lobular structure. 
The lobules are hexagonally shaped functional units of the liver consisting of a central 
tributary of the hepatic vein and at the periphery a portal tract containing the bile duct, 
portal vein radicle and hepatic artery branch. Columns of hepatocytes and sinusoids 
extend between these two systems. 
 
More recently the acinar structure has been described (Figure 2). The acinus has been 
portrayed as the functional unit of the liver (1;2). Each acinus is centered on the portal 
triad with its terminal brach of portal vein, hepatic artery and bile duct (zone1). These 
inderdiginate with terminal hepatic veins of adjacent acini. The circulatory peripheries of 
acini (adjacent to terminal hepatic veins) (zone 3) suffer most injury and bridging fibrosis is 
located in this area. 
 
Sinusoids –  
These are small blood vessels separated by rows of hepatocytes. The sinusoids are lined 
by endothelial cells. Kupffer cells are attached to the endothelium. The sub-endothelial 
space that lies between the sinusoids and hepatocytes is the space of Disse, which 
contains is filled with matrix rich laminin, type IV collagen and heparin sulphate 
proteoglycans as well as stellate cells (2). Sinusoids receive oxygen rich blood from 
hepatic artery and nutrients from the portal vein. Oxygen and nutrients diffuse through 
capillary walls to the liver cells. 
 
Portal Tract – 
At the corner of each lobule is a complex composed of branches of the portal vein, hepatic 
artery, bile duct and nerve. 
 
Bile Duct – Bile is drained from liver cells by canaliculi. The intra lobular canalicular 
network drains into small ducts that unite to form the hepatic duct (main bile duct from the 
liver) which then joins the cystic duct and then the common bile duct. 
 
Central Vein – Found in the middle of each lobule, receives blood from the portal vein and 
hepatic artery via the sinusoids and drains into the hepatic vein. 
 
    3 Figure 2.  Diagram of a functional acinus:  Zones 1, 2 and 3 represent areas supplied 
by blood with zone 1 being best oxygenated. Zone 3 is supplied from blood 
remote from afferent vessels and is in the microcirculatory periphery of the 
acinus(3). 
 
                                     
                   
             
1.1.3  Component cells of the liver 
 
Hepatocyte 
This is the most numerous cell in the liver making up 80% of the parenchyma. It is 




These are fenestrated cells which lie in the extracellular matrix of the space of Disse. 
 
Kupffer Cell 
These are highly mobile macrophages attached to the endothelial lining of the sinusoid, 
particularly in the peri-portal area. They are responsible for removing old and damaged 
blood cells or cellular debris as well as bacteria, viruses and tumour cells by phagocytosis. 
Kupffer cells are activated by a wide range of agents, including endotoxins, sepsis, shock, 
TNFα and IFNγ. The result of activation is the production of a range of products including 
cytokines - TNFα, IL-1, IL-6, IL-10 
 
    4 Hepatic stellate cell 
These cells sit within the sub-endothelial space of Disse and have long cytoplasmic 
extensions. In normal liver they are the major storage site of retinoids which are retained 
in the cytoplasm as lipid droplets. Following liver injury, they loose their lipid droplets, 
proliferate, migrate to zone 3 of the acinus, change to a myelofibroblast-like phenotype 
and produce collagen type I, III and IV and laminin. Stellate cells also release matrix 
proteinases and inhibitory molecules of matrix proteinases (tissue inhibitor of 
metalloproteinases (TIMP). Collagenization of the space of Disse results in decreased 
access of protein-bound substrates to the hepatocyte.    
 
1.2  The Liver – Function: 
 
1.2.1 Protein  Metabolism: 
The liver is the principal site of synthesis of most circulating proteins with the exception of 
γ-globulins. The liver receives amino acids from the intestines and muscles and, by 
controlling the rate of gluconeogenesis and transamination, regulates levels in the plasma. 
 
Around half of the circulating protein is albumin which is important for maintaining plasma 
oncotic pressure and transporting water-insoluble substances such as bilirubin, hormones 
and drugs. Other proteins produced in the liver include the carrier proteins, transferring 
and caeruloplasmin, clotting factors and components of the complement system.  
 
Amino acids are degraded by transamination and oxidative deamination to produce 
ammonia, which is then converted to urea and excreted by the kidneys. This is the major 
pathway for the elimination of nitrogenous waste (2;4). 
 
1.2.2 Carbohydrate  Metabolism 
Glucose homeostasis and the maintenance of the blood sugar is a major function of the 
liver. It stores approximately 80g of glycogen. In the immediate fasting state, blood 
glucose is maintained either by glucose released from the breakdown of glycogen 
(glycogenolysis) or by newly synthesized glucose (gluconeogenesis). Sources for 
gluconeogenesis are lactate, pyruvate, amino acids from muscle and glycerol from 
lipolysis of fat stores. In prolonged starvation, ketone bodies and fatty acids are used as 
alternative sources of fuel and the body tissues adapt to lower glucose requirement (2;4). 
    5 1.2.3 Lipid  Metabolism 
The liver has a major role in the metabolism of lipoproteins. It synthesizes very-low-
density lipoproteins (VLDL) and high-density lipoproteins (HDL). Triglycerides are mainly 
of dietary origin but are also formed in the liver from circulating free fatty acids (FFAs) and 
glycerol and incorporated into VLDLs. Oxidation or de novo synthesis of FFA occurs in the 
liver, depending on the availability of dietary fat. 
Cholesterol may be of dietary origin but most is synthesized from acetyl co-A in the liver, 
intestine and adrenal cortex
 (2;4). 
 
1.2.4  Formation of bile 
Bile consists of water, electrolytes, bile acids, cholesterol, phospholipids and bilirubin. Bile 
acids are synthesized from cholesterol and act as detergents; their main function is lipid 
solubilization. Bilirubin is produced mainly from the breakdown of haem containing 
proteins, especially haemoglobin. It is conjugated with glucuronic acid in the liver making it 
water soluble and excreted into the intestine with the bile (2;4). 
 
1.2.5  Hormone and drug inactivation 
The liver catabolises hormones such as insulin, glucagon, oestrogens, growth hormone, 
glucocorticoids and parathyroid hormone. It is also the prime target organ for many 
hormones e.g. insulin. 
 
It is the most important site for the metabolism of drugs and alcohol. Fat soluble drugs are 













    6 Figure 3  Metabolic pathways of the liver(5)  
 
 




Hepatitis C virus was identified in 1989 by Houghton et al
 (6) after recognition of the 
phenomenon of post-transfusional hepatitis following the administration of blood and 
blood products causing ”non-A, non-B hepatitis”. After extensive testing of serum from 
experimentally infected animals, the virus was cloned using molecular biology techniques. 
 
The hepatitis C virus is an enveloped RNA virus that belongs to the Flaviviridae family and 
is the only member of the Hepacivirus genus (7). Its genome is a positive sense single 
stranded RNA 9.6kb length that comprises a long open reading frame (ORF) encoding for 
a large polyprotein, flanked on either side by 5’ and 3’ non coding regions,.
 
 
The viral genome is translated as a single polyprotein, which is subsequently cleaved by 
viral and host proteases to produce both structural and non-structural proteins of the virus 
(8;9) (figure 4).  
 
Structural proteins include core protein, which forms most of the nucleocapsid and 
glycosylated membrane protiens E1 and E2 that form the viral particle. The structural 
region is followed by the small integral membrane protein, p7, currently thought to be a 
viroporin (an ion channel that mediates membrane permeability and secretion) The 
remainder of the genome includes non-structural proteins NS2, NS3, NS4, NS4B, NS5A 
and NS5B which co-ordinate intracellular processes of the virus life cycle including 
proteolytic activity, formation of replication complexes, RNA binding and RNA-dependant 
RNA polymerase (10)
 
Two viral peptidases play a part in post-translational processing of the polyprotein—the 
HCV proteins NS2 and NS3/4A. NS2 and the N-terminal domain of NS3 form NS2-3 
proteinase, a zinc-dependent metalloproteinase that cleaves the site between NS2 and 
NS3 in the polyprotein(11). NS3 contains a serine protease, RNA helicase and Nucleotide 
triphosphatase (NTPase) activities. The coupled NTPase and helicase unwinds duplex 
RNA structures and has a crucial role in viral replication, whereas the serine protease 
(which requires the cofactor NS4A) is implicated in polyprotein processing(12) 
    8 The non-structural protein NS5B is the RNA-dependent RNA polymerase that catalyses 
replication of the viral genome. Negative-sense RNA intermediates are formed, which 
serve as templates for synthesis of new positive-sense RNA(13). These RNA strands are 
either encapsulated to form new viruses or used as mRNA for viral protein synthesis. The 
mechanism by which new virions are assembled and released is poorly understood 
although it probably entails interaction of the core protein with genomic RNA(14)  
At each end of the genome are short untranslated regions (UTR) – 5’and 3’, required for 
replication of the genome. The long UTR at the 5’ end of the genome is the most 
conserved of the genome, allowing it to be used as a diagnostic locus (genotype) and 
marker (HCV RNA) by PCR. Within this region is a translation initiation locus termed an 
internal ribosomal entry site (IRES) is found. Translation of viral proteins is dependant on 
IRES which comprises a complex RNA structure element that interacts directly with the 
40S ribosomal subunit during translation initiation. 
 
Figure 4.  Structure of HCV Virus 
 
    9 1.3.2  Life cycle of HCV 
 
The HCV lifecycle is not completely understood. The virus replicates in the cytoplasm of 
host cells using its own RNA dependant RNA polymerase in combination with the hosts 




HCV entry into hepatocytes is a highly coordinated and multistep process requiring viral 
and host cell factors. The viral envelope glycoproteins E1 and E2 are essential for HCV 
entry. Lipoproteins have also been shown to associate with the viral particle and interfere 
with viral entry. The role of E1 in HCV entry is not completely understood, while several 
E2 domains play pivotal roles in HCV entry i.e. putative domain binding of two HCV entry 
factors, CD81 and  scavenger receptor class B type 1 (SCAR-B1). 
 
Host factors mediating viral attachment and binding to hepatocytes involve several cell 
surface molecules that interact with HCV and have been identified as putative receptors 
for HCV, including CD81, SCAR-B1 binding lectins, low-density lipoprotein receptor 
(LDLR), highly sulfated heparan sulfate, DC-SIGN and L-SIGN, claudin 1 and occludin 
(15-17). 
 
In vivo, HCV enters the liver through the sinusoidal blood. Capture of circulating HCV 
particles by liver sinusoidal cells may thus facilitate the viral infection of neighboring 
hepatocytes which are not in direct contact with circulating blood. This process may be 
mediated by DC-SIGN, which is expressed in Kupffer cells that localize close to liver 
sinusoidal endothelial cells (LSEC) and hepatocytes, and L-SIGN that is highly expressed 
in LSEC. DC-SIGN and L-SIGN have been shown to bind envelope glycoprotein E2 with 
high affinity. On hepatocytes, HS glycosaminoglycans represent first attachment sites that 
may help to concentrate the virus on the target cell surface and allow further interactions 
with other host factors triggering viral entry (18). 
 
CD81 is a ubiquitously expressed tetraspanin in hepatocytes as well as many other cell 
types. CD81 has been the first molecule described to interact with a soluble truncated 
form of HCV E2 and to be a critical host cell factor for viral entry (18).  
    10  Human SR-BI is an 82 kDa glycoprotein with a large extracellular loop highly expressed in 
the liver. SR-BI binds a variety of lipoproteins (HDL, LDL, oxLDL) and is involved in bi-
directional cholesterol transport at the cell membrane. SR-BI may play a dual role during 
the HCV entry process, during both binding and post-binding steps. 
 
CLDN1 and OCLN, are four transmembrane proteins, both identified as host cell factors 
critical for HCV hepatocyte entry. They are critical components of tight junctions (TJ) 
regulating paracellular permeability and polarity.  
 
All these host entry factors have been shown to be required for productive HCV infection 
and suggests that HCV entry may be mediated through the formation of a tightly 
orchestrated HCV-entry factor complex at the plasma membrane (18). CD81 requires a 
co-receptor or modulator for HCV entry (15;19), since other cell types expressing CD81 
alone are not vulnerable to HCV infection.  
 
In addition to the presence of specific entry factors in hepatocytes, absence of a particular 
inhibitor might also contribute to the hepatotropism of HCV. EWI-2wint, is expressed in 
several cell lines but not in hepatocytes. Ectopic expression of EWI-2wint in a hepatoma 
cell line susceptible to HCV infection blocked viral entry by inhibition of the interaction 
between HCV envelope glycoproteins and CD81(20).   
 
Once attached, the virus-receptor complex is internalized. This is thought to be dependant 
on claritin-mediated endocytosis (18). This transports the virus-receptor complex into early 
and late endosomes. The acidic pH in endosomes provides an essential cue that triggers 
penetration and uncoating. Fusion between viral and endosomal membranes is followed 
by release of the viral nucleic acid into the host cell cytoplasm where translation and 
replication take place. HCV particles are then assembled and released from the host cell. 
An alternative route of viral entry is direct cell–cell transmission to infect neighboring cells 
which is resistant to neutralizing antibodies (18). 
 
Translation of the viral RNA is facilitated by an internal ribosome entry site (IRES) in the 
highly conserved 5’ untranslated region of the genome, to which 40S ribosome binds. 
Viral proteins are produced and HCV forms a membrane-associated replication complex, 
composed of viral proteins, replicating RNA, altered cellular membranes and additional 
host cell factors. A specific membrane alteration, referred to as the membranous web, 
    11  was recently identified as the site of RNA replication in Huh-7 cells harboring subgenomic 
HCV replicons (21). Intracellular membranes therefore play a crucial role in HCV 
replication. Recent data underline the importance of a specific lipid environment for HCV 
RNA replication with the use of lipid rafts, which are microdomains that are enriched in 
cholesterol and sphingolipid. They are known to play a critical role in many biological 
processes such as regulators and organizing centers of signal transduction and 
membrane traffic pathways(22).  
 
 











    12  1.3.3 Viral  Heterogeneity: 
 
HCV has a high rate of genetic mutation due to RNA replication being highly error prone, 
due to lack of a proofreading function capacity of the RNA dependant RNA polymerase, 
resulting in nucleotide mis-incorporation. Many of these errors are lethal to the virus 
resulting in a nonfunctional genome or a replication incompetent virus (lethal mutants) but 




Certain nucleotide substitutions may lead to changes in the amino acid sequence that 
confer survival advantage to the virus, either by improving replication efficiency or allowing 
immune evasion through epitope changes. Thus a single host will be infected with multiple 
quasi-species of the virus, usually with one dominant strain. Quasi-species are families of 
different, but highly similar, strains that develop within an infected host over time. 
Quasispecies are genetically related but sequence distinct, with minor differences in <5% 
of the viral genome (9). There is evidence that quasi-species may be important in the 
persistence of virus, natural history of infection and the response to treatment. The 




Over decades and centuries, the degree of HCV diversity has evolved into several distinct 
genotypes of the virus. HCV is currently divided into 6 major genotypes each divided 
further into subtypes within these genotypes varying up to 35% in their nucleotide 
sequence (23). Within any infected individual there are further minor variants or 
quasispecies, which are viral variants that differ slightly and emerge under selective 
pressures of host immunity and drug treatment (24).  
 
The evolution of genotypes has probably been influenced by several factors, including 
immune selection, infection patterns, and replication efficiency and population migration. 
For this reason there is a distinct geographical distribution of the six HCV genotypes as 
shown in figure 6. Some strains are distributed worldwide, whereas others are found
 only 
in specific geographic regions. HCV genotypes 1a, 1b, and
 3a are highly prevalent 
"epidemic" strains that are found globally.
 These strains spread swiftly around the world 
during the 20th
 century, most likely through infected blood and blood products,
 injecting 
    13  drug use and invasive medical procedures, and have relatively low levels of genetic
 
variation. In contrast, other HCV strains exhibit high local genetic variation, long-term
 local 
persistence
 but are found in restricted geographic areas. These "endemic"
 strains reflect 
long-term transmission at low levels in particular
 populations and represent the source 
populations for
 the epidemic strains. Genotypes 1, 2, and 4 appear to be endemic
 to 
regions of West and Central Africa and the Middle East, whereas
 divergent endemic 
strains of genotypes 3 and 6 are found in
 Southeast Asia (25). 
In the US, genotype 1a and 1b together account for two thirds of HCV (57% 1a and 17% 
1b). Another 15% are affected by genotype 2 (3.5% 2a and 11.5% 2b) and 7% with 
genotype 3a. Genotype 6 accounts for 3% while Genotype 4 only 1%.  
 
In England, 50% are infected with genotype 1, with 3a being the next most prominent and 
then genotype 2, together making up another 40-50% of cases. In Europe, genotype 1 is 
prominent and found in 15-30% of infected Europeans. Genotype 3 is also prominent in 
Europe, especially in Scandinavia but is most common in India and the Far East. 
Genotype 4 is found most exclusively in the Middle East and Africa, Genotype 5 in South 
Africa and Genotype 6 in South East Asia. 
 
However, the picture described above is not static and has changed during the last 15–20 
years, due to a combination of several factors including eradication of transfusion-
associated infections, improvement in health-care-related standards and a sharp increase 
in immigration from endemic areas(26).  
 
With respect to Europe, since blood products screening was introduced, IVDU has 
become the main risk factor for HCV transmission and has switched the HCV genotype 
distribution found in Europe from 1b and 2 among blood donors and young patients to 
IVDU-related genotypes 1a, 3a and 4. Even among IVDUs, relative genotype distribution 
is rapidly changing with genotype 4 spreading into Central and Northern Europe and 
increasing in Southern Europe (26). 
 
Several European countries have sustained high net migration rates for decades, but 
uncontrolled migratory flows from developing countries are more recent and a substantial 
proportion in the EU have arrived during the last 15 years. In some countries up to 12% of 
the population is composed of immigrants and in some countries such as Spain, this is a 
    14  new phenomenon. This immigration from endemic areas diversifies HCV genotype 
distribution with unusual subtypes being identified (1g, 2e 3k, 4a and 4k) (27).  
 
HCV genotypes are clinically significant and relevant to clinical management of chronic 
HCV infection. They are epidemiologically relevant as genotypes previously in different 
locations are indicative of the spread of infection. Furthermore, the HCV genotype is the 




Figure 6.    Geographical distribution of hepatitis C virus genotype (Adapted from Fang                      










    15  1.4   Hepatitis C - The Disease: 
 
1.4.1  Routes of infection 
 
Hepatitis C is a parenterally transmitted virus. The commonest route of infection varies 
with the geographical region studied. 
 
In the UK, the commonest risk factor for transmission of hepatitis C is intravenous drug 
use (IVDU). In addition needle sharing, sharing of other drug paraphernalia – such as foils 
and spoons, has been implicated in HCV transmission.  It is estimated that 80-90% of 
injection drug users become positive for anti-hepatitis C antibodies after repeated 
injections suggesting almost universal exposure in this population.  
 
Exposure to blood or blood products (clotting factors, platelets, immunoglobulins etc) prior 
to the introduction of screening in 1991, is the next most common mode of transmission in 
the UK. The risk of HCV infection from blood transfusion prior to 1991 was low but 
immunoglobulins and clotting factors produced by pooling serum from multiple donors 
carried a much higher risk. Almost 100% of UK haemophiliacs have evidence of HCV 
exposure from infected factor VIII. With current screening methods, HCV transmission 
through transfusion of contaminated blood products has been virtually eliminated. 
 
Other well recognised modes of transmission with less well defined transmission rates 
include vertical transmission which carries about a 5% transmission rate at the time of 
delivery and is two to four-fold higher in mothers co-infected with HIV (28). Currently there 
are no randomised controlled trials to suggest that caesarean section offers an advantage 
over vaginal delivery (29). The rate of sexual transmission is controversial and in a stable 
heterosexual relationship is thought to be low (1-3%)(30). Co-infection with HIV, duration 
of the relationship or chronic liver disease may be factors that increase the risk. Rates of 
transmission are higher with certain high-risk behaviours amongst men who have sex with 
men (30). Other modes of transmission include tattooing, body piercing and occupational 
exposure (needlestick) and sharing toothbrushes and razors. 
 
A potential risk factor can be identified in approximately 90% of persons with HCV 
infection. In the remaining 10%, no recognized source of infection can be identified, 
although most persons in this category are associated with low socioeconomic level(31). 
 
    16  1.4.2 Diagnosis: 
 
A combination of serological and molecular assays is needed to diagnose HCV infection. 
In clinical practice, the usual approach is to test initially for antibodies to HCV (anti-HCV). 
These antibodies can be detected by enzyme-linked immunoassays (ELISA), with false 
positives excluded using supplementary reverse immunoblot assay (RIBA)(32). Both of 
these tests use recombinant viral proteins to detect HCV specific antibodies in the serum. 
The sensitivity and specificity is high, however, there are greater false positive rates in low 
risk groups and the tests are less sensitive and specific in immuno-compromised 
population(33). Antibodies are usually detectable an average of 8 weeks after infection. 
 
Hepatitis C viraemia is documented using HCV ribonucleic acid (RNA). HCV RNA can be 
measured qualitatively or quantitatively by either reverse transcription PCR or branched 
DNA (bDNA) assays. 
 
Qualitative assays: 
The qualitative PCR assays report results as the presence or absence of HCV RNA. 
These assays are considered the most sensitive tests for the diagnosis of HCV infection. 
 
Quantitative assays: 
Quantitation of HCV RNA titers, i.e., measuring the amount of HCV RNA per millilitre 
of serum, can be estimated with the use of quantitative reverse transcriptase PCR (RT-
PCR) assays or branched-chain DNA (bDNA) assays. Several quantitative HCV RNA 
assays are commercially available, with the most sensitive assays currently being able to 
measure down to about 10IU/ml. These assays help to predict the likelihood of response 
to treatment and the change in the level of HCV RNA during treatment can be used to 
monitor response. 
 
There is a window from infection to positive PCR of 1-4 weeks during which all PCR tests 







    17  1.4.3 Acute  infection 
 
Acute hepatitis C infection is usually asymptomatic. About 20% of patients with acute HCV 
may develop clinical symptoms which may include fever, malaise, weakness, anorexia 
and jaundice. Acute HCV infection can be severe but fulminant hepatic failure is extremely 
rare, but may be more common in patients with underlying chronic hepatitis B virus 
infection(34). 
 
HCV RNA is usually detectable in the serum within 1-4 weeks after exposure. Serum 
aminotransferases (ALT) begin rising 2-8 weeks after exposure and often reach levels of 
greater than 10 times the upper limit of normal(35). In self-limited acute hepatitis C, 
symptoms can last several weeks and subside as ALT and HCV RNA levels decline. 
 
Detectable HCV specific antibodies develop 1 to 3 months after exposure. Almost all 
patients eventually develop the antibody to HCV, however, titres can be low or 
undetectable in immunodeficient patients(34). 
 
Spontaneous and sustained virological clearance occurs in between 15-30% of infected 
individuals. Clinical symptoms are more frequent in those who successfully clear the virus 
but may be mistaken for a ‘flu like’ illness. 
 
1.4.4 Chronic  Infection 
 
85% of HCV infected patients develop chronic infection defined as the persistence of HCV 
RNA in the blood 6 months after the onset of acute infection. Once chronic infection is 
established the annual rate of spontaneous clearance is negligible. The majority of these 
patients are unaware of their acute infection. 
 
Chronic infection may give non-specific symptoms of fatigue, malaise and vague 
abdominal pains. Frequently the diagnosis of chronic HCV is made when routine blood 
tests reveal a raised alanine transferase (ALT). A persistently raised and fluctuating ALT 
is often the only indication of chronic infection. However, in many cases the ALT will be 
normal, even in cases with significant liver damage. 
 
Chronic infection is associated with positive anti-HCV antibodies in the serum together 
with persistently detectable HCV RNA by PCR. 
    18  1.4.5  Natural history of chronic hepatitis C 
 
The natural history of chronic hepatitis C has been difficult to clearly define because of the 
long course of the disease and the difficulty in identifying the onset of disease in many 
patients. Several studies have provided estimates of the proportion of patients with 
chronic infection who develop cirrhosis within 20 years (35-42)
 and suggest approximately 
20 to 30 percent of chronically infected individuals develop cirrhosis over a 20- to 30-year 
period of time but the outcome is variable (figure 7). However, a more recent meta- 
analysis conducted on patients with a variety of etiologies for HCV infection estimated the 
20-year cirrhosis prevalence to range from 7% to 18% (43). Chronic HCV is the most 




Several factors have been shown to be important determinants of disease progression in 
individual patients including excessive alcohol intake, concomitant diseases associated 
with liver injury (hepatitis B, steatohepatitis), concomitant HIV infection, advanced 
histological grade, persistently elevated aminotransferase activity, male gender, older age, 
ethnicity, obesity, immunosupression and certain HLA halotypes. Patients who acquire the 
disease from a blood transfusion may be at increased risk for disease progression 
compared to those infected via other modes (44). However, this relationship has not been 
confirmed in all studies with others showing no correlation of prognosis with the source of 
HCV (39). 
Alcohol - Alcohol consumption appears to be one of the most influential factors driving 
fibrosis progression in patients with chronic hepatitis C. There is convincing evidence that 
higher levels of alcohol consumption contributes to the development of progressive liver 
disease and a higher prevalence of cirrhosis (45). 
Age at onset of infection - Several studies have shown a significant association between 
the rate of fibrosis and the age at time of infection with a significantly higher stage of 
fibrosis in those infected at an older age (>40 years) (46). 
 
Sex – The mechanism by which sex affects disease progression is not understood; 
however, an antifibrogenic role for oestrogens has been proposed. The menopause has 
been associated with a high stage of fibrosis, and hormone replacement therapy has been 
shown to have a protective role(47). 
    19  Co-infection with HIV and HBV – Co-infection with HCV and HIV is very common among 
hemophiliacs and injection drug users. HIV seropositivity and low CD4 count appears to 
accelerate HCV liver fibrosis(47). Conversely, HCV has been associated with a faster 
progression of HIV to acquired immunodeficiency syndrome (AIDS)(48). Similarly, HCV 
co-infection with HBV also exhibits higher rates of progression to cirrhosis. 
 
Figure 7  The natural history of HCV (42)
 
 












    20  1.4.6  Extra hepatic manifestations of chronic hepatitis C 
A number of extrahepatic diseases have been associated with chronic HCV infection(49). 
Approximately 1%-2% of HCV-infected individuals will develop extrahepatic 
manifestations. HCV shows particular lymphotropism in addition to hepatotropism, and 
this effect could account for many extrahepatic manifestations(50). Most cases appear to 
be directly related to the HCV infection but may be from the underlying immune 
stimulation caused by chronic infection. They can involve multiple organ systems including 
renal, dermatological, haematological and rhematological: 
Haematologic diseases – essential mixed cryoglobulinemia is the commonest 
extrahepatic condition and cryoglobilins are found in 50% of patients with chronic HCV. 
However, only 25-30% develop clinical symptoms (51) ranging from fatigue, skin rashes, 
purpura, arthralgias, Raynaud's phenomenon, vasculitis, proliferative glomerularnephritis, 
and peripheral neuropathies. The clinical manifestations are thought to be caused by 
immune complex deposition in various organs. There is also an association between 
chronic HCV and non-Hodgkin’s and Hodgkin’s lymphoma. 
Renal disease - particularly membranoproliferative glomerulonephritis  
Autoimmune disorders – thyroiditis, Sjogren’s syndrome and seronegative arthritis 
Dermatologic conditions - porphyria cutanea tarda, lichen planus and vitiligo 
 
1.4.7  Assessment of severity of liver damage 
 
Acute HCV infection is not commonly clinically apparent and serological liver function 
tests are used to assess severity. Biochemical and haematological markers are used to 
monitor the severity of the hepatitis, whilst PCR is used to identify virological responses. 
Liver biopsy is seldom required. Any hepatocellular damage associated with the acute 
hepatitis will resolve completely within 3-6 months if there is sustained viral clearance. 
 
Chronic HCV infection is usually silent and conventional biochemical and haematological 
markers are of little value. Clinical history and examination may reveal the duration of 
infection and clinical evidence of chronic liver disease but liver biopsy at present still 
remains the gold standard for staging liver disease and facilitates detection of secondary 
pathologies. Liver tissue is obtained by percutaneous, transjugular or intra operative 
    21  biopsy. There are several validated scoring systems used to assess the severity of liver 
damage, allowing intra and inter-patient comparisons to be drawn(52;53). 
However, a liver biopsy has many limitations. Because it is invasive and causes significant 
pain in at least 30% of cases, it is usually not welcomed by patients. There is a small but 
significant morbidity and mortality rate. In addition, it can only sample a small portion of 
the liver and is thereby susceptible to sampling error and inter- and intra-observer 
variation in pathology reporting. It also provides only a static picture of liver architecture in 
a dynamic disease process. 
These issues provided the rationale for the development and use of non-invasive methods 
for the assessment of liver fibrosis to compliment or replace biopsy and may provide a 
more rapid and cost-effective means of identifying patients with more advanced fibrosis 
and cirrhosis, in determining prognosis and informing treatment options in patients with 
CHC.  
A number of tools are currently available or in development for the non-invasive 
assessment of hepatic fibrosis. Cross-sectional imaging studies such as CT and MRI 
scans can reliably demonstrate features of advanced liver disease such nodularity and 
signs of portal hypertension. However, the resolution of hepatic parenchyma with any of 
the available modalities is insufficient to determine the earlier stages of fibrosis. Transient 
hepatic elastography is a novel technology demonstrating promise as a non-invasive 
means of fibrosis determination(54). 
Serum markers of liver fibrosis may allow dynamic calibration of fibrosis, and may be 
more cost effective. The diagnostic accuracy appears greatest and most promising in the 
studies using a panel of markers(55). Currently there are three serum markers that have 
been most extensively validated: Fibrospect(56), Fibrotest(57), marketed in the United 
States by Labcorp and the European Liver Fibrosis Study Group panel(58) using a 
diagnostic algorithm developed by Bayer HealthCare Diagnostics. All three assays 
demonstrate significant accuracy in differentiating none or early fibrosis (METAVIR F0-F1) 
from advanced fibrosis (F2-F4) for HCV but are particularly accurate for detecting 






    22  1.5  The Immune Response 
 
1.5.1 Innate Immunity: 
 
The innate immune response forms the first line of defence by a host against pathogens, 
providing a non specific immediate response. It is directly activated in the early stages by 
infectious agents, inflammation or tumour and its defensive properties can limit 
proliferation and spread of pathogen within the body. The onset of the innate immune 
response is immediate and does not require conditioning through prior exposure to 
pathogens. The innate immune response delivers two main functions - direct killing of 
pathogens and initiation and modulation of adaptive immune responses. 
 
It was previously thought that innate immunity was involved only with phagocytosis of 
pathogens in a non-specific manner, digestion of these and presentation of pathogen-
derived antigen to T cells involved in acquired immunity. However, more recently it has 
been shown that the innate immune system has a greater degree of specificity than 
previously thought having evolved to recognise conserved pathogen-associated molecular 
patterns (PAMPS) by proteins termed pathogen-recognition receptors (PRRs). PPRs 
include toll like receptors and RIG1 like helicases. Toll like receptors (TLRs) expressed on 
cell surfaces of innate cells are a particularly important group of PPRs (see chapter 
1.5.1.3) allowing discrimination between self and foreign pathogens. Recognition of 
invading pathogens triggers cytokine production and up-regulation of co-stimulatory 
molecules and phagocytosis, leading to activation of T cells (60). A wide range of innate 
mechanisms operate which are not programmed by repeated exposure to infection.  
 
The major constituents of innate immunity are cellular and non cellular components. 
Cellular components include dendritic cells (see chapter 1.5.1.1), NK cells and NKT cells 
(see chapter 1.5.1.2), neutrophils, granulocytes, monocytes, macrophages and other 
inflammatory cells including eosinophils and basophils as well as epithelial cells such as 
the skin, lung and gut. Non cellular aspects include the complement system and acute 
phase reactants including CRP and fibronectin. 
 
The Interferon system:  
 
The interferon family is subdivided into two subfamilies: Type I and Type II. Type I 
interferons (IFNs) are a family of monomeric cytokines with an amino acid similarity of 30-
    23  80%, very similar three-dimensional structure (5-alpha helix-bundle), that use the same 
receptor (IFNAR) to initiate a signaling response. The type I IFNs present in humans are 
IFN-α, IFN-β and IFN-ω. 
Type I IFNs have many roles including their ability to confer an antiviral state on cells, 
anti-proliferative effects and immuno-regulatory activities. Secreted IFNs are recognised 
by neighbouring cells and cause them to express potent antiviral proteins. This slows virus 
multiplication and the organism buys time for establishment of adaptive immune 
responses. Induced IFNs lead to a number of secondary effects that link the innate 
immune response with adaptive immune responses. These include the activation of NK 
cells and cytotoxic lymphocyte responses as well as maturation of plasmacytoid DCs 
(pDCs). 
All type I IFNs bind to a specific cell surface receptor complex known as the IFN-α 
receptor (IFNAR) that consists of IFNAR1 and IFNAR2 chains. Binding to IFNAR leads to 
dimerization and the activation of the receptor associated Janus-activated kinase 1 (Jak1) 
and tyrosine kinase 2 (Tyk2). The activated kinases phosphorylate the signal transducer 
and activator of transcription proteins 1 and 2 (STAT1 and STAT2). The phosphorylated 
STATs dimerize, associate with IFN-regulatory factor 9 (IRF9) and Interferon-stimulated 
gene factor 3 (ISGF3G) to form a complex termed ISGF3 transcription factor which enters 
the nucleus. ISGF3 binds to the IFN stimulated response element (IRES) on cellular DNA 
to activate the transcription of multiple interferon stimulated genes (ISGs), including the 
genes for RNA-activated serine/threonine protein kinase, 2’5’-oliogoandenylate 
synthetase (2’5’OAS), Mx protein GTPases (Mx), RNA-specific adenosine deaminase 1 
(ADAR1) and RNA-dependant protein kinase (PKR)(61;62)
 each of which induce an 
antiviral state through different pathways. 
 
PKR is a well characterized ISG. PKR activation inhibits mRNA translation by 
phosphorylating the translation initiation factor 2α. Mx1 is another well characterized 
human ISG which inhibits RNA synthesis and alters cellular vesicle trafficking. 2’5’ OAS is 
an important ISG which is stimulated by dsRNA and catalyses the synthesis of 2,5-
oligoadenylates (2,5-A). 2,5,-A activates ribonuclease L (RNAse L) which leads to 
suppression of translation through cleavage and subsequent inactivation of viral 
RNA(61;62). Levels of induction of 2’5-OAS have been used in studies as a surrogate 
marker of IFNα activity(63).  
 
    24  1.5.1.1    Dendritic Cells: 
 
Dendritic cells were first discovered by Ralph Steinman and Zanvil Cohn over three 
decades ago(64). Dendritic cells (DCs) are potent antigen presenting cells, capable of 
priming naïve T cells, leading to the activation of adaptive immunity(65). DCs, therefore, 
play a pivotal role linking innate and adaptive immunity.  
 
They are produced by haemopoetic stem cells or CD34 progenitors in the bone marrow.  
Dendritic cells reside at sites of interaction between the individual and the environment, 
such as skin and mucosal surfaces and also circulate in blood. In the periphery, resident 
dendritic cells are found in an immature form acting as sentinels, being on alert for 
microbial pathogens that they can bind and internalize. In the immature state they are very 
effective at antigen capture and processing with low expression of MHC and co-
stimulatory molecules on their surface. 
 
DCs recognize pathogens through pathogen recognition receptors (PRRs) e.g. toll like 
receptors (TLRs, see 1.5.1.3), mannose receptors and C type lectins. Upon encountering 
pathogen, they undergo maturation process that includes acquisition of migration capacity 
to T cell areas in secondary lymphoid tissues (spleen and lymph nodes) and potent T cell 
stimulatory ability via up-regulation of cell surface co-stimulatory molecules (CD83, CD86 
and CD80) and MHC class I and II(66). This is accompanied by production of cytokines 
from DCs (IL12, TNFa, IFNa and IL10) which are essential for the polarization of T cells 
towards a Th1 or Th2 immune response. They also produce chemokines which favour 
lymphocyte recruitment and activation. Ultimately, these events result in enhanced 
antigen presentation and a greater capacity to promote T cell proliferation and maintains 
the adaptive immune response(66;67). 
 
DCs provide naïve T cells with two signals required for their activation(68). The first signal 
is the antigen-specific signal received as a result of binding of the T cell receptor to 
peptide presented by the MHC molecule. The second is provided by co-stimulatory 
molecules such as CD83 and CD86, which are expressed by DCs and which trigger CD28 
expressed on naïve T cells. Naïve CD4+ T cells differentiate in Th1 or Th2 cells 
dependant on the density of peptide presented, co-stimulatory cells expressed and 
cytokines secreted by DCs. DCs, in turn, then activate NK cells (see chapter 1.5.1.2) to 
drive the non-specific innate immune response. This maturation process is coupled with 
downregulation of dendritic cell capacity for antigen uptake. 
    25  Subtypes of dendritic cells: 
 
Two distinct groups of dendritic cells have been identified, myeloid (mDC) and 
plasmacytoid (pDC). Although the common functions are antigen presentation and T 
lymphocyte activation, they differ in surface markers, migratory patterns and cytokine 
production(69). The ability of DCs to respond to certain pathogens relates to the TLR 
expression. The 2 subsets of DCs are distinct in their TLR expression as well as cytokine 
production profile as discussed below. 
 
Myeloid dendritic cells (mDCs): 
 
Myeloid DCs are CD11c
+, HLA DR 
+, CD14-, BDCA1+, CD83+ and express myeloid 
markers CD13, CD33 derived from a myeloid bone marrow precursor. The receptors that 
have been identified on mDCs include TLR 2, 3, 4, 5, 7 and 8, C type lectin family of 
transmembrane glycoproteins: Blood Dendritic Cell Antigen 1 and 3 (BDCA 1 and 3), DC-
SIGN, DC-LAMP and the Mannose receptor. 
 
They are found at a frequency of 0.5-1% in peripheral blood(70). They play an important 
role in adaptive anti viral immune responses and are required for priming T cells in vivo. 
 
In peripheral tissues they act as sentinels, where they alert the immune system to 
pathogens and then initiate immune response in secondary lymphoid organs by 
processing viral antigens into peptides for MHC presentation to T cells(71). They are more 
potent at antigen presentation and stimulation of T cell response than pDCs. 
 
mDCs recognise virus-derived double stranded RNA (dsRNA). Activated mDCs produce 
high levels of pro-inflammatory cytokines, especially IL12 which is essential for effective 
innate immune responses(72) and drives T helper type 1 (TH1) polarization(73) and the 
production INFγ from the Th1 cells. There is flexibility for them to give rise to Th2 
responses but they produce relatively little INFα in response to viral stimulus. 
 
 
Plasmacytoid dendritic cells (pDC): 
 
Plasmacytoid DCs are HLA-DR bright, CD123bright and CD11c-. They are derived from 
lymphocytes (as shown by the presence of preTCR α chain) and have a plasma cell like 
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up only 0.2 – 0.5% of PBMC
’s(74).  
 
These cells were originally termed ‘natural IFN producing cells’ (NIPCs) as they were 
found to be the cell that produced the majority of the type 1 IFN (IFNα, IFN-ß, IFN, IFN-λ) 
and a broad spectrum of IFNα subtypes in response to enveloped viruses. Although many 
cell types in the body are capable of producing type I IFN, these lineage-negative cells 
were found to be particularly potent, with a single cell able to produce 10-100 times more 
than most other cells in response to a viral stimulus with higher amounts seen with a 
strong stimulus such as Herpes Simplex virus. 
 
In addition to IFNs, TLR-activated pDCs produce high levels of TNFα and IL-6 in response 
to enveloped viruses, bacterial components (75) i.e. CpG oligonucleotides and synthetic 
TLR7 agonists, as well as waves of chemokines including CCL2, CCL3, CCL5, CXCL10 
and IL-8. However, they do not produce significant amounts of IL-12p70 (76). pDC also 
express the recently described IL-28a, IL-28b and IL-29 in response to viral stimulation or 
to TLR7 and −9 agonists. 
 
Their main functions are directed against viral infections and they represent the key cells 
in the innate immune responses. In the early stages of viral infection, pDCs promptly 
secrete massive amounts of type I IFN (77), activating NK cells, NKT cells, B cells, T cells 
and mDCs. pDCs, once activated, differentiate into mature DCs and play a major role in 
adaptive immunity, acting as professional antigen presenting cells with the ability to 
induce the proliferation of naïve T lymphocytes (65) but their efficiency at stimulating T 
cells compared to mDCs is controversial (67;78). 
 
In health they are found in primary lymphoid organs and not in peripheral tissues, unlike 
mDCs. They migrate to and accumulate in inflammatory sites and are driven by 
inflammatory stimuli(69). 
 
Human pDCs uniquely express only TLR7 and 9 which are expressed in their endosomal 
compartment. This exclusive TLR repertoire allows them to be specialized in microbial 
nucleic acid sensing, only responding to some DNA and RNA viruses (See TLRs 1.5.1.3). 
They have also been found to express unique markers, DC Ag-2 (BDCA-2) and DC-Ag-4 
(BDCA-4) belonging to the C type lectin family (79).  
 
    27  1.5.1.2   NK Cells: 
 
NK cells represent an important lymphocyte population of the innate immune system and 
comprise 10-15% of PBMCs. They play an important part in the first line of defence 
against viral infections, rapidly recognising and killing virus-infected cells via perforin 
release and induction of apoptosis and also secreting inflammatory cytokines, such as 
IFNγ, which have direct antiviral effects, inhibiting viral replication as well as activating and 
polarizing Th1 and cytotoxic lymphocyte responses(80;81). Therefore they provide a 
pivitol link between innate and adaptive immunity. 
 
NK cells express CD56, the 140kDa isoform of the neural cell adhesion molecule (NCAM). 
NK cells are not a homogeneous cell population and can be divided into several subsets 
according to functional and phenotypic differences.  
 
The major subset of NK cells (90%) in peripheral blood dimly expresses CD56 and shows 
co-expression of CD16 (82) with a low affinity receptor for the IgG (CD56 
dim / CD16
+). 
This subset represent about 7% (2-14%) of all PBMCs and 90% are found in the 
peripheral blood (75). This cell population also expresses killer cell immunoglobulin-like 
receptor (KIRs) and CD94-associated lectin-like NKG2 receptors and have homing 
markers for inflamed peripheral sites. Consequently, they exhibit strong antibody-
dependant cell-mediated cytotoxicity (ADCC) and natural cell-mediated cytotoxicity(81;83) 
but have low cytokine production capacity. 
 
Another subset of NK cells is characterised by high expression of CD56 and is negative 
for CD16 (CD56 
bright / CD16
-). These are a minor subset of NK cells in peripheral blood 
(10%) and represent about 1-2% of all PBMCs. They express homing markers for 
secondary lymphoid tissues(81) where they accumulate and are found predominantly in 
the liver. They lack the expression of killer cell immunoglobulin-like receptors (KIRs), 
contain low levels of perforin, and for this reason they neither show antibody-dependant 
cell-mediated cytotoxicity (ADCC), nor strong natural cell-mediated cytotoxicity. However, 
they have high cytokine production capacity, unlike CD56
dimCD16+ cells and thus it is 
suggested that they have an immunoregulatory role. They predominantly secrete INF-
γ(81;84;85) (as well as TNFα, GM CSF, IL10 and IL13) which aids reciprocal interactions 
with other cells of the innate and adaptive immunity, mainly dendritic cells and T 
cells(86;87). 
 
    28  NK cell receptors: 
 
The functional activities of NK cells are precisely controlled by a variety
 of stimulatory, co-
stimulatory and inhibitory receptors(88). NK receptors regulate NK cell mediated 
cytotoxicity and cytokine production with a balance between stimulatory and inhibitory 
receptors belonging to the immunoglobulin-like receptor and C-type-lectin receptor 
families. The receptors bind to various ligands on target cells to regulate NK response. 
The dominant default feature of NK class 1 receptors is inhibition and there needs to be 
downregulation of these inhibitory signals or multiple activating signals to override these. 
 
Receptor classes: 
Immunoglobulin class: (Ligands HLA-A,B,C) 
Killer Cell Immunoglobulin Like Receptor (KIR) 
KIRnDSx – activating 
KIRnDLX – inhibitory 
 
Lectin like receptors: (Ligands MIC-A and MIC-B) 
Natural Killer group 2, member A (NKG2A) / CD94 – inhibitory 
Natural Killer group 2, member C NKG2C / CD94 – activating 
Natural Killer group 2, member D NKG2D / CD94 – activating 
 
Natural Cytotoxicity Receptors: 
NKp30, NKp44 and NKp46 
 
Others: 
ILT2 /LIR1 (leukocyte inhibitory Receptor)  
 
NK cell function: 
 
The main functions of NK cells are cytotoxicity of tumour and virus infected cells and 
cytokine release. NK cells are the primary anti-viral effector population of the innate 
immune system (89). They are activated early after viral infection by type I IFN and IL-12 
and in turn rapidly secrete large amounts of cytokines such as IFN-γ and chemokines, IP-
10 and MIP-1, which may have direct effects on the hosts’ immune response as well as 
serving to recruit other cell types involved in host defence. IFN-γ is considered the 
prototypic NK-cell cytokine and its production by NK cells is known to shape the TH1 
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immune responses as well as activating macrophage killing. IFN-γ also has anti-
proliferative effects on viral and malignant transformed cells.  
 
Production of IFN-γ from NK cells requires 2 signals(89) and one of these almost always 
includes IL-12. The second
 can be IL-1, IL-2, IL-15 or IL-18, or engagement of an NK-
activating
 receptor such as CD16 (Fc RIIIa) or NKG2D. These
 cytokines are released 




dim NK cells have the ability to lyse target cells without prior stimulation and without 
the need for antibody recognition(89). NK cells do not have Ag specific receptors, but 
mediate MHC-unrestricted cytolysis of susceptible cells. NK cells recognise infected cells 
in an antigen independent manner and destroy them due to their cytotoxic activity. They 
use two main pathways to induce apoptosis of target cells(90): granule exocytosis and 
death-receptor engagement. NK cells can also be directly activated to induce antibody-
dependant cellular cytotoxicity (ADCC)(81). NK cell mediated cytotoxicity is regulated 
through a balance between inhibitory and activating receptors. 
 
NK cells and DC cross talk: 
 
Interactions between DCs and NK cells have been documented in a variety of settings 
with emerging evidence of complex bidirectional crosstalk between the two cell types 
which help each to acquire their complete functions both in the periphery and secondary 
lymphoid organs(90). 
 
Mature DCs are able to stimulate NK cells via the production of cytokines, IL-12, IL18, IL-
15 and IFNα and through the expression of NK activating ligands with subsequent 
activation of adaptive immune responses. IL-12 and IL-18 promote optimal cytokine 
production by NK cells while IL15 has been shown to promote NK cell survival and 
differentiation in vivo. Mature mDCs are a major source of IL-12 which enhances NK cell-
mediated cytotoxicity and IFN-γ production. Type I IFN secreted by pDCs are crucial for 
DC-induced NK-cell activation and have an important role in the induction of NK cell 
cytotoxicity by modulating the expression of ligands for the NK cell receptor NKG2D(91). 
DCs may also activate NK cells indirectly by promoting the expansion of antigen-specific T 
cells, which secrete IL-2, which in turn activates NK cells. 
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NK cells can reciprocally regulate the function of DCs. NK cells produce TNF-α which is 
involved in maturation of DCs leading to the subsequent activation of the adaptive 
immune response. It has been reported that immature DCs are uniquely susceptible to NK 
cell mediated cytolysis while mature DCs are protected (91). NK cells may also play a role 
in both differentiation of adaptive T cells as well as their subsequent proliferation. 
 
 
1.5.1.3    Toll Like Receptors: 
 
Toll like receptors (TLRs) were first discovered in Drosophilia (fruit fly), and were found to 
be involved in their immunity to fungal infections. They were discovered in mammals in 
1997 and at least 11 TLRs have been identified in mammals(92). 
 
TLRs are a type of pathogen recognition receptor (PRR). They are type 1 intergral 
transmembrane proteins critical to innate immune responses and are the first line of 
defence against pathogens. 
 
Conserved pathogen-associated molecular patterns (PAMPs) are recognised by TLRs 
expressed on the cell surface of immune cells which include macrophages, monocytes, 
dendritic cells and B cells. PAMPS come from a range of sources including bacterium, 




The structure of all the TLRs is similar. They all have an extracellular ligand recognition 
and binding domain that contains leucine-rich repeats. All have a single transmembrane 
domain. The cytoplasmic domain is homologous to the interlukin-1 receptor and is called a 




After PAMP recognition by TLRs, expressed on the surface of effector cells of the innate 
immune response, signalling pathways are activated which originate from the cytoplasmic 
portion of TLRs, the Toll/IL-1 receptor (TIR) domain. Downstream signals are transmitted 
via the recruitment of TIR containing adaptor proteins including myeloid differentiation 
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adaptor-inducing IFN (Trif) and the Toll-receptor-associated molecule (TRAM)(93) with the 
downstream activation of transcription factors including the NFkB protein complex and 
AP-1 (Figure 8)(93-97). These transcription factors regulate a multitude of genes, 
including those encoding pro-inflammatory cytokines, chemokines, antimicrobial genes 
and type 1 IFNs through induction of transcription factors IRF3 and IRF7. 
   
In addition, upregulation of MHC molecules and co-stimulatory molecules (CD40, CD54, 
CD80, CD86) results in activation and maturation of antigen presenting cells (APCs). In 
turn, these APCs, dendritic cells being the most potent, can present antigen, initiate T cell 
priming and contribute to the establishment of an adaptive immune response. Thus these 
stimuli serve to link innate and adaptive immunity. 
 




    
 
 
Which signalling pathway is activated following TLR engagement varies depending on the 
recruitment or not of adaptor protein (MyD88). 
 
    32  MyD88 dependant pathway: 
The MyD88-dependant pathway is the best studied pathway (Figure 8). Activation of all 
TLRs, except TLR 3, by pathogen triggers recruitment of MyD88 adaptor molecule 
(contained within the TIR domain), either by itself (TLR5, 7, 8 and 9) or together with 
adaptor molecule TIR domain-containing adaptor molecule (TIRAP; TLR 1/2, 2/6 and 
4)(92;96). MyD88 contains a C terminal TIR domain and structural region, the N terminal 
death domain, which allows it to associate with molecules that further transmit signals. 
 
Upon stimulation of TLRs, the MyD88 adaptor connects through interlukin-1 receptor 
associated kinases 1 and 4 (IRAK1 and IRAK4), tumour necrosis factor receptor 
associated factor 6 (TRAF6) and transforming growth factor beta activated protein kinase 
1 (TAK1). These molecules are linked to at least three major downstream pahways (84): 
the NF-kB pathway, the pathway involving mitogen-activated protein kinases (MAPKs) 
and the Interferon regulatory factor (IRF) pathways. 
 
The NF-kB pathway: 
NF-κB is a protein complex which plays a key role in regulating the immune response to 
infection. All proteins of the NF-κB family share a Rel homology domain in their N-
terminus. There are five proteins in the mammalian NF-κB family (NFKB1, NFKB2, RELA, 
RELB and REL).  
 
In unstimulated cells, the NF-κB dimers are sequestered in the cytoplasm by a family of 
inhibitors, called IκBs (Inhibitor of κB). Activation of the TAK1 adaptor may also lead to 
activation of the inhibitor of NF-kappa B kinase (IKK). Once activated, the IKK complex 
induces phosphorylation and subsequent degradation of IkB (98). This phosphorylation 
reaction dissociates IkB from nuclear factor-kB (NF-kB) allowing the NF-kB complex to 
translocate into the nucleus where it induces genes encoding proinflammatory proteins 
(IL6, IL-1B, TNFa, IL12p40) and co-stimulatory molecules.  
 
The MAPK pathway: 
MyD88 connects through IRAK 1 and 4, TRAF6 and TAK1. TAK1 phosphylates members 
of the MAPK kinase family which subsequently activate JNK and p38MAPK.  
This complex cascade culminates in activation of the hetrodimeric transcription factors 
known as AP-1 and the production of pro-inflammatory cytokines and costimulatory 
molecules. 
    33  IRF pathway: 
This pathway leads to type I IFN production and subsequently to induction of IFN-
responsive genes. The pathway is activated through TLR7, 8 and 9 by inducing the 
transcription factors, interferon regulatory factors, IRF3 and 7 (figure 9).  
IRF3 is a constitutively expressed protein that resides in the cytoplasm in unstimulated 
cells, but virus infection triggers IRF3 phosphorylation which allows IRF3 to form a 
homodimer, translocate into the nucleus, and bind to DNA to regulate expression of IFNβ 
and other IFN-stimulated genes (ISGs)(99).  
IRF7 is structurally the most similar to IRF3, whose activation is also controlled by 
phosphorylation. IRF7 is constitutively expressed by pDCs(100) but weakly in other 
unstimulated cells but dramatically induced by stimulation with type I IFN or other stimuli. 
Activation of pDCs through TLR 7 or 9 activates adaptor molecule, MyD88, which directly 
interacts with IRF7 through its death domain(67). This interaction seems to induce IRF7 
phosphylation and activation by forming a complex containing adaptor molecule TRAF6, 
and protein kinases IRAK1 and IRAK4. IRAK4 facilitates phosphorylation of IRAK1. 
Activated IRAK1 then causes the phosphorylation of IRF7 and TRAF6 mediates 
ubiquitination required for IRF7 activation. IRF7, once activated, is translocated to the 
nucleus where it regulates expression of target genes. ISRES (IFN-stimulated response 
element) found in the promoters of genes that are regulated by type 1 IFNs, is bound by 
IRF7. 
 
TRAF6 may also interact with TRAF-family-member-asoociated NF-kappaB activator-
binding kinase 1 (TBK1), which activates interferon regulatory factors, IRF3 and IRF7, 
leading to production of type 1 Interferons. 
 
IRF5 is also required for proinflammatory cytokine induction through TLR 7, 8 and 9. IRF5 
associates with MyD88 and translocates to the nucleus in response to TLR activation. In 
the nucleus it binds to typical interferon-stimulated response element motifs in promoter 
regions of cytokine genes causing them to be expressed. This culminates in nuclear 
translocation of NFκB with activation of mitogen activated protein (MAP) and transcription 





    34  MyD88 Independent Pathway(93): 
 
There is a MyD88 independent pathway, used by TLR3 and TLR4, which culminates in 
activation of NF-kB and induction of IFN-inducible genes and co-stimulatory molecules. 
 The pathway utilizes adaptors, TRIF (TIR domain containing adaptor inducing interferon 
b), TRAM, TIRAP (TIR domain containing adaptor molecule/Mal). TIRAP is also involved 
in My88-independent activation of IRF 3 to induce INF type 1. In response to stimulation, 
IRF3 is phosphorylated by IKKs and TBK1 and then translocates to the nucleus to induce 
mainly INF β. 
 
Figure 9  Recognition of viral nucleic acids by TLR7, TLR8 and TLR9 in pDCs     








    35  Specific TLRs: 
 
Each TLR family recognises molecular patterns associated with a specific class of 
microbial agents(101) .  
 
TLR1, TLR6 and TLR10 form heterodimers with TLR2. The hetrodimer of TLR2 with TLR1 
is expressed on mDCs and the TLR2 and TLR6 hetrodimer is expressed on mast cells 
and they signal via the MyD88 pathway with the TIRAP adaptor. The hetrodimers 
recognize fungi (Sarcomyces cereviciea, Candida albicans, and Aspergillus fumigatus), 
parasites (Trypanosoma cruzi), Gram positive bacteria-derived peptidoglycan (PGN) and 
bacterial lipoproteins, lipoarabinomannan from Mycobacterium tuberculosis, Treponema 
pallidum-derived glycolipid and lipoteichoic acid. TLR2 can also recognize certain viruses 
such as cytomegalovirus, measles virus and core and NS3 proteins of HCV.  
 
TLRs 3, 7, 8 and 9 are intracellular receptors specialized in the recognition of viral nucleic 
acids and recognize ligands in endosomes and lysosomes. 
 
TLR3 detects double stranded RNA (dsRNA)(102). It may also bind to synthetic double 
stranded RNA such as polycytidylic acid (Poly I:C). TLR3 is expressed on B and T 
lymphocytes and NK cells. It signals via a MyD88 independent pathway (Trif) and induces 
production of type 1 IFN in addition to inflammatory cytokines 
 
TLR-7, 8 and 9 are located on the endosomal membrane and are homologous. 
TLR-7 and TLR8 are very similar in their ligand binding and signaling. TLR7 is expressed 
in B cells and plasmacytoid dendritic cells. There is some controversy as to whether 
myeloid DCs express TLR-7. TLR8 is expressed in mDCs and mast cells. They recognize 
synthetic imidazoquinolone-like molecules, guanosine analogues such as loxoribine and 
single-stranded RNA derived from viruses(103). Both signal directly through MyD88. 
Hepatitis C is a single-stranded ss-RNA virus and therefore susceptible to detection by 
TLR7 and 8. It induces a rapid IFN response with a rapid induction of IFN-regulated 
genes, such as 2’5’oligoadenylate synthetase. 
 
TLR 9 recognises unmethylated 2’-deoxyribo (cytidine-phosphate-guanosine (CpG) 
DNA(104).  Bacterial DNA contains unmethylated CpG motifs, which confer 
immunostimulatory activity. In vertebrates, the frequency of CpG motifs are severely 
reduced and the cysteine residues of CpG motifs are highly methylated, leading to 
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unmethylated CpG-dinucleotide (CpG-DNA) lead to activation of TLR9 which is expressed 
on pDCs, B cells and T cells. TLR9 subfamily transmit signals by solely utilizing MyD88.  
 
The principal ligand for TLR4 is the lipopolysaccharide (LPS) of gram-negative 
bacteria(105). Additional ligands include the fusion protein of respiratory syncytial virus, 
Cryptococcus neoformans and the plant product Taxol. TLR4 is expressed on mDCs and 
mast cells and its signaling utilizes 2 pathways, namely, MyD88 with TIRAP but it may 
also induce type 1 IFN through the MyD88 independent pathway via TRAM and Trif. 
 
Bacterial flagellin has been identified as a TLR5 ligand(106). It is expressed on mDCs and 
transduces signals via MyD88. 
 
 








    37  1.5.2   Adaptive Immunity: 
 
The adaptive immune response is composed of humoral immune responses (antibodies 
produced by B cells) and cellular immune response (CD4 and CD8 T cells), most 
important in viral infections. It is characterised by specificity, flexibility and memory and is 
required for resolution of infection.  
 
Flexibility is provided by the unique way in which T and B cell recognise antigens. Unlike 
innate responses, which use a fixed repertoire of inherited receptors, T and B cells have 
the capacity to undergo a recombination of antigen receptor genes to create novel and 
unique antigen receptors capable of recognising virtually any antigen. Memory is provided 
through the long term persistence of B and T cells that have encountered antigen  that 
retain the capacity to deliver  rapid and specific responses to re-exposure to antigens.  
 
1.5.2.1   The Humoral Immune Response: 
 
B lymphocytes (B cells) are the effector cells of the humoral immune response. The 
principal function of B cells is to make antibodies against soluble antigens which they 
express on their surface. Antibody expressed on the B cell membrane acts as the B cell 
receptor. B cell activation requires not only recognition of antigen but also clonal 
proliferation and differentiation into plasma cells (Naive B cells can be activated in a T-cell 
dependent or independent manner, but two signals are always required to initiate 
activation). Secreted antibodies bind to antigens on the surfaces of invading microbes 
(such as viruses or bacteria), which flags them for destruction.  
 
B cell activation depends on one of three mechanisms: 
T cell-independent (polyclonal) activation where the B cell is stimulated directly by antigen 
to produce antibodies. 
T cell- independent activation, in which macrophages present several of the same antigen 
in a way that causes cross-linking of antibodies on the surface of B cells. 
T cell-dependant activation in which an antigen presenting cell (APC) presents a 
processed antigen to a helper T (TH) cell, priming it. When a B cell processes and 
presents the same antigen to the primed TH cell, the T cell releases cytokines that activate 
the B cell. Signal 1 is between the B lymphocyte expressed antigen and the TCR. Signal2 
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CD40L on the TH2 lymphocyte. 
 
Antibodies: 
Also, known as immunoglobulins, these are glycoproteins synthesized and secreted by 
plasma cells that are derived from B cells. 
Structure: Immunoglobulins are composed of four polypeptide chains, 2 heavy and 2 
light, bound together by di-sulphide bonds (figure 11). 
Heavy chains: There are five types of mammalian Immunoglobulin heavy chain denoted 
by the Greek letters: α, δ, ε, γ, and μ. The type of heavy chain present defines the class of 
antibody; these chains are found in IgA, IgD, IgE, IgG, and IgM antibodies, respectively. 
Heavy chains contain one variable domain and three or four constant domains, depending 
on the class of the immunoglobulin. The constant region is identical in all antibodies of the 
same isotype, but differs in antibodies of different isotypes. The variable region of the 
heavy chain, at the amino-terminal domain, differs in antibodies produced by different B 
cells, but is the same for all antibodies produced by a single B cell or B cell clone.  
Light Chains: In mammals there are two types of light chain, which are called lambda (λ) 
and kappa (κ). A light chain has one constant domain and one variable domain. Each 
antibody contains two light chains that are always identical. 
Fab and Fc Regions: The antigen binding (Fab – Fragment, antigen binding) region is 
composed of the combined amino-terminal ends of the heavy and the light chain 
representing the hypervariable domains of one heavy and one light chain of the antibody. 
The carboxy-terminal portions of the heavy chains trigger various effector functions 
following combination of the immunoglobulin molecule with its specific antigen and is 




    39  Figure 11:  Structure of an immunoglubulin molecule 
 





Antibodies are used by the immune system to identify and neutralize foreign objects like 
bacteria and viruses. Each antibody recognizes a specific antigen unique to its target. By 
binding their specific antigens, antibodies can cause agglutination and precipitation of 
antibody-antigen products, prime for phagocytosis by macrophages and other cells, block 
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1.5.2.2   Cell Mediated Immunity: 
 
T cells are lymphocytes that play a central role in cell mediated immunity. T lymphocytes 
mature in the thymus and respond to antigen encountered on the surface of infected host 
cells. T cells can only recognise and be activated by antigen bound to Major 
Histocompatibility Complex (MHC) or Human Leukocyte Antigen (HLA) Molecules. 
 
T Cell Subsets: 
There are several different subsets of T lymphocytes(107): 
 
1.  T Helper (TH) cells 
T helper cells (TH cells) recognise antigens presented by MHC class II molecules on the 
surface of antigen presenting cells and subsequently CD4 T cells perform multiple effector 
functions, including direct activation of macrophages and antigen-specific B cells as well 
as activation of CD8 T cells in a cytokine dependant manner. The cytokines they secrete 
during the initial TH-APC interaction provoke proliferation of further TH lymphocytes and 
depending on the cytokine signal received, these cells differentiate into either TH1 or TH2 
cells which in turn secrete characteristic groups of cytokines: 
 TH1 cells secrete proinflammatory cytokines: INFγ, TNFβ and IL2 and promote cell 
mediated immunity and cytotoxic T cells as well as delayed hypersensitivity responses 
while TH2 cells secrete IL4, IL5, IL6, and IL13 and promote humoral immune responses. 
 
The cytokine profiles of these two TH subsets are mutually inhibitory making a switch from 
cell mediated to humoral immunity or vice versa a rare occurrence once dominance is 
established. Uncontrolled TH1 and TH2 responses can cause chronic inflammatory, 
autoimmune disease and allergy respectively. 
 
In TH cells the defining accessory molecule is CD4 which is invariable and therefore 
conserved between individuals of a given species but unable to specifically recognise 
variable ligands such as antigens.  
 
2.  Cytotoxic T (TC) cells 
Cytotoxic T cells recognise antigens presented by MHC class I molecules. Subsequently, 
TC cells perform different effector functions, such as the killing of infected target cells 
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TNFα that can inhibit viral replication without killing the infected cell.  
TC cells express the invariable accessory molecule CD8. This is either a hetrodimer of di-
sulphide linked α and β invariant chains or homodimer with α chains. The CD8 molecule 
binds to the class I MHC molecule and acts to stabilize the TCR bond to the peptide MHC 
complex and transduce an activating signal to the T cell (108;109). 
 
3. Memory T cells 
These cells are a subset of antigen-specific T cells that persist long-term after an infection 
has resolved. They are capable of rapid clonal expansion to generate large numbers of 
effector T cells upon re-exposure to their cognate antigen, thus providing the immune 
system with "memory" against past infections. Memory T cells comprise two subtypes: 
central memory T cells (TCM cells) and effector memory T cells (TEM cells). Memory cells 
may be either CD4+ or CD8+. 
4. Regulatory T cells 
Formerly known as suppressor T cells, these cells are crucial for the establishment of 
immunological self-tolerance and maintenance of immune hameostasis(110;111). Their 
major role is to shut down T cell-mediated immunity toward the end of an immune reaction 
and to suppress auto-reactive T cells that escaped the process of negative selection in the 
thymus. Two major classes of CD4+ regulatory T cells have been described, including the 
naturally occurring Treg cells and the adaptive Treg cells.  
Naturally occurring Treg cells (also known as CD4
+CD25
+FoxP3
+ Treg cells) constitutively 
express the interlukin (IL)-2 receptor α chain (CD25) and arise in the thymus. Their 
development and function depend on the expression of the transcription factor FOXP3. 
Naturally occurring Treg cells can be distinguished from other T cells by the presence of an 
intracellular molecule called FoxP3 which is a master regulator of Treg function. Mutations 
of FoxP3 result in Treg deficiency(112). 
 Adaptive Treg cells may originate during a normal immune response in response to newly 
encountered T cell epiptopes in the absence of co-stimulatory signals(113). They include 
IL-10-secreting T regulatory 1 (Tr1) cells, transforming growth factor (TGF)-β-secreting T 
helper (Th)3 cells, certain γ/δ T cell receptor (TCR)-expressing CD4
−CD8
− T cells, and 
CD8
+CD28
− T cells. 
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5. Natural Killer T cells (NKT cells) 
These cells are a special kind of lymphocyte that link the adaptive immune system and the 
innate immune system. Unlike conventional T cells that recognize peptide antigen 
presented by MHC molecules, NKT cells express both CD56 and T cell receptor. They 
recognize glycolipid antigen presented by a molecule called CD1d. Once activated, these 
cells can perform functions ascribed to both Th and Tc cells (i.e., cytokine production and 
expression of  cytolytic/cell killing molecules). They interact with antigen presenting cells 
and impact on the adaptive immune response. 
6. Gamma delta T cells (γδ T cells) 
These cells represent a small subset of T cells that possess a distinct T cell receptor 
(TCR) on their surface which is made up of one γ-chain and one δ-chain. This group of T 
cell are found at their highest abundance in the gut mucosa, within a population of 
lymphocytes known as intraepithelial lymphocytes (IELs) (114).  
The antigenic molecules that activate γδ T cells are still largely unknown. However, γδ T 
cells are unusual in that they do not seem to require antigen processing and MHC 
presentation of peptide epitopes although some recognize MHC class IB molecules. 
Furthermore, γδ T cells are believed to have a prominent role in recognition of lipid 
antigens. Human Vγ9/Vδ2 T cells, which constitute the major γδ T cell population in 
peripheral blood, are unique in that they specifically and rapidly respond to a set of non-
peptidic phosphorylated metabolites precursors of cholesterol, collectively named 
phosphoantigens. Phosphoantigens are produced by virtually all living cells. 
Mature γδ T cells are divided into functionally distinct subsets. Like other T cell subsets 
bearing invariant TCRs, such as CD1d-restricted Natural Killer T cells, γδ T cells exhibit 
several characteristics that place them at the border of the innate and adaptive immune 
system. On one hand, γδ T cells may be considered a component of adaptive immunity in 
that they rearrange TCR genes to produce junctional diversity and will develop a memory 
phenotype. However, the various subsets may also be considered part of the innate 
immunity where a restricted TCR may be used as a pattern recognition receptor 
(115;116). Recent work has shown that human Vγ9/Vδ2 T cells are also capable of 
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monocytes and dendritic cells. 
The T cell Receptor (TCR): 
The TCR is a hetrodimer consisting of alpha and beta chains in 95% of T cells, covalently 
joined by di-sulphide bonds (figure 12). Activation by engagement with antigen and MHC 
molecule, results in a series of biochemical events mediated by associated enzymes, co-
receptors and specialized accessory molecules. 
Each chain of the TCR is a member of the immunoglobulin superfamily and possesses 
one N-terminal immunoglobulin (Ig)-variable (V) domain, one Ig-constant (C) domain, a 
transmembrane/cell membrane-spanning region, and a short cytoplasmic tail at the C-
terminal end. 
Analogous with antibody, the TCR variable domain is responsible for antigen recognition 
and comprises V, D and J segments. 
There are three hypervariable or complementary determining regions (CDRs) on each 
chain of the TCR (α and β), but there is an extra region in the V domain on the β chain 
responsible for binding super-antigens (e.g. enterotoxins). CDR3 on both chains of the 
TCR at the V-(D)-J junctions contain random nucleotide additions and therefore have the 
most sequence variability. It is the main CDR responsible for recognizing processed 
antigen while CDR1 and CDR2 (and sometimes CDR3) are thought to recognise the MHC 
complex. 
Variation of TCR antigen binding regions are also generated both genetically through 
gene diversity of alleles encoding V and J regions and through somatic mutation through 
recombination of V and J regions giving rise to greater than 10
25 different TCRs(117)  
The constant domain of the TCR domain consists of short connecting sequences in which 
a cysteine residue forms disulfide bonds, which forms a link between the two chains. It is 
responsible for membrane binding to the cell. 
The transmembrane region of the TCR is composed of positively-charged amino acids. It 
is thought that this allows the TCR to associate with other molecules like CD3, that 
possess three distinct chains (γ, δ, and ε) in mammals and the ζ-chain. These accessory 
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intracellular signalling from the TCR leading to gene activation; the cytoplasmic tail of the 
TCR is extremely short, making it unlikely to participate in signaling. The CD3- and ζ-
chains, together with the TCR, form what is known as the T cell receptor complex. 
The signal from the T cell receptor complex is enhanced by simultaneous binding of the 
MHC molecules by a specific co-receptor. On TH cells, this co-receptor is CD4 that 
exclusively binds the class II MHC while on TC cells, the co-receptor is CD8 that is specific 
for class I MHC. The co-receptor not only ensures the specificity of the TCR for the 
correctly-presented antigen but also allows prolonged engagement between the antigen 
presenting cell and the T cell and recruits essential molecules (e.g., LCK) inside the cell 
that are involved in the signaling of that activated T lymphocyte.  
 
Figure 12.  Structure of the T cell receptor 
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T Cell Activation: 
Although the specific mechanisms of activation vary slightly between different types of T 
cells, the "two-signal model" in CD4+ T cells holds true for most. 
 
The first signal is provided by binding of the T cell receptor to a short peptide presented by 
the major histocompatibility complex (MHC) on another cell, usually antigen presenting 
cells. This ensures that only a T cell with a TCR specific to that peptide is activated. 
The second signal comes from co-stimulation, in which surface receptors on the APC are 
induced by a relatively small number of stimuli, usually products of pathogens. The only 
co-stimulatory receptor expressed constitutively by naïve T cells is CD28, so co-
stimulation for these cells comes from the CD80 and CD86 proteins on the APC. The 
second signal allows the T cell to respond to an antigen. Without it, the T cell becomes 
anergic, and it becomes more difficult for it to activate in future. This mechanism prevents 
inappropriate responses to self, as self-peptides will not usually be presented with suitable 
co-stimulation. 
 
1.6   The Immune Respone in Hepatitis C: 
 
Acute hepatitis C infection is spontaneously cleared by 20% of patients. The remainder 
develop chronic infection. The host’s immune response is important in determining its 
ability to clear the virus either spontaneously or in response to treatment.   
 
Multiple arms of the host response, including the innate, humoral and cellular immune 
responses, have been implicated in determining the outcome of infection with HCV. 
Interaction between the innate and adaptive immune response plays a pivotal role in 
perpetuation or clearance of HCV infection.  
 
To replicate and spread successfully, viruses direct various strategies to evade host 
defences. These measures seem effective since 85% progress to persistent infection and 
up to 60% do not respond to IFN therapy or relapse once stopped.  
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1.6.1   Innate Immune Response in HCV: 
 
The innate immune response forms the first line of defense against pathogens providing a 
non specific immediate response. There is accumulating evidence that HCV affects the 
early innate immune responses preventing timely and appropriate T cell priming. 
 
Innate immune cells recognise patterns of infectious agents (PAMPs) through receptors 
expressed on the hosts cells e.g. TLR receptors, thereby directing the selection of antigen 
by T and B lymphocytes and secretion of cytokines by TH lymphocytes that promote 
appropriate host response to infection. 
 
1.6.1.1   Dendritic Cell dysfunction: 
 
Dendritic cells are key components of the innate immune system (Chapter 1.5.1.1). They 
activate and shape the immune response and link innate and adaptive immunity. As 
professional antigen presenting cells they are the most efficient activators of naïve T cells. 
Consequently their functions may be targeted by viruses.  
 
Evidence points towards DC dysfunction in patients with chronic hepatitis C that may 
compromise their capacity to mount and sustain an effective antiviral immune response, 
thus leading to viral persistence. 
Blood DCs are scarce and cannot be expanded readily in vitro. Blood monocytes have 
been widely used as a DC source in studies, developing into DCs in the presence of GM-
CSF and IL-4. Cultured monocyte-derived DCs (MoDCs) are thought to most closely 
resemble myeloid DCs. 
 
The first studies of DC function in chronic HCV found that MoDCs had an immature 
phenotype (reflected by the pattern of cell surface markers) and impaired maturation and 
T cell allostimulatory function(118-121).  The direct mechanism underlying the defective 
function of these dendritic cells has not been clearly identified and varies between studies. 
However, more recent studies have found no defect in MoDCs from patients with 
CHC(122-124). MacDonald et al(125) found only a subtle defect that was overcome by 
increasing the magnitude of the maturational stimulus or DC numbers. The differences 
among these studies may be explained in part by differences in culturing conditions. 
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situation in vivo(126)  where liver DCs are derived, not from monocytes, but from 
circulating precursors, the myeloid and plasmacytoid DCs (mDC and pDC respectively).  
 
More recently, studies have looked at circulating dendritic cells directly ex vivo, and have 
shown, both pDCs and mDCs to be numerically and functionally impaired in CHC 
patients(127-130) with a reduced allostimulatory function, reduced production of IFNα and 
IL12 and increased priming of IL10-producing T cells. It has also been reported that while 
numbers of DCs are reduced in the peripheral compartment, increased numbers of DCs 
have been shown in the livers of HCV patients, suggesting hepatic DC 
sequestration(121;127;131;132).  
 
Other studies(131;133-135) including data from Southampton(136) have shown that the 
DC subpopulations are differentially affected in chronic HCV with selective impairment of 
pDCs production of IFNα. These findings would impact on both innate and adaptive 
immunity and favor viral persistence. However, these findings are controversial with 
others finding fully functional circulating plasmacytoid DCs(137;138) and myeloid 
DCs(138) 
 although reduced in numbers. 
In patients with CHC it has been shown that the allostimulatory function of DCs return to 
normal after treatment induced HCV clearance(119;122;127) However, DC function in 
these patients was not monitored regularly throughout treatment. Itose et al (139)
  followed 
patients through treatment and found impaired DC function and lower pDC ratio in non- 
responders and transient responders compared to sustained responders. 
 
In subjects who had spontaneously resolved HCV infection in the past, frequencies and 
function of circulating DCs have been found to be comparable to normal subjects(127).
 
These findings together reveal evidence of HCV-induced DC disability and that dendritic 
cell function may be restored by antiviral therapy. 
 
 While these studies suggest a relationship between chronic HCV infection and impaired 
DC function, with impaired T cell polarization ability, it is not clear if DC dysfunction does 
result from a direct suppression by the virus or is a secondary consequence of the chronic 
inflammation. Indeed, a reverse correlation between frequencies of pDCs and mDCs and 
serum ALT levels has been demonstrated in CHC, suggesting that the liver disease per se 
may lead to reduction in peripheral blood DCs(127).  
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studies(119;127;129;131;137) have looked at DC function in patients with other forms of 
liver disease including hepatitis B, primary sclerosing cholangitis, autoimmune hepatitis 
and primary biliary cirrhosis, drug induced hepatitis and steatohepatits and one looked at 
patients with generalized bacterial infection. Although inconclusive, these studies suggest 
that different types of hepatic inflammation may cause similar impairment in DC function 
to those seen in chronic HCV with a paucity of peripheral DCs possibly due to impaired 
DC mobilization from the bone marrow, or by increasing DC migration to the liver. It is not 
totally clear therefore if the defect seen in DCs in HCV is directly induced by the virus as 
an immune evasion strategy.
 
 
As discussed, reduction in frequency and impaired function of DCs in CHC patients has 
been reported by several groups, with some conflicting results on whether either mDCs, 
pDCs, both subsets or neither are affected. Plausible explanations which may explain the 
mechanisms underlying any dysfunction that has been reported include: 1) direct HCV 
infection of DC. The HCV genome has been reported to have been isolated from Mo-DC 
or blood DC from chronically infected patients (119;138) or 2) the presence of circulating 
HCV proteins that affect DC function and number.  
 
1.6.1.2   NK Cell dysfunction: 
 
NK cells are the first line of defense against viral infection. Once activated, they secrete 
inflammatory cytokines, such as IFNγ, which inhibits replication of HCV through a non-
cytolytic mechanism (Chapter 1.5.1.2). They play an important role to prevent persistent 
HCV infection.  
 
The phenotypes and/or functional activities of
 various populations of these cells have 
been reported to be
 impaired in patients with chronic HCV infection(140-146). While many 
studies found reduced frequency of NK cells associated with significant reductions in NK 
cytolytic
 activity in patients with chronic HCV infection(140;143;146) others found no 
decrease in frequency or cytolytic activity(147;148) and one found a normal frequency but 
a lower level of spontaneous cytotoxicity than normal controls(141) which may be due to 
the reported depletion in the cytotoxic CD56
dim NK subset with expansion of the IFNγ 
producing CD56
bright NK subset in CHC patients(149).
 
 
    49  The functional activities of NK cells are controlled by a variety
 of stimulatory, co-
stimulatory and inhibitory receptors. HCV may have also developed strategies to impair 
NK cell function by expression of the inhibitory receptor CD94/NKG2A which has been 
shown to be up-regulated on NK cells in patients with CHC(150). This correlates with an 
impaired capacity to activate dendritic cells, a reduced ability to kill hepatoma cells and 
reduced interferon-gamma production(151).  
 
Others have suggested that HCV can modulate NK cell activity, having evolved 
mechanisms by which it can inhibit the responses
 of NK cells either directly by binding
 of 
the HCV envelope-2 protein to CD81(152;153) or indirectly by
 inducing the expression of 
inhibitory ligands for NK cells(154;155). 
HCV may also inhibit NK cell activation by altering the functional
 activities of mDCs and/or 
pDCs (119;156;157). T cells that exhibit NK phenotypes and functions, including
 CD56
+ T 
cells(142;146) and natural killer T (NKT) cells expressing
 invariant Vα24Vβ11 T cell 
receptors(142;158), have also been
 reported to be depleted in blood and/or livers of 
patients with
 chronic HCV infection. 
 
Finally, the NK cell mediated innate immune response may be genetically programmed to 
determine the chance of spontaneously resolving acute HCV infection. Subjects 
homozygous for a polymorphism in the inhibitory NK receptor KIR2DL3 and its ligand 
HLA-c1, predicted to lessen inhibition, were 2-3 times more likely to spontaneously 
resolve infection(159). However, this was a retrospective study and functional differences 
have not been described in acute infection.  
 
 
1.6.2   Adaptive Immune Response in HCV: 
 
The adaptive immune response is required for resolution of the infection and involves a 
mechanism for enhancing specificity of recognition and generating immunological 
memory. HCV persistence and disease progression may be related to inhibition in the 
adaptive immune response as well as to a failure of CD4+ T cells to support an effective 
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1.6.2.1   Cell Mediated Response: 
A large amount of evidence points to a crucial role for cellular immune responses in 
determining the outcome of HCV(160).  
 
Clearance of the HCV is attributed to strong early HCV specific CD4 TH1 and CD8 TC cell 
response against a variety of HCV-peptide epitopes. Conversely, in chronic infection the 
HCV-specific T cell response is less vigorous(161) and only transitory with a gradual loss 
of the CD4+ and CD8+ responses to HCV and contraction of the range of peptide 
epitopes recognized. In patients followed longitudinally from the time of infection it is 
failure to sustain these responses that correlates with progression to CHC.  
 
Viral persistence and progression to chronic infection is also associated with an altered 
balance of TH1 and TH2 CD4+ T cell responses. Whereas a strong TH1 response is 
considered important for the clearance of infection, in patients with CHC, the HCV-specific 
CD4+ T cell response is biased towards the production of TH2 cytokines and regulatory 
cytokines, notably IL10(160). 
 
Both T cell subsets secrete TH1 cytokines including IL2, INFγ and TNFα in response to 
viral pathogens. A TH1 cytokine response is important in the early phase of the viral 
infection with the aim of controlling the infection. Later in the infection, T cells differentiate 
into TH 2 T cells,  producing IL4, IL5, IL6, IL13 and IL10, providing help for humoral  
immune responses and limiting/ controlling the host TH1 response thereby protecting the 
host from continual inflammatory response.  
 
Viral Evasion Strategies from adaptive immune responses: 
 
Various mechanisms of virus specific T cell failure leading to HCV persistence have been 
suggested including impaired antigen induction of T cells, T cell exhaustion, HCV escape 
mutation, functional anergy or T cell stunning and induction of regulatory T cell function. 
 
1. Inefficient induction of T cells 
Dendritic cell dysfunction reported in HCV (chapter 1.6.1.1) may lead to ineffective T cell 
priming leading to insufficient responses to clear the virus(161).  
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2. Mutability of RNA genome: 
The HCV virus, like most RNA viruses, exist as quasispecies – a collection of related but 
generally distinct viral variants – due to their highly error prone replication mechanisms 
due to lack of proof reading activity of the HCV RNA polymerase. The existence of 
quasispecies may provide the necessary diversity to the virus and facilitate escape from 
specific host-immune responses with mutations of antigenic epitopes leading to reduced 
recognition by CD8
+ T cells. This is thought to be one of the major viral evasion strategies 
and an explanation for the persistence of HCV infection(162;163). It has been suggested 
that T cell escape occurs early during infection since chronically infected patients have 
been shown not to diversify their escape mutations after several years of follow up. 
Resolution of acute HCV is associated with overall decrease in viral quasispecies. 
 
3. T cell exhaustion 
HCV has a high rate of replication with the production of overwhelming quantities of HCV 
antigens. Exhaustion of an initially vigorous response is thought to result from chronic 
stimulation of immune response. 
 
4. Functional Anergy: 
Recent studies have shown that HCV-specific CD8+ T cells may be functionally impaired, 
or anergic, in chronic disease(164) and consistent with this loss of function, may exhibit an 
immature phenotype resulting in impaired proliferative state, cytotoxic capacity, and ability 
to secrete TNFα and IFNγ upon stimulation, referred to as stunned phenotype. CD8+ T 
cell dysfunction has been seen early in the course of acute infection irrespective of 
outcome. However those who progressed to chronic, CD8+ T cell function remained 
suppressed compared to those with self limited disease there was recovery of CD8+ T cell 
function(164). 
 
5. Increased Regulatory T cell (Tregs) function:  
Tregs may be natural or induced after prolonged antigenic stimulation. They actively 
control induction and effector functions of other immune cells by suppressing their 
functional activity via contact dependant mechanisms as well as by secreting 
immunosuppressive cytokines such as IL-10 and TGF-B. It is likely that they play a role in 
preventing immune mediated pathology during chronic HCV. The frequency of naturally 
occurring  CD4+CD25+ Tregs in the periphery is reported to be higher in HCV infected 
patients when compared to recovered or uninfected patients(165). In addition, there is 
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response by secreting IL-10(165), thus favouring HCV persistence and limited liver injury. 
 
 
1.6.2.2   Humoral Immune response: 
 
HCV infection results in antibody production to various HCV proteins in nearly all 
immunocompetent patients. HCV-specific antibodies are usually detectable 7-8 weeks 
after infection. Whether antibodies neutralize HCV infectivity is still unclear and the role of 
antibodies in protection against HCV have been questioned since in chimpanzees and 
humans, antibodies do not prevent re-infection and do not correlate with a favourable 
outcome(166). 
 
Chronic infection is characterised by high titres of HCV-specific antibodies. No antibodies 
conferring immunity to HCV has been detected. Spontaneous viral clearance after acute 
infection has been described in patients with hypogammaglobulinemia, arguing that 
antibodies are not essential for HCV clearance. 
 
In the natural course of HCV infection humoral immunity seems to fail as it coexists with 
high HCV titres and is therefore insufficient to block HCV entry into cells and clear 
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1.7.1   Current Treatment for CHC: 
 
The current standard of care for patients with chronic hepatitis C (CHC) is combination 
therapy with pegylated (PEG) interferon alpha and ribavirin. For many years, the mainstay 
of treatment was monotherapy with conventional interferon alpha, which led to a low 
sustained virological response rate (SVR) of 8% for a treatment period of 6 months, rising 
to 27% when treated for 12-24 months(167).  
 
The introduction of ribavirin in combination with Interferon α in the late 1990s was a major 
breakthrough in the treatment of HCV infection. Although ribavirin monotherapy had been 
shown to be ineffective(168;169), combination therapy was consistently shown to improve 
response rates with a 40% chance of eradicating the HCV virus(170;171) and its most 
striking effect to decrease the relapse rate after stopping treatment(172). 
 
The effectiveness of treatment is related to genotype of the virus with sustained viral 
response being achieved by approximately 80% of patients with genotype 2 or 3 
infection(173)
 and approximately 50% of those with genotype 1 with an overall sustained 
virological response (SVR) rates of 50-60%(174). Introduction of the pegylated form of 




The current treatment strategy for individuals infected with genotypes 2 and 3 is 24 weeks 
of combined pegylated interferon α and ribavirin. For patients infected with other 
genotypes, virological response is ascertained by quantification of HCV-RNA viral load 
after 12 weeks of treatment (169). Individuals with an early virological response (defined 
as >2 log10 decrease in HCV-RNA level) continue for a total of 48 weeks, while those who 
do not attain this level stop. 
 
Prior to August 2006, NICE guidance recommended treatment only for those patients with 
histological evidence of moderate or severe disease, or those with significant symptoms of 
hepatitis C virus (HCV) infection sufficient to impair quality of life. Following revision of the 
NICE guidance in August 2008 (177), patients with mild disease are now considered 
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the numbers of patients eligible for treatment. 
 
Anti-viral therapy for HCV with ribavirin and PEG interferon is cost effective with improved 
response rates resulting in a decreased rate of disease progression and liver related 
complications. 
 
The mechanisms by which IFNα and ribavirin act against HCV are not well defined. The 
importance of understanding the biological pathways, cellular effects and antiviral 
activities of these agents is important in development of new effective treatments against 
HCV infection. 
 
1.7.1.1  Mode of Action of IFNα: 
 
Interferons are a family of pleiotropic cytokines with antiviral, anti-proliferative and 
immuno-modulatory properties. The interferon family is subdivided into two subfamilies: 
Type I and Type II. Type I interferons are a family of monomeric cytokines with an amino 
acid similarity of 30-80%, very similar three-dimensional structure (5-alpha helix-bundle), 
that use the same receptor (IFNAR) to initiate a signalling response (see IFN signaling). 
The type I interferons present in humans are IFN-α, IFN-β and IFN-ω. 
 
IFNα is a type 1 interferon which is spontaneously expressed at low levels under normal 
physiological conditions and whose expression is highly enhanced after exposure to 
viruses. It is produced by a wide variety of cells, including fibroblasts, epithelial cells and 
hepatocytes but it is particularly abundantly expressed by pDCs, also known as interferon-
producing cells (IPCs) and these are probably the major source in most viral infections. 
IFNα has been used in the treatment for hepatitis C for many years, initially as 
monotherapy and is known to have direct anti-viral effects as well as a number of 
immunomodulatory activities that can enhance antiviral immune responses.  
 
Anti-viral effects 
The ability of interferon to establish an antiviral state is their fundamental property and 
essential for survival against viral infection. Mice deficient in IFNalpha/beta are extremely 
susceptible to viral infections. Interferons interfere with a number of steps in the viral 
replication cycle including cell entry, transcription, RNA stability, initiation of translation, 
maturation and assembly. 
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IFNα has potent antiviral activity but does not act directly on the virus or replication 
complex. Instead it acts on interferon-stimulated genes (ISGs) which establish a non-
virus-specific anti viral state within the cell(178). Circulating IFNα binds to IFN cell surface 
receptor subunits (IFNAR), leading to their dimerization and the activation of the receptor 
associated Janus-activated kinase 1 (Jak1) and tyrosine kinase 2 (Tyk2). The activated 
kinases phosphorylate the signal transducer and activator of transcription proteins 1 and 2 
(STAT1 and STAT2). The phosphorylated STATs dimerize, associate with IFN-regulatory 
factor 9 (IRF9) and Interferon-stimulated gene factor 3 (ISGF3G) to form a complex 
termed ISGF3 transcription factor which enters the nucleus. ISGF3 binds to the IRES on 
cellular DNA to activate the transcription of multiple ISGs. Hundreds of genes are induced 
by type 1 IFN, many related to antiviral activity and inflammatory cell responses. 
 
Immunomodulation 
It has been suggested that IFNα enhances humoral immunity by increasing proliferation of 
B cells, which secrete antibodies against invading antigens.  
 
With regards to the cellular immune response, IFNα supports the proliferation, functional 
activity and survival of certain T cell subsets which might promote a T-helper 1 (TH1) over 
TH2 phenotype. IFNα enhances the CD8+ cytotoxic T cell (TC cell) response by 
upregulating the expression of MHC class I molecules on the surface of the cells. MHC I 
molecules are responsible for presenting viral antigens to TC cell, thereby triggering the 
destruction of the infected cell. Additionally, Th1 cells are responsible for amplifying CD8+ 
TC cells in response to IL-12 and induce proliferation. Type I interferons appear to 
upregulate IL-12Rβ, a component of IL-12 receptor on TH cells that allows T cells to 
respond to IL12 and thereby develop into TH1 cells, enhancing the TH1 response further. 
IFNα also promotes memory T cell proliferation, prevents T cell apoptosis and may 
prevent immune exhaustion. 
  
IFNα has also been reported to induce the innate immune response as well as 
development of adaptive immunity. NK cells are capable of lysing target cells without prior 
sensitization (see chapter 1.5.1.2). They act very rapidly upon viral infection and together 
with interferons are considered the first line of defence against viral infections and 
tumours. Interferon alpha has been shown to augment NK activity in vitro thus boosting 
the innate immune responses. 
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IFNa may increase the expression of MHC class II molecules increasing presentation of 
antigen to helper T cells. It may promote DC differentiation/activation(179;180) and 
survival and stimulate DC maturation with enhanced co stimulatory marker 
expression(181;182) but some reports suggest it has inhibitory effects on these 
processes(183-185). Enhanced DC maturation leads to enhanced T cell activation and 
has a major role in the development of adaptive immune responses. 
  
Similarly, while some studies show that DCs generated in the presence of IFNα stimulated 
IFNγ production by TH1 cells(180;186;187), while others show that IFNα is a poor inducer 
of IL12p70 production by DCs, instead favouring IL10 release(183;187) and the induction 
of  regulatory T cells(187). The ultimate fate of DCs with IFNα seems determined by the 
presence or absence of other influencing factors(182)




Interferons have the ability to arrest cell growth. It seems that both direct and indirect (via 
the immune system) inhibition of the tumor cells might be involved, however, the exact 
mechanism of action is unclear. No specific genes have been linked to the antiproliferative 
activity of interferons, however, STAT1 is believed to be involved since it is often deficient 
in tumours. The mechanism of cellular arrest in not known, but it is likely to target 
components of the cell-cycle control apparatus, including induction of CDK inhibitors such 




1.5.1.2  Mode of Action of Ribavirin: 
 
Ribavirin, first discovered in 1970, is a purine nucleoside analogue that is activated or 
metabolized through intracellular phosphylation to form the monophosphate (RMP), 
diphosphate (RDP) and triphosphate (RTP), the active form of the drug.  
 
The mechanisms of action of ribavirin are poorly understood but several have been 
proposed from in vitro studies(178;182;188) 
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1. Direct inhibition of viral RNA polymerases: 
RTP, the active metabolite of ribavirin has been implicated in the inhibition of the activity 
of many viral polymerases at high doses causing a direct effect on RNA replication.  The 
misincorporation of RTP by RNA polymerases could lead to premature primer chain 
termination and inhibition of replication. RTP has been shown to be incorporated by HCV 
RdRp into viral RNA opposite cytosine or uridine, resulting in significant block of RNA 
elongation(189).  
 
Against the role of ribavirin in direct inhibition of viral replication is the lack of significant 
first phase decline of plasma HCV RNA with the onset of ribavirin therapy that is seen with 
IFN therapy and any decline that is seen seems to be transient. It is unlikely therefore that 
direct inhibition of HCV-RNA replication is the major mechanism of action against hepatitis 
C. 
 
2. Inhibition of IMPDH  
RMP can cause a depletion of intracellular GTP pools, essential for viral RNA synthesis, 
by competitively inhibiting the hosts enzyme inosine 5’-monophospahate dehydrogenase 
(IMPDH), essential for de novo synthesis of GTP(190). GTP depletion may influence viral 
replication in 2 ways: 
First, it may inhibit viral RNA replication because of lack of an adequate supply of GTP, a 
critical building block required for RNA synthesis and second, it may promote the 
incorporation of RTP in place of GTP and thus increase the error rate during replication, 
contributing to the mutagenic activity of ribavirin.   
 
3. Mutagenesis 
RNA viruses typically exist as quasispecies – a collection of related but not identical 
genomes – due to their highly error prone replication mechanisms due to lack of proof 
reading activity of the HCV RNA polymerase. The existence of quasispecies may provide 
the necessary diversity to the viruses and facilitate escape from specific host-immune 
responses and drug therapy. However, if the error rate during replication crosses a 
threshold, the quasispecies may be driven into error catastrophe, resulting in meltdown of 
genetic information.  
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being incorporated in place of guanosine or adenosine in viral RNA strands by viral RNA 
polymerases. This erroneous incorporation may inhibit chain elongation and, in the 
extreme situation, cause chain termination. Thus ribavirin may potentially drive viruses to 
extinction by inducing an error catastrophe(191). Several recent studies demonstrate that 
ribavirin has an early effect in elevating mutation rates, lending support to mutagenesis as 
a key mechanism of the antiviral(192-197). However these findings are conflicting with 
others finding no increase in mutational frequency(198-200).  
 
3. Immunomodulation: 
With the clinical observation that ribavirin monotherapy had minimal effect on HCV 
viraemia despite significant reduction in ALT levels(201), it was proposed that ribavirin 
may exert its effect on the host immune response. 
Previous studies using mitogen stimulated PBMCs(202-205) or animal models(206-208) 
have shown that ribavirin promotes TH1 type responses either by suppressing Th2 
cytokine profile(206) and/or by increasing TH1 cytokine response with production of 
tumour necrosis factor and IFNγ and decrease in IL10 (202-205;207;208). A TH1 bias 
implies a stronger cellular rather than antibody response against infection and 
accumulating evidence has shown that an early TH1 immune response leads to viral 
clearance, whereas TH2 response favours chronic evolution.  
 
In patients receiving treatment with ribavirin and IFNα, studies have shown that a 
favourable response was associated with induction of a TH1 cytokine production with 
elevated IFNγ and IL-12 responses, in contrast to non responsders who showed a 
decrease in INFγ and IL12 and an increase in IL-10 expression(209)
 
 
Thus ribavirin can modulate the immune system but how this is achieved and whether it is 
relevant to responses to treatment remain unclear. 
 
4. TLR agonist: 
As ribavirin is a purine analogue, it may excert immunomodulatory activities via toll-like 
receptor (TLR). However, ribavirin was not found to stimulate TLR7 or TLR8-mediated 
signalling in cells transfected with these TLRs at the biologically active concentrations (1-
5uM) (210) 
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associated with improvements in serum aminotransferases (211) suggesting that it may 
have an effect on inflammation and the host immune response, downregulating cell-
mediated immune responses. This, however, goes against the notion that ribavirin 
induces TH2 to TH1 shift, since this would increase cell mediated immune response.  
 
When used in combination with IFNα, ribavrin doubles the SVR, primarily through the 
prevention of virological relapse after the discontinuation of therapy (212) This is 
consistent with findings from viral kinetic studies of ribavirin mainly targeting the 
characteristic second and/or third phases of viral decay (190). The improved SVR with 
combination therapy suggests they act synergistically to achieve the initial clearance of 
virus. It may act by shortening the half life of infected cells in the presence of IFNα. 
 
Ribavirin appears to be pleotropic agent with many intrinsic mechanisms that can 
influence its overall antiviral properties. Understanding of the key mechanisms of action of 
ribavirin will help design better therapy for patients with HCV. 
 
 
1.7.2   Novel Treatment for CHC: 
 
Although combination therapy with PEG-IFN α and ribavirin has significantly improved 
SVR rates with sustained response rates of 54-56%, still a large number of patients do not 
have any lasting improvement with treatment. Furthermore, treatment is expensive, 
associated with a wide spectrum of side effects and complications and contraindicated in 
many patients due to co-morbidities, leading to a relatively small number of patients being 
offered treatment and a large number discontinuing treatment due to adverse events. 
 
For this reason there is continuing need for novel anti-HCV therapies to improve response 
rates and reduce adverse effects. A number of new treatments for HCV are undergoing 
clinical trials (Table 1). HCV is highly mutable and direct antiviral strategies are associated 
with drug resistance suggesting that future regimens will continue to include 
immunomodulatory drugs. Better understanding of the immunological factors determining 
successful versus failed anti-HCV treatment would aid identifying candidates for new HCV 
treatments directed at the immune response. 
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BILN 2061 or ciluprevir  II 
VX-950 or telaprevir  III 
SCH 503034 or bocepravir  II 
Nucleoside polymerase inhibitors 
NM283 or valopicitabine  IIb 
R1626 II 
R7128 I 
Non-nucleoside polymerase inhibitors 




Cyclophilin B inhibitors 
DEBIO-025 II 
α glucosidase inhibitors 
Celgosivir or MX-3253  II 
Oligonucleotides   





ANA245 or isatorabine  I 
Resiquimod II 
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1.7.2.1   New Interferon Molecules: 
New forms of IFNα are being developed with more potent antiviral effects and possibly 
more potent immunomodulatory effects as well as enhanced bioavailability and better 
pharmokinetics with less peaks and troughs. 
 
Albuferon (albumin-linked IFNa) is a recombinant single polypeptide molecule, coded by 
the fusion of the human serum albumin (HAS) and the IFN-α genes. It has been shown to 
induce a significant biphasic decline in HCV replication with benefits of less frequent 
dosing(213). It is well tolerated with comparible efficacy to current treatment standard of 
care and is now in phase 3 trials. 
 
Consensus interferon (CIFN) is a recombinant type 1 IFN containing 166 amino acids. 
CIFN was derived by scanning the sequences of several natural alpha IFNs and assigning 
the most frequently observed amino acid at each corresponding position. Therapy with 
CIFN together with ribavirin seems to have promising results especially in difficult patients 
with cirrhosis(214) and non-responders to previous therapies(215). 
 
Omega IFN is a new type-1 interferon that has been designed for continuous delivery by 
an implantable device. 
 
IFN lambda (IL-28A, B, IL-29) is a type III IFN that binds to a unique receptor. In phase Ib 
trials it has been shown to be well tolerated with significant antiviral activity(216) 
 
1.5.2.2   Modified or improved forms of ribavirin: 
The main dose limiting side effect of ribavirin is haemolytic anaemia and alternatives to 
ribavirin with fewer side effects are under development. 
 
IMPDH inhibitors are being evaluated as antiviral drugs, since this enzyme catalyzes an 
essential step in the biosynthesis of guanine nucleotides. However, they have so far 
proven disappointing with none or minimal direct antiviral efficacy. 
 
A prodrug of ribavirin, viramidine (taribavarin), becomes activated in the liver (limiting 
exposure to erythrocytes) and has demonstrated significant antiviral activities and 
erythrocyte-sparing properties. However, SVR rates have been lower when compared to 
ribavirin(217). 
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1.5.2.3   Specifically Targeted Antiviral Therapy (STAT-C): 
With an improved understanding of the molecular structure of the HCV, its component 
proteins, the various phases of the replication cycle of the virus and the new culture 
methods and animal models for HCV, specific small molecules, inhibitors of the viral 
enzymes have been developed, so called STAT-C (specifically targeted antiviral therapy; 
table 2).  
 
The HCV virus exists as quasi-species in nature, with high replication rate in vivo and long 
duration of disease. Therefore, drug resistant mutants may already pre-exist in HCV-
infected patients. These new inhibitors that target directly the enzymes entailed in HCV 
replication are likely to prompt emergence of drug-resistant strains and this is a major 
hurdle to overcome with these new agents. Combination therapy has been shown to be 
more effective and less prone to resistance development than monotherapy, as seen in 
HIV. 
 
Table 2  STAT-C agents in development for HCV 
 
STAT-C Agents  Mechanism  Phase of Study 
 
GS9132  Protease inhibitor Failed (renal toxicity) 
BILN 2061  Protease inhibitor Failed (cardiac toxicity) 
MK7009  Protease inhibitor Phase 1 
BI12202  Protease inhibitor Phase 1 
ITMN-191 (R7227)  Protease inhibitor Phase 1 
TMC435350  Protease inhibitor Phase 2 
Telaprevir (VX-950) Protease inhibitor Phase 3 
Boceprevir (SCH-
503034) 
Protease inhibitor Phase 3 
Valopicitabine 
(NM283) 
NucPolymerase  Failed (gastrointestinal 
effects) 
MK-0608  NucPolymerase  Preclinical 
R7128  NucPolymerase  Phase 1 
R-1626  NucPolymerase  Phase 2 
HCV-796  NNPoylmerase  Failed (hepatotoxicity) 
GS-9190  NNPolymerase  Phase 1 
VCH-759  NNPolymerase  Phase 1 
NIM811  Cyclophilin 
inhibitor 
Phase 1 







    63  Inhibition of translation: 
 
-  Protease Inhibitors – (NS3-4A Serine) 
NS3/4A protease is an attractive target because it plays a part in viral replication(218) and 
provokes abrogation of induction of the interferon and cytokine pathways by cleavage of 
the adaptor molecule TRIF and CARDIF/MAVS. This process favours viral propagation 
and presumably, chronicity in HCV infection. 
Two classes of inhibitor have been developed: (1) peptidomimetic and (2) non-peptidic 
molecules and several have been evaluated in clinical trials: BILN 2061 (Ciluprevir) was 
one of the first but trials were halted due to cardiac toxicity in animal models(219), 
however, these results provided ‘proof of concept’ for the efficacy of targeting the 
NS3/NS4 potease. Further trials have shown that monotherapy with these agents is not 
possible due to development of resisiatance and INFα and ribavirin are required to 
enhance antiviral activity and reduce the frequency of resistance.
 
 
The leading candidate at present is telaprevir (VX-950), a reversible, selective, and 
specific peptidomimetic inhibitor of the NS3/NS4a protease, which is orally 
bioavailable(220).
 Combination of telaprevir with IFNα2a has shown enhanced efficacy 
with a significant reduction in HCV RNA(221) and triple therapy with ribavirin augments 
the response further with less resistance developing (222). Two phase II studies – 
PROVE 1 and 2 – have shown safety and efficacy of the triple regimen in patients with 
untreated chronic HCV (genotype 1)(223;224) and the PROVE 3 study is now looking at 
triple therapy in non-responders to previous treatment . 
 
 
A second protease inhibitor, boceprevir (SGH 503034), which is peptidomimetic, has 
shown efficacy in combination with pegylated IFNα in patients with genotype 1 infection 
that were previous non-responders to conventional treatment (RESPOND-1 study)(225)
 
and in genotype 1 treatment naïve patients the SVR rate was almost doubled when used 
in combination with IFNα and ribavirin (SPRINT-1 study)(226). Phase III trials are now 
underway in non-responders and treatment naïve patients (RESPOND II and SPRINTII 
respectively). 
 
Others in phase III trials at present include ITMN-191(227), MK-7009, BI2202 and  
TMC435350(228). 
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1. Direct inhibition of RNA-dependant RNA polymerase 
The three dimensional crystal structure of HCV RNA dependant RNA polymerase has 
been solved. This enzyme is essential for viral replication and no host equivalent exists, 
making it an attractive target. Two structurally distinct classes of inhibitors with different 
modes of action have been reported: (1) nucleoside analogues which generally target the 
polymerase active site in a competitive manner and typically show broad-spectrum 
activity; and (2) non-nucleoside analogue molecules which have much greater specificity 
and act either by direct interference with the active site or by binding to an allosteric site 
and preventing the initiation process. Many of these compounds have neen discontinued 
due bone marrow and GI toxicity, lack of efficacy or the development of resistance.  
 
- Nucleoside polymerase Inhibitors 
NM-283 (valopicitabine) is the oral prodrug of the nucleoside analogue 2’-C 
methylcytidine, which undergoes intracellular phosphorylation to form the active inhibitor. 
It was found to be a promising polymerase inhibitor in clinical trials with reasonable 
antiviral activity but high side effect profile halted drug development (229). 
 
Others include R1626(230), a pro-drug of the nucleoside analogue R1479, which is a 
potent inhibitor of HCV replication in vitro and has shown encouraging results in a phase II 
study. An oral nucleoside analogue, R7128(231;232), a pro drug of PSI-6130 has shown 
encouraging results in efficacy with the absence of additional toxic effects. 
 
Viral resistance is a major issue with these molecules and enforces the need to combine 
these new treatments with ‘old therapies’ in order to control the emergence of resistant 
strains. 
 
- Non-nucleoside Inhibitors (NNIs) 
The non-nucleoside polymerase inhibitors are drugs which bind allosterically on the 
enzyme surface near to its active site to disturb its structure and function. HCV-796, the 
first NNI of the HCV polymerase, showed significant HCV antiviral activity against multiple 
genotypes(233). However, the development of this drug was discontinued due to findings 
in a phase II study showing hepatotoxicity. GS-9190 is a novel non-nucleoside HCV NS5b 
polymerase inhibitor with potent antiviral activity (234).  
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- cyclophilin inhibitor:  
Cyclophilin B promotes RNA binding activity of the HCV RNA-dependent RNA polymerase 
(NS5B) in vitro. Early observations with cyclosporine, an immunosuppressive drug with 
CYP-inhibiting activity, showed anti-HCV activity in vitro. Non-immunosuppressive 
cyclophilin inhibitors have subsequently been developed, including DEBIO-025(235;236) 
whose clinical profile was encouraging in phase I trials. NIM811, another non-
immunosuppressive cyclophilin antagonist, has also entered early-phase clinical studies 
with encouraging preclinical studies.
 
 
Inhibition of protein synthesis: 
- IRES Inhibitors – 
Translation of HCV RNA is initiated by internal entry of ribosomes into the IRES. IRES 
inhibitors include small interfering RNAs (siRNA), anti-sense oligonucleotides and 
ribozymes. 
 
Small interfering RNAs (siRNA) – RNA interference is a natural process used by all 
eukaryotic cells to recognize and destroy abnormal or exogenous RNA. In mammalian 
cells, introduction of double stranded RNA (dsRNA) activates the interferon pathway and 
induces non-specific degradation of RNA, inhibition of mRNA translation and cell death. 
Induction of RNA interference process in mammalian cells is possible by small dsRNA 
(called siRNA) and this strategy is being exploited as antiviral therapy. The siRNA drug 




Anti-sense oligonucleotides are short synthetic nucleotide sequences that bind an RNA 
target forming RNA–RNA (antisense RNA) or RNA–DNA (antisense DNA) hybrids which 
result in inhibition of RNA translation and/or replication of viral proteins. ISIS 14803 is a 
20-base antisense oligonucleotide that is complementary to the HCV translation initiation 
region within the IRES. Promising results were seen in early phase II trials but subsequent 
aminotransferase flares and poor viral efficacy led to discontinuation of further 
studies(239). A phase II study of another compound, AV-4065, is underway. 
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where they cleave specific HCV sequences. Unfortunately studies with the ribozyme RPI-
13919 (heptazyme), designed to cleave the HCV IRES from the 5’-UTR region of the HCV 
genome were halted because of toxicity in primates(240). 
 
One of the major issues that will determine the success of these drugs is the efficient 
delivery of the synthetic polymers to the appropriate cells in vivo. 
 
 
1.7.2.4 Immune  Modulators - Toll Like Receptor Agonists 
 
The experience with IFN-based therapies has demonstrated that HCV infection can be 
eradicated by agents that stimulate the hosts innate and adaptive immunity. In 
hepatocytes, there are two major pathways of host defence: one is the retinoic acid-
inducible gene I (RIG-I) and the other is the Toll-like receptor (TLR) (chapter 1.5.1.3).  
 
TLR agonists are known to selectively induce the interferon system through activation of 
TLRs, a group of pattern–recognition receptors that play a crucial role in antigen 
recognition. The induction a range of different type 1 interferon subtypes triggers the 
activation of intracellular antiviral responses and a TH1-adaptive immune response. TLR 
3, 7, 8 and 9 are known to be responsible for detection of viral molecules. 
 
Stimulation of the appropriate TLRs by artificial ligands may therefore help restore the 
innate and adaptive immune functions that are dysfunctional in hepatitis C infected hosts 
and help to eradicate HCV infection. 
 
Recently TLR7 and TLR9 agonists have been shown to have clinical efficacy against HCV 
and both are highly expressed on plasmacytoid dendritic cells which are known secrete 
high amounts of endogenous IFNα. 
 
TLR-7 Agonists: 
The natural ligands for TLR7 are patterns within viral single stranded RNAs but several 
synthetic compounds that are structurally related to nucleic acids are also recognised. 
These include imidazoquinolines, loxoribine and bropirimine.  TLR-7 stimulation leads to 
activation of the transcription factor NF-kB through a MyD88 dependant signaling pathway 
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cytokines, especially IFNα. 
 
Isatoribine (ANA245; Anadys Pharmaceuticals) is a guanine nucleoside analogue whose 
immunostimulatory activity depends on its agonistic activity on TLR-7. It has been shown 
to induce a modest reduction in viral replication in some HCV infected patients with 
evidence of immune modulation as shown by upregulation of the interferon-response 
gene, 2’5’OAS and increased production of IFNα, IP10 and neopterin (a marker of 
immune activation produced by activated macrophages) (241). Following these 
encouraging results an oral prodrug ANA975, was being investigated(242). The prodrug 
enables convenient oral dosing while avoiding the GI symptoms associated with the oral 
route. However, ongoing clinical trials with ANA245 and ANA975 were suspended in 2007 
for safety reasons because of information obtained from preclinical toxicology studies 
consistent with intense immune stimulation in animals even at dose levels where desired 
immunostimulatory effects were not measurable(243).  
Clinical investigation of the TLR7 mechanism for the treatment of chronic hepatitis C has 
now resumed with investigation of ANA773, an orally administered prodrug of a novel 
TLR7-specific agonist. Results from pre-clinical pharmacology studies have shown that 
ANA773 can elicit desired immune responses and that the profile of response can be 
modulated by both dose and schedule of administration. Results of recently completed 13-
week GLP toxicology studies have shown that with every-other-day dosing of ANA773, 
immune stimulation of a magnitude believed to confer therapeutic potential can be 
achieved without adverse toxicology findings. The immune stimulation observed with 
every-other-day dosing of ANA773 in monkeys included induction of IFNα and interferon 
dependent responses at levels that are sustained over 13 weeks of dosing. Phase 1 trials 
have shown a dose related IFN-dependant response and was typically well tolerated in 
healthy volunteers and trials in HCV patients are now underway (244).  
Resiquimod, a TLR 7 and 8 agonist has been assessed in CHC patients and shown some 
reduction in HCV RNA levels(245) but was also associated with intense adverse events 
because of IFNα induction.  
 
SM-360320 (9-benzyl-8-hydroxy-2-(2-methoxyethoxy)adenine) is a specific TLR-7 agonist 
and a potent inducer of INFα in vivo and in vitro. Further studies have shown it also to be 
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was used in this study to further explore its effects in HCV. 
 
Results from clinical trials have indicated that TLR7 agonists have poor tolerability when 
administered orally compared with either topical or intravenous administration. Adverse 
events with the oral administration often include significant GI symptoms by virtue of the 
large amount of immune tissue associated with the gut wall. Doses sufficient to achieve 
effective systemic concentrations lead to side effects including nausea, sickness, 
gastroenteritis and localized systemic effects.  
 
TLR-9 Agonists: 
TLR9 is expressed in human B cells and pDCs and signals through a MyD88-dependant 
signaling pathway to activate NF-kB leading to the activation of DCs and secretion of INFα 
and pro-inflammatory cytokines, IL-12 and TNFα. TLR-9 recognizes unmethylated 
cytidine-phosphate-guanosine (CpG) rich sequences which are present frequently in 
bacterial and viral DNA which can be mimicked by synthetic CpG oligonucleotides (CpG-
ODNs) which contain unmethylated CpG dinucleotides in particular sequence contexts 
(CpG motifs). These CpG motifs are present at a 20-fold greater frequency in bacterial 
DNA compared to mammalian DNA. They have been used for therapeutic purposes to 
stimulate TLR-9.  
 
Different classes or subtypes of CpG-ODN have been described and the 
immunostimulatory activity of the CpG-ODN is dependant on the sequences surrounding 
the CpG dinucleotide as well as the secondary structure formed by the ODN(247). 
Type A ODNs (2216) have been shown to activate pDCs to mature, upregulate 
costimulatory molecules and to secrete type-1 interferons, but they are not potent 
activators of B cells. These CpG-ODNs contain a central palindromic sequences allowing 
for the potential of secondary structure formation. 
Type B CpG-ODNs (2006) contain 3 human CpG motifs and are potent activators of B 
cells mediating cytokine and immunoglobulin secretion. These ODNs do not strongly 
activate pDCs and are therefore not associated with high levels of IFNα secretion but they 
still promote survival and maturation of pDCs. They lack the secondary-structure forming 
palindromic sequences and rather it is the dinucleotide flanking purines and pyrimidines 
that influence the immunostimulatory activity. 
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proliferation of B cells and high induction of pDCs inducing IFNα secretion as well as 
TNFα and IL12. 
 
CPG10101, (Actilon
TM, COLEY Pharmaceutical Group, USA) is an investigational, class C 
synthetic ODN that contains immunostimulatory CpG motifs optimized for activation of 
human TLR9 and is being developed as an antiviral and enhancer drug for treatment of 
chronic HCV infection. It been shown to activate and mature B cells and pDCs in both 
healthy volunteers and HCV patients, and to stimulate production of cytokines, including 
those with known antiviral activity such as IFNα (248;249).
 
In a phase 1B trial it was found to induce moderate HCV RNA load reductions in infected 
patients with elevation of IFNα and β levels(250). In relapsed and non-responder patients 
to previous ribavirin and Interferon, reductions in HCV-RNA were significantly greater in 
the CPG combined treatment group(251).
 
 
Clinical studies with Actilon have however been ceased at present, suggesting possible 
exhaustion of limitation in endogenous IFNα producing capacity in CHC (251). 
 
The therapeutic application of TLR agonists should be evaluated with some caution 
however because they may have multiple detrimental effects. Excessive production or 
imbalanced amounts of TLR agonist induced cytokines may favour the development of 
non-infectious or autoimmune diseases. 
 
Other Immunomodulatory Drugs 
Several interleukins have been investigated, with encouraging results. Interleukin 10, an 
anti-inflammatory drug, given to patients with no response to IFN can reduce 
aminotransferase levels and improve liver histological findings(252) and interleukin 29 has 
shown promise in animal work. Other immunomodulators include Histamine 
dihydrochloride which inhibits phagocyte-derived oxidative stress and inflammation and 
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Attempts are being made to develop both prophylactic and therapeutic vaccines capable 
of stimulating functional CD4 and CD8 T-cell responses in chronic hepatitis C patients. 
Development of such vaccines has so far been unsuccessful predominately because of 
the rapid evolution of the virus which continuously generates mutants that escape immune 
surveillance. All new agents will be heavily influenced by their ability to inhibit all viral 
variants and prevent emergence of escape mutants 
 
Preclinical and early human studies indicate that therapeutic vaccines using various forms 
of HCV recombinant polypeptide together with various adjuvants have been investigated 
(253). Some genes have been found to be more mutable than others. The HCV envelope 
proteins, E1 and E2 have been shown to have the best potential for serving as efficacious 
vaccines. When administered with an adjuvant, these recombinant antigens have been 
found to evoke robust anti-envelope antibody and T-cell responses, giving chimpanzees 
partial protection from becoming chronically infected. 
 
Vaccines designed to augment the immune response to HCV are in development.  
INO-101, a proprietary E1 protein is being tested with alum adjuvant as a therapeutic 
vaccine and shown to enhance both humoral and cellular immune responses. It did not 
affect viral load but was able to slow disease progression (254). IC-41 is a proprietary 
combination vaccine that has been shown to increase T-cell responses and reduce viral 
load by an average of 60% in hepatitis C in those unresponsive to previous treatments 
(255). 
 
Another vaccination strategy makes use of attenuated or defective viral vectors 
expressing one or more of the HCV genes for priming humoral or cellular immune 
responses. Adenovirus(256), vaccinia virus (257) and canarypox derived vectors are all 
used for this purpose. 
 
T-cell vaccine based on the HLA and HCV genotype cross-reactivity (258) and dendritic 
cell-based vaccines(259) are novel and very promising approaches for therapeutic 
immunization in patients with CHC. In particular, dendritic cell vaccination is able to elicit 
potent activation of antigen-specific cellular immunity against HCV proteins. In recent 
studies, immunization of mice with beads coated with NS5 protein and anti-DEC205-
    71  endocytosis receptor of dendritic cell was able to induce a significant cellular immune 
response(260;261).  
Preventative vaccination 
A phase 1 trial of a candidate vaccine demonstrated safety and significant antibody and 
lymphocyte proliferation response in healthy volunteers(262). A T cell HCV vaccine was 
protective against acute infection in chimpanzees(263). A third vaccine, based on 
recombinant HCV-like particles produced in insect cells, also controlled HCV challenge in 
a chimpanzee model(264). 
 
Hepatitis C immunoglobulin 
Unlike hepatitis B, no effective immunoglobulin prophylaxis exists for hepatitis C. Passive 
immunization with hyper-immune hepatitis C immunoglubulins (HCIg) has been shown to 
decrease HCV replication and reduce aminotransferase levels in chimpanzees with 
CHC(265;266). Several experimental immunoglobulin preparations are in various stages 
of testing with current development focused in liver transplantation. Civacir is an antibody 
preparation specifically targeted to HCV. It is currently in clinical trials for the prevention of 
HCV infection in transplanted livers(267;268). HepeX-c is a HCV specific monoclonal 
antibody preparation in early-phase clinical trial for the prevention of re-infection in HCV-
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2.1.1  General Consumables 
Standard tissue culture plasticware, including flat-bottomed 6, 12, 24, 48 and 96 well  
tissue plates and 15 and 50ml Falcon tubes were from Corning (Dorset, UK) and were  
chosen for low endotoxin levels. U botton and V-bottom plates 96 well plates were from  
Millipore (Watford, UK). 
 
2.1.2  Buffers and Solutions 
Stock solutions: 
Sterile pyrogen-free water  Pharmacy, Southampton General 
Hospital, Southampton, UK 
Rothwell Park Memorial Institute (RPMI) [1640]  
medium,without L-glutamine and phenol red    Invitrogen, Paisley, Scotland,  
10x Phosphate Buffered Saline (PBS), sterile.    Gibco, Invitrogen  
Bovine serum albumin (BSA)        Miltenyi Biotec, Bisley, UK 
0.5M ethylenediaminetetraacetic acid (EDTA)  Invitrogen, Paisley, Scotland 
Foetal calf serum (FCS), low endotoxin   Hyclone, Perbio Science UK Ltd, 
Tattenhall, UK. Heat inactivated at 
56
0C, 30 mins. 
Human AB serum (HAB)  Sigma Chemical Company Ltd, Poole, 
UK. Heat inactivated at 56
0C, 30 mins 
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Sterile phosphate buffered saline (PBS):  Prepared from 10x PBS stock diluted 1:10 
with sterile pyrogen free water 
Running Buffer        1x PBS / 2mM EDTA / 0.5% BSA 
Rinsing Buffer         1x PBS / 2mM EDTA 
Culture Medium  RPMI 1640 supplemented with 10% FCS, in 
2mM L-Glutamine, 80IU/ml Penicillin, 80IU/ml 
Streptomycin (Sigma, Poole, UK) 
FACS wash           1x PBS, 1%BSA, 0.1% sodium azide 
FACS block  FACS wash containing 100ug/ml 
Chromepure human IgG (Jackson 
Immunoreserch, Stratech Scientific Ltd, 
Suffolk, UK)  
 
2.1.3  Cytokines and cell culture additives  
Recombinant human (rh)GM-CSF    R & D Systems, Abingdon, UK  
(100 000IU/ml) 
Recombinant human (rh) IL-4      R & D Systems, Abingdon, UK (1ug/ml) 
Stock solutions of the cytokines were prepared by dissolving the lyophilized powder in 
sterile PBS containing 0.1% Human AB serum and filter-sterilised through 0.2µm syringe 
filters. Solutions were aliquoted and frozen. 
 
2.1.4  Antibodies:    
Monoclonal antibodies used for flow cytometric analysis of cell surface markers are listed 
below. The antibodies were directly conjugated with fluorescein isothiocyanate (FITC), 




    74  Isotype controls    Mouse IgG2a FITC 
    Mouse IgG1 APC 
    Mouse IgG1 FITC     
    Mouse IgG1 PE     
Cell surface markers    Mouse anti-human HLA-DR FITC 
    Mouse anti-human HLA CIass I APC 
Mouse anti-human CD40 APC 
Mouse anti-human CD86 APC 
Mouse anti-human CD83 APC 
Mouse anti-human CD4 FITC      
    Mouse anti-human CD69 FITC   
Mouse anti-human CD56 APC    (Miltenyi Biotech, UK) 
Mouse anti-human CD3 PE         
Intra-cellular Cytokines  Mouse anti-human IFN-gamma FITC 
   
2.1.5  Stimuli 
Tetanus  Toxoid    Calbiochem,  USA 
Lipopolysaccharride    Sigma,  Poole,  UK 
Loxoribine     InvivoGen,  San  Diego,  USA 
rOv-ASP-1        New York blood centre, NY, USA 
ODN  M362     InvivoGen,  San  Diego,  USA 
Ribavirin        Provided by iQur Ltd, Southampton, UK 
CD40L- transfected CHO cells  Gift from Professor M. Glennie (Tenovus, 
Southampton, UK)  
TLR7 agonist, SM360320  Pfizer, Sandwich, UK 




    75  2.1.6  Cell Purification / Isolation  
CD14 Microbeads         Miltenyi Biotech, Surrey, UK   
BDCA-4 dendritic cell isolation kit    Miltenyi Biotech, Surrey, UK   
Naïve CD4 T cell isolation kit     Miltenyi Biotech, Surrey, UK 
Pan T cell isolation kit       Miltenyi Biotech, Surrey, UK 
 
2.1.7   Identification and Classification of Subjects: 
2.1.7.1   Recruitment of Subjects 
Ethical approval for this study was obtained from Southampton and S.W Hants Joint 
Research Committee (ref: 05/Q1703/45 ). 
Subjects falling into the following groups were investigated: 
1.  Normal, uninfected volunteers 
Healthy controls were identified from volunteers within the research unit and medical 
school. Volunteers were deemed to be normal and uninfected with HCV if they did not 
present with any current or previous risk factors for HCV infection. They were not 
tested for evidence of HCV or any other blood-borne virus. Written, informed consent 
was taken. Included in this group were patients with hereditary haemochromatosis for 
whom regular phlebotomy is part of their treatment, all of whom were screened for 
blood-borne viruses.  
2.  Subjects with CHC infection 
Chronic hepatitis C was diagnosed on the basis of detection of HCV viraemia by PCR 
testing (Cobas Amplicor HCV Monitor test, Roche Molecular Systems, NJ, USA). 
Subjects with CHC were sourced from the pool of past and present patients attending 
the Hepatology Clinics at the Southampton University Hospitals NHS Trust and Royal 
Bournemouth and Christchurch NHS Trust. As part of the routine screening of patients 
with suspected CHC, most patients had already undergone a liver biopsy and PCR-
based tests to determine the presence of HCV RNA in the serum and the HCV 
genotype. The subjects with ongoing HCV-infection had either 
•  Not yet received anti-HCV treatment, or 
•  Had failed to respond to prior treatment which had ceased at least 6 months 
before recruitment in the study. 
All subjects gave written, informed consent. 
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6mls and 90ml of blood was collected into vacutainers attached to a butterfly cannula 
containing sodium citrate and EDTA respectively in an appropriate clinical area using 
asceptic technique. Blood tubes were labeled for identification and transported to either 
the containment level 3 suite (if HCV infected) or to the containment level 2 laboratory (for 
NHDs) in a sealed polythene bag.  
 
2.1.8   Gathering Clinical Information 
Clinical information on each patient or volunteer was gathered by direct questioning. 
Additional details on the CHC patients were obtained from medical records and 
computerized pathology record system. Data collected is shown in table 3. The patients all 
gave prior consent to examination of their records for information relevant to the study. 
The information gathered on the CHC patients was entered into a database for analysis. 
 
Table 3: Clinical information collected from patients 
           
        Healthy Volunteers 
 
         Hepatitis C patients 
                     Age                       Age 
                     Sex                       Sex 
                  Ethnicity                     Ethnicity 
              Route of infection 
           Alcohol consumption 
                      ALT 
         Genotype and Viral Load 
           Liver Biopsy IPA score 
     Concurrent medical conditions 
       Previous treatment for HCV 
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All centrifugations were performed in a Mistral 3000i refrigerated centrifuge (Jepson 
Bolton Laboratory Equipment, Watford, UK) unless otherwise stated. All incubations at 37
0 
C, 5% CO2 were performed in a Heraeus 6000 series incubator (Kendro Laboratory, 
Stevenage, UK). 
 
2.2.1  Cell Purification: 
2.2.1.1   Isolation of Peripheral Blood Mononuclear Cells (PBMC): 
Freshly drawn EDTA-treated blood was diluted 1:1 with RPMI 1640 (no additives), pre-
equilibrated to room temperature. In sterile 50ml falcon tubes, 40mls of diluted blood was 
carefully overlayed onto 10mls Lymphoprep (Robbins Scientific, Solihull, UK) and 
centrifuged at 1550rpm for 20-25 minutes at room temperature, with the brake off. PBMCs 
were recovered from the interface between the lymphoprep and serum using a plastic 
Pasteur pipette, transferred into a 50ml falcon tube and diluted with RPMI. Cells were 
spun at 1400rpm for 10 minutes at room temperature. The cell pellet was resuspended in 
sterile running buffer (see buffers and solutions) and spun at 1100rpm for 10 minutes at 
4
0C, to remove platelets. Cells were resuspended in 10mls of sterile running buffer and a 
live cell count performed using trypan blue in PBS and a cell counter. The required 
number of cells were removed, spun at 4
0C and the pellet resuspended into culture 
medium at the required density. If they were to be stored for future use, they were 
cryopreserved in 90% FCS and 10% sterile culture grade dimethyl sulfoxide (DMSO, 
HybriMAX, Sigma). 
 
2.2.1.2  Isolation of Monocytes from PBMCs: 
Freshly isolated PBMCs (section 2.2.1.1) were resuspended in cold running buffer (80µl / 
1.0 x 10
7 PBMCs). CD14 Microbeads (20 μl / 1 x 10
7 PBMCs), were added and incubated 
for 15 minutes at 4-8 
0C. The cells were then washed with running buffer and centrifuged 
at 1250rpm for 10 minutes at 4 
0C. Up to 10
8 cells were resuspended in 500ul of running 
buffer and loaded onto the Auto MACS (Miltenyi Biotech, Surrey, Uk). The separation 
programme, POSSEL, was selected and the positive fraction collected from port ‘pos1’. 
The positive fraction was resuspended in running buffer to 10mls and a live cell count 
performed using trypan blue exclusion. 
    78  2.2.1.3   Isolation of Plasmacytoid Dendritic cells from PBMCs: 
Freshly isolated PBMCs (2.2.1.1) were washed and pelleted. The pellet was resuspended 
in cold running buffer (300μl / 10
8 PBMCs). 100µl of FcR Blocking reagent was added per 
10
8 PBMCs, followed by 100μl of anti-BDCA-4 Microbeads per 10
8 PBMCs. This mixture 
was incubated for 15 minutes at 6-12 
0C. The cells were then washed in running buffer, 
spun at 1250rpm and resuspended in 500µl cold running buffer per 10
8 cells. The cells 
were loaded onto the AutoMACS (Miltenyi Biotech) and the separation programme, 
POSSEL was selected. The positive fraction was collected at port ‘pos2’. A live cell count 
was performed using tryphan blue exclusion and cells spun and resuspended in culture 
medium at the required density. 
 
2.2.1.4   Isolation of T Cells from PBMCs 
Naïve CD4 T cell Isolation: 
Freshly isolated PBMCs (2.2.1.1) were washed and pelleted. Cells were resuspended in 
running buffer. Biotin-antibody was added (10µl /10
7 cells) and left in fridge for 10 minutes. 
Running buffer was then added (30µl / 10
7 cells) followed anti-biotin beads (20µl / 10
7 
cells) and left in the fridge for a further 15 minutes. Cells were washed with running buffer, 
spun at 1200rpm and resuspended in 500µl of running buffer per 10
7 cells. The cells were 
loaded onto the AutoMACs (Miltenyi Biotech) and the separation programme, DEPLETE 
was selected. The negative fraction was collected from port ‘neg1’ for naïve CD4 cells. A 
live cell count was taken using trypan blue exclusion and cells spun and resuspended in 
culture medium at 2 x 10
6 cells/ml. 
Pan T cell Isolation: 
Freshly isolated PBMCs (2.2.1.1) were washed and pelleted. Cells were resuspended in  
running buffer (40µl / 10
7 cells). Biotin-antibody was added (10µl / 10
7 cells) and left in 
fridge for 10 minutes. Running buffer was then added (30µl / 10
7 cells) followed anti-biotin 
beads (20µl / 10
7 cells) and left in the fridge for a further 15 minutes. Cells were washed 
with running buffer, spun at 1200rpm and resuspended in 500ul of running buffer per 10
7 
cells. The cells were loaded onto the AutoMACs (Miltenyi Biotech) and the separation 
programme, DEPLETE was selected. The negative fraction was collected from port ‘neg1’ 
for enriched T cells. A cell count was taken and cells spun and resuspended in culture 
medium at 2 x 10
6 cells/ml. 
    79  2.2.2  Monoctye-Derived Dendritic Cell Cultures: 
Purified monocytes (2.2.1.2) were resuspended in culture medium at 1 x 10
6 cells/ml in 
sterile flat bottomed, 6-well tissue culture plates at 3mls per well. The culture medium was 
supplemented with 50ng/ml rhGM-CSF and 1000IU/ml rhIL4. Cells were incubated at 
37
0C and 5% CO2. After 2 days the cultures were supplied with 0.5mls of fresh medium 
containing 50ng/ml GM-CSF and 1000IU/ml IL4 per well and this was repeated after 
another 3 days, when MoDCs were harvested to be used as immature MoDCs. 
    
2.2.3   Stimulation of Mo-DCs and pDCs 
2.2.3.1   Stimulation of MoDCs: 
Day 5 immature MoDCs (section 2.2.2) were harvested, washed and resuspended in 
culture medium supplemented with IL4 and GM-CSF (1 x 10
5 cells/ml). Cells were plated 
into a 24-well, flat bottomed tissue culture plate (2mls / well). MoDCs were cultured with 
medium alone or in a 1:1 ratio with CD40 ligand-transfected Chinese hamster ovary cells 
(hCD40L-CHO) with or without different concentrations of ribavirin (4, 20, 100 and 
500µM). As known stimuli of maturation, comparison was made with the TLR4 ligand 
lipopolysaccharide (100 µg/ml) and the TLR7/8 agonist, loxoribine (250μM). For the 
Helminth protein study (chapter 4), Mo-DCs were exposed to rOv-ASP at concentration of 
5ug/ml alone or in a 1:1 ratio with a CD40L-transfected cell line. Cells were incubated at 
37
0C in 5% CO2.
 
 
2.2.3.2    Stimulation of pDCs 
Freshly isolated pDCs were plated into 96 well (200µl /well) cell culture plates at a 
concentration of 2 x 10
4 / ml. pDCs were cultured under the following conditions; (1) 
medium alone (2) in a 1:1 ratio with hCD40L-CHO cells, (3) with 1µM M362, a TLR9 
agonist or (4) 250µM loxoribine, a TLR7 agonist each with or without different 
concentrations of ribavirin (4, 20, 100 and 500µM). Cells were incubated at 37





    80  2.2.4  Immunostaining Techniques for Flow Cytometry 
2.2.4.1   Staining MoDCs and pDCs for Cell Surface Markers: 
MoDCs and pDCs cultured for 48 and 24 hours respectively in the presence or absence of 
additional stimuli (2.2.3.1 and 2.2.3.2), were harvested to investigate their phenotype. 
Each treatment was harvested into a 15ml falcon tube and spun in the centrifuge at 
1200rpm at 4
0C for 10 minutes. The cells were resusupended in FACS block (2.1.2), 
allowing 50µl for each staining condition to be carried out. 50μl of the blocked cells were 
transferred into the required number of wells on a v-bottom 96 well plate and incubated on 
ice for 30 minutes. Antibodies were diluted with FACS block to optimal concentrations for 
flow cytometry and 50ul of appropriate antibody added to 50ul of block already in the well. 
Cells were incubated on ice for 30 minutes. The cells were washed 2 times in 200μl FACS 
wash and spun at 1200rpm at 4 c for 7 minutes. The supernatant was removed and cells 
resuspended in 150μl FACS wash (2.1.2) with 50ul 4% paraformaldehyde (PFA) to fix the 
cells in order to retain the fluorescence. The cells were transferred to micronic tubes and 
placed on ice in the dark pending analysis by FACS. 
 
2.2.4.2   2 Colour Flow cytometric analysis of surface molecules: 
Fluorescently labeled cell suspensions were passed through a Fluorescence-Activated 
Cell Scanner (FACScalibur© FACS machine, B D Biosciences, Oxford, UK) and cell 
populations were analysed using Cell Quest
© Software (BD Biosciences) and WinMDI. 
Unlabelled cells were used to set the sensitivity of the fluorescence detectors to 
appropriate levels, such that on a histogram the peak of cells lay in the first decade of a 
four log scale. Singly-stained cells labeled with FITC were used to compensate the 
fluorescence signal in FL1. Cells stained with PE were used to compensate the 
fluorescence signal in FL2. This was done using the standard compensation circuits on 
the instrument. MoDCs and pDCs were typically detected using forward and side scatter 





    81  2.2.5  Identification of apoptotic cells and cell death by flow cytometry 
 
2.2.5.1   Immunostaining of apoptotic cells for flow cytometry: 
Apoptotic cells were determined by their ability to bind annexin V. Freshly isolated pDCs 
were plated into 96 well cell culture plates at a concentration of 2 x 10
4/ml in complete 
medium in the presence of M362 with and without ribavirin at different concentration 
(500uM, 100uM, 20uM and 4uM) for 24 hours.  
Cultured cells were harvested into 15ml Falcon tubes and centrifuged at 1200rpm for 10 
minutes. The supernatant was aspirated and each culture condition resuspended in 300μl 
cold PBS and divided into 3 wells of a v-bottomed 96 well plate. The cells were washed 
twice in cold PBS at 1200rpm, 4 c for 10 minutes and resuspended into 100μl of binding 
buffer (BD Biosciences, Oxford, UK). Annexin V-FITC (BD Biosciences) alone (5μl) was 
added to one well, PI (BD Biosciences) alone (5μl) to another well, and PI in combination 
with annexin V-FITC in the final well. Following incubation for 15minutes at room 
temperature in the dark, 100μl of binding buffer was added to the wells. Cells were 
transferred to micronic tubes and a further 50μl binding buffer added to them. Apoptotic 
cells were analysed within two hours using a FACScan cytometer. 
 
2.2.5.2   Flow cytometric identification of apoptotic cells: 
pDCS were detected on forward and side scatter and gated to eliminate cell debris. PI-
labeled cells were used to compensate the fluorescence signal in FL2 and cells stained 
with annexin V-FITC were used to compensate the fluorescence in FL1. Early apoptotic 
cells were identified as cells showing labeling for annexin-V but impermeable to PI. Late 
apoptotic cells were identified as cells showing labeling for annexin-V and permeable to 
PI. Live cells were identified as showing no labeling for annexin –V and impermeable to 








    82  2.2.6   Techniques for Cytokine Analysis
 
2.2.6.1   Enzyme Linked Immuno-Sorbent Assays 
Commercially available Human IFN-α multi-species Enzyme-Linked Immunosorbent 
Assay (ELISA) (PBL Biomedical Laboratories, NJ, US) was used to detect IFNα. 
ELISAs were performed at room temperature according to the supplier’s instructions using 
the solutions supplied with the kit. In brief, supernatant were harvested after 24 hours of 
culture. The supernatants were harvested and stored at -20 c until ELISAs were 
undertaken.  
A standard curve from 0 – 5000pg/ml was constructed by serial dilutions of the Human 
Interferon Alpha Solution in the dilution buffer. Assay samples were diluted to optimal 
concentrations with dilution buffer. 100μl of the assay samples or standards prepared 
above were placed in individual wells of the microtitre plate in duplicate (figure 13). The 
plate was sealed and incubated for one hour in a closed chamber at 24
0C. After the first 
incubation, the contents of the plate was emptied and the wells washed once only with the 
Final Wash Solution, filling each well when washing. After washing, the plate was inverted 
and blotted on lint-free absorbent paper and the plate tapped dry. 
The antibody solution was diluted with 2.9μl of antibody concentrate added to 1ml of 
dilution buffer for each strip of microtitre plate. 100µl of this was added to each well and 
the plate sealed and incubated for 1 hour at 24
0C and then emptied and washed 3 times 
as before. HRP Conjugate concentrate was diluted 1:80 and 100μl added to each well. 
The plate was covered and incubated for a further 1 hour at 24
0C and then emptied and 
washed four times as before. During the incubation, the TMB solution was warmed to 
24
0C and 100μl added to each well. The plate was covered and incubated for 15minutes 
at 24
0C in the dark to allow the colour reaction to develop. Before the negative on the 
standard curve began to change colour, the reaction was stopped by the addition of 100μl 
of ‘stop’ solution to each well. The optical density of each well was then determined using 
a microtiter plate reader set to 450nm with a reference filter at 570nm. 





    83  Figure 13:    Layout for IFNα ELISA: 
 
  1  2  3  4  5  6  7  8  9  10  11  12 
A  BK  BK             
B  BK  BK             
C  S1  S1             
D  S2  S2             
E  S3  S3             
F  S4  S4             
G  S5  S5             
H  S6  S6             
   




BK- Blank,  S1-6: Standards 
   
2.2.6.2   Multiplex Fluorescent Bead Immunoassay (FBI): 
 
The Bender MedSystems human Th1/Th2 10plex kit II (Bender MedSystems, Burlingame, 
CA) allows simultaneous measurement of up to 10 cytokines (TNFα, IFNγ, IL-1B, IL2, IL4, 
IL5, IL6, IL8, IL10, IL12p70). The kit was used at room temperature, according to the 







The contents (50mls) of the 10x assay buffer concentrate was added to 450mls of distilled 
water and stored at 2-8
0C. The standard was prepared by taking each vial of standard for 
the 10 cytokines and centrifuging briefly. Each standard was reconstituted with distilled 
water, according to the labels on the vial to give 400ng/ml stock. The vial was vortexed to 
ensure complete solubilisation and left to stand for 10 minutes.   
Tubes were labeled from 1 to 7. 100ul of assay buffer was added to each. To tube 1, 10μl 
of each of the 10 reconstituted standards was added and mixed well. 50μl from standard 1 
was transferred to tube 2 and mixed thoroughly. 50μl was transferred from standard 2 to 
tube 3 and this was continued until 50μl has been transferred from tube 6 to 7. The vials 
containing the fluorescent beads for all 10 cytokines were vortexed for 5 seconds each. 
To make sufficient bead mixture for a full 96-weel plate, 150μl of each of the 10 bead sets 
were transferred into one tube. The vials containing the biotin conjugates specific for all 10 
cytokines were vortexed briefly. 300μl of each of the 10 biotin conjugates was added to 
the same tube. The filter plate was prepared by wetting each well wit 50μl of assay buffer 
and then aspirating using a vacuum manifold, blotting the bottom of the plate after 
filtration. 
 
    84  12.5μl of the appropriate standard or blank was added as follows:  
A1 and A2: standard 1, B1: standard 2, C1: standard 3, D1: standard 4, E1: standard 5, 
F1: standard 6, G1: standard 7, H1: assay buffer as blank. 
12.5μl of each undiluted test supernatant was added from B2 onwards. To all wells, 12.5µl 
of 10-plex bead mixture and 25μl of biotin-conjugate mixture was added. The plate was 
covered with adhesive film, wrapped in foil to exclude light and incubated for 2 hours at 
room temperature on a microplate shaker at 500rpm. 
After incubation, the wells were emptied using a filtration manifold and 100μl of assay 
buffer was added to each well and then emptied using the vacuum manifold. This was 
repeated once more. 
The streptavidin-PE (SA-PE) was prepared by diluting with assay buffer at 1:31.35  
50μl of assay buffer was added to each well followed by 25μl SA-PE. The plate was 
covered, wrapped in foil and incubated for 1 hour at room temperature on the microplate 
shaker at 500rpm. The plate was emptied using the vacuum manifold and 100μl of assay 
buffer added to each well twice as before. 150μl of assay buffer was added to each well 
and using the multichannel pipette the beads in each well were resuspended and the 
contents of each of the wells were transferred into micronic tubes and a further 100μl 
assay buffer added to each micronic tube. Cytokines were identified using flow cytometry 
(FACSCalibur) and analysed using CellQuest software. 
 
2.2.7  Lymphocyte Proliferation Assays: 
2.2.7.1    Allogeneic Mixed Lymphocyte Reaction (MLR): 
Proliferation of T cells in response to stimulated MoDCs was compared using MLR in the 
helminth study (chapter 4). 
Day 5 immature MoDCs (2.2.2) were stimulated with rOv-ASP-1 at 5ug/ml for 48 hours. 
Allogeneic naïve CD4 T cells were isolated as previously described (2.2.1.4) and 
resuspended in complete medium (containing HAB serum) at a concentration of 2 x 
10
6/ml and plated into 96-well flat bottomed plates. MoDCs were serially diluted in 
complete medium (from 8 x 10(4)/ml – 625/ml) and 100μl added to 100μl of T cells 
resulting in ratio of DC to T cell of 1:5, 1:10, 1:20, 1:40, 1:80, 1:160, 1:320, 1:640 and 
1:1280 (in triplicate). Controls were also prepared containing T cells or DCs alone. 
    85  The cells were incubated at 37
0c for 5 days before 1μCi tritiated [methyl-H
3} thymidine 
(GE Healthcare) was added to each well. Following 18 hours incubation at 37
0c, 5% CO2, 
thymidine incorporation was stopped by washing the plate. Using a 96-well plate cell 
harvester the cells from each plate were harvested onto separate glass fibre filters. The 
filters were air dried and 2ml Liquid Scintillant (Microscint 40, Perkin Elmer LAS, UK) 
added. T cell proliferation was quantified by measuring H3-thymidine incorporation as 
counts per minute (cpm) by a β-Plate reader (Packard Top Count NXT (Model 9902V), 
Groningen, Netherlands). 
2.2.7.2   Proliferation assay for Antigen specific T cell responses : 
To determine if rOV-ASP1 treatment enhances the ability of MoDCs to support TT-
induced T cell proliferation by autologous T cells Chapter 4) we measured antigen specific 
T cell proliferation by tritiated [methyl-H
3} thymidine incorporation. 
Day 5 MoDCs (2.2.2) were cultured (0.5 x 10
5) in complete media alone, or with tetanus 
toxoid (1µg/ml). After 6 hours, rOv-ASP-1 (5µg/ml) was added to one of the wells of the 
two groups and cells cultured for a further 24 hours. Autologous Pan T cells were isolated 
as previously described (2.2.1.4) and resuspended in complete medium (containing HAB 
serum) at a concentration of 2 x 10
6/ml.  Purified T cells were co-cultured in triplicates with 
the different MoDCs groups at various DC : T cell ratios (1:2, 1:10, 1:50 and 1:250
 ) in U 
bottom 96-well plates for 5 days at 37
0c, 5% CO2. During the last 18 hours of incubation, 
the cultures were pulsed with1μCi/ml 
3H-thymidine. Thymidine incorporation was stopped 
after 18 hours by washing the plate and using a 96-well plate cell harvester the cells from 
each plate were harvested onto separate glass fibre filters and the incorporated tritium 











    86  2.2.8  Evaluating the antiviral and immunostimulatory actions of TLR  
          Agonist in chronic hepatitis C. 
 
2.2.8.1   Preparation of assay plates 
 
TLR7 agonist (SM360320) stock (2.1.5) was diluted 10 times in a serial dilution in  
phosphate buffered saline (PBS) + 0.1% dimethyl sulphoxide (DMSO). IFNα stock 
(2.1.5)was also diluted 10 times in PBS, 10% foetal calf serum and 1% DMSO. The 
background controls for these experiments were PBS with 0.1% DMSO. 
Compounds were aliquoted into 24 well assay plates as shown in figure 14 at 50ul/well for 
anti-viral action assays and 100ul/well for NK assays. Assay plates were prepared in 
advance of blood collections and stored at -20 C until used. 
 
Figure 14  24-well plate layout for stimulating whole blood with TLR7 agonist 
1 2 3 4 5 6 
1%DMSO  200IU/ml 
IFNα 
100000nM 100nM  10000nM 1000nM  Donor 1  A 
B 
1%DMSO  200IU/ml 
IFNα 
100000nM  100nM  10000nM 1000nM  Donor 2  C 
D 
 
NB: Molarities of the stimuli solutions are shown. In the final assay, these will be diluted 1/10 by 






    87  2.2.8.2    Assay set up: 
Pre-prepared assay plates (2.2.8.1) containing the compound were thawed at room 
temperature in a class II hood for at least 30 minutes prior to addition of blood or PBMCs 
to allow equilibration of the plates to room temperature.  
 
Aliquots of fresh blood (450ul) collected into sodium citrate vacutainers (2.1.7.2) were 
transferred into 24-well assay plates containing 50μl pre-prepared agonist, SM-360320, 
IFNα or no stimulus according to the plate plan (figure 14). Final concentrations of SM-
360320 were 0.1μM – 10μM and IFNα was 20IU/ml. The plate was sealed using a 
breathable membrane, placed on an orbital shaker and incubated for 5 hours at 37
0C / 5% 
CO2.  
 
2.2.8.3.1  Harvest of samples: 
After the incubation period, aliquots (4 x 25µl) of the stimulated blood from each well were 
transferred to a U bottomed 96 well plate as shown in layout below (figure 15) and mixed 
thoroughly with multichannel pipette with MagMAX lysis/binding solution (130μl/well of 
MagMax 96 blood lysis buffer (Ambion) mixed with isopropanol in a 1:1 ratio). Fresh blood 
from NHDs (180μl) was transferred to 96-well plates containing 20µl of SM-360320 (1μM), 
IFNα 20IU/ml) or no stimulus. One aliquot of stimulated blood was removed into MagMax 
buffer.  
 
The blood remaining in the 24 or 96 well assay plates was transferred into 2ml screw 
capped eppendorf tubes and spun (5 minutes at 500rpm) and the plasma was removed 
and frozen at -80
0C. The remaining cell pellet was resuspended in the residual plasma 
(~300µl) and 1.3mls RNALater (Ambion) was added to stabilize the samples. These 
samples were also frozen at -80 C pending further analysis for gene expression, cytokine 









    88  Figure 15:  96-well plate layout for gene expression analysis 
 
 
Donor 1  Donor 2 
 







T4  T4 
T5  T5 
T6  T6 
 
 
T1: treatment 1, 10000nM TLR7   T2: treatment 2, 1000nM TLR7 
T3: treatment 3, 100nM TLR7   T4: treatment 4, 10nM TLR7 












    89  2.2.8.4   Evaluating the anti-viral effects of TLR7 agonist, SM-360320  
 
2.2.8.4.1    Gene Expression Analysis (performed at Pfizer):RNA extraction and 
analysis by PCR was done to determine the induction of IFN-inducible genes e.g. 2’-5’ 
OAS: 
After thawing, RNA was extracted from blood mixed with MagMAX lysis/binding solution 
using the MagMAX 96 well blood RNA isolation kit (Ambion; #1837) according to the 
manufacturer’s instructions.  
Complementary deoxyribonucleic acid (cDNA) was prepared using high capacity cDNA 
archive kits (Applied Biosystems, USA) using 10mL RNA in 20mL reactions. Each 
reaction contained 2mL of 10x reverse transcriptase (RT) buffer, 0.8mL of 25 x 
deoxyribonucleotide triphosphate (dNTP) mixture, 2 mL of 10 x random primers, 1 mL of 
Multiscribe RT (50U / mL) and 4.2 mL of RNase free water. 
2’5’OAS gene expression was quantified using real time taqman Quantitative Polymerase 
Chain Reactions (QPCR) using ‘assay on demand reagents’ (Applied Biosystems, USA) 
in multiplex reactions as described by the manufacturer. Each reaction contained 12.5 μL 
of Taqman mix, 1.25 μL of 20 x actin reagents and 20 x 2’5’OAS reagents, 5 μL of cDNA 
and 5 μL of RNase free water. β-actin and 18S were used as housekeeping genes. QPCR 
amplification reactions were performed on a 7900 real time PCR machine (Applied 
Biosystems) over 40 cycles; annealing at 60ºC for 45 seconds, primer extension at 72ºC 
for 1 minute and denaturation at 94ºC for 20 seconds. 
2.2.8.4.2  HCV replicon assay (Performed at Pfizer) 
The presence of soluble factors with anti-viral activities was measured by evaluating their 
ability to inhibit HCV replication in an HCV-replicon system. 
 
Huh7 cell culture and cell harvest: Huh7 1b replicon cells were cultured in flasks 
(T225cm
2) to confluency of around 80% in Huh7 media (RPMI, 10% FCS, 5mls non-
essential amino acids, 5 mLs sodium pyruvate, 5 mLs Penicillin/streptomycin and 5 mLs 
geneticin). Spent media was poured off the flasks and cells were rinsed with 20mls sterile 
PBS. After rinsing, 5mls of accutase was applied to the cells and the excess was disposed 
of. After 5 minutes, flasks were tapped to remove cells from flask wall and 40mls of assay 
medium (Huh7 medium without geneticin) was added to the cells.  
 
    90  Cells were centrifuged (5 minutes at 1000rpm) and the supernatant was removed. Cells 
were resuspended in assay medium (25mL), counted and seeded at 111,111 cells/ml. 90 
uL was seeded into each well of both a 96 well white and clear bottom plate. Plates were 
incubated at 37°C/5% CO2 in a humidified incubator. 
 
Supernatants (10 uL) from whole blood ex vivo experiments were added to the replicon 
cells – one white and one clear plate. Plates were incubated in a humidified incubator as 
above for 24 hours.  
Cellular Proliferation assay: To each white plate, 100 uL of Bright-Glo mix – lyophilized 
substrate reconstituted in bright-glo assay buffer (Promega, #E2650) was added. 
Luminescence was read using an Analyst plate reader (using default luminescence 
programme). 
WST-1 cellular viability assay: To each clear plate, 100 uL of WST-1 diluted 1:3 with PBS 
at RT was added. Plates were incubated in a humidified incubator for 1-4 hours and 
absorbance was read at 450nm on the Wallac victor using the photometry>abs 450 at 
0.1second. 
HCV Replicon levels were then quantified using a luciferase reporter assay (270). 
 
2.2.8.4.3  Cytokine analysis (Performed at Pfizer): 
Levels of pro-inflammatory cytokines IFNα, IP-10, TNFα, IL-1 IL-1β, IL-2, IL-4, IL-6, IL-8, 
IL-10, IL-12p70 and IFNγ were determined using a custom multiplex 
electrochemiluminescence Enzyme-Linked ImmunoSorbent Assay (ELISA) as described 
by the manufacturer (Meso Scale Discovery). Harvested plasma from whole blood ex vivo 
assays was used to quantify production of cytokines.  Aliquots of plasma (25μL) from 
whole blood ex vivo assays were added to custom 10-plex multispot ultrasensitive 
cytokine detection plates (MS600, MSD, 9238 Gaither Road, Gaithersburg, Maryland 
20877, USA).  Only values that fell between the highest and lowest concentrations on the 
standard curve were used. Below the limit of quantification (BLQ) is defined as less than 
or equal to 20 pg/ml, and any results below that were reported as BLQ.  
 
                             
 
    91  2.2.8.5   Evaluating the immunomodulatory actions of SM-360320
 
2.2.8.5.1  NK cell Experiments 
 
NK cell Activation: 
Previously cryopreserved  PBMCs (2.2.1.1) were thawed rapidly in a pre-warmed 
waterbath at 37°C. Thawed cells were added drop-wise to 10mls RMPI 1640 with 20% 
FCS and 2mM L-glutamine and 1% penicillin-streptomycin and left to rest for 5 hrs at 
37°C in a 5% CO2 humidfied incubator prior to the assay. 
 
Cells were resuspended to 2 x 10
6 / ml in RPMI 1640 (no phenol) containing 10% FCS, 
2mM L-glutamine & 1% PS. 900ul PBMCs were plated into duplicate wells of a 24 well 
plate containing 100μl pre-prepared agonist per well, 100μl IFNα2b.or 100μl of dilutent 
only (2.2.8.1). After 5 hours incubation at 37°C, 1ul of Brefeldin-A (Sigma, Poole, Uk) was 




Figure 16  24-well plate layout for NK Cell Activation 
1 2 3 4 5 6 
1%DMSO  200IU/ml 
IFNα 
100000nM 100nM  10000nM 1000nM  BFA  added  A 
B 
1%DMSO  200IU/ml 
IFNα 




    92  NK Cell Surface Staining : 
After a total culture period of 24 hours, PBMCs were harvested and labelled for four-
colour flow cytometry to identify activated CD56
+ CD16
+ NK cells on the basis of cell 
surface CD69 expression and cytoplasmic interferon gamma (IFNγ) expression by 
intracellular staining.  
Cells were resuspended in FACS block, allowing 50µl for each staining condition to be 
carried out. 50μl of the blocked cells were transferred into the required number of wells on 
a v-bottom 96 well plate and incubated on ice for 30 minutes.  
Antibodies (CD56-APC, CD4-FITC, CD69-FITC, CD3-PE) and their isotypes (IgG1-APC, -
FITC, -PE) were diluted with FACS block to optimal concentrations for flow cytometry and 
50ul of appropriate antibody added to 50ul of block already in the well. Cells were 
incubated on ice for 30 minutes. The cells were washed 2 times in 200μl FACS wash and 
spun at 1200rpm at 4 c for 7 minutes. The supernatant was removed and cells 
resuspended in 200μl FACS wash (2.1.2). The cells were transferred to micronic tubes 
(table 4) and placed on ice in the dark pending analysis using FACS Calibur flow 
cytometer with cell quest software. 
 
Intracellular IFNγ Staining 
 
For intracellular staining, the cells to which BFA was added were harvested, blocked on 
ice and surface stained as above. Once washed twice with FACS wash, they were 
resuspended in 100ul fixation/permeabilisation buffer (BD Biosciences, Oxford, UK) and 
incubated on ice for a further 20 minutes. After washing with permeabilisation buffer, cells 
were stained with FITC-labelled anti-human IFNγ or IgG1 (50ul added to each well), 
diluted to the optimal concentration and left on ice for a further 40 minutes in the dark. 
After staining cell were washed twice with permeabilisation buffer, resuspended in FACS 






    93  Table 4  Sample plate set up for NK cell staining 
 
Cells without BFA: 
Tube Surface  Stain 
1  Buffer only 
2  IgG1FITC + IgG1PE + IgG1APC 
(1/30) 
3  CD4 FITC  (1/30) 
4  CD3 PE  (1/30) 
5  CD56 APC (1/30) 
6  CD56APC + CD3PE+ CD69FITC 
(1/30)        (1/30)       (1/50) 
7  CD56APC + CD3PE+ IgG1FITC 
    (1/30)        (1/30)     (1/500) 
 
 
Cells with BFA: 
Tube  Surface Stain  Intracellular Stain 
1  Buffer only  Buffer only 
2  IgG1FITC + IgG1PE + IgG1APC 
(1/30) 
Buffer only 
3  CD56APC + CD3PE (1/30)  IgG1FITC ICCS (1/500) 






    94  Fluorescence Activated Cell Scanning of stained PBMCs 
Unlabelled PBMCs (tube 1) were used to set the sensitivity of the fluorescence detectors 
to appropriate levels, so that on a histogram the peak of the cells lay in the first decade of 
a four-log scale. Singly-stained cells with CD4-FITC, CD3-PE were used to compensate 
the fluorescence signal in FL1 and FL2 and cells stained with CD3-PE and CD56-APC 
were used to compensate the fluorescence signal in FL4. This was done using the 
standard compensation circuits on the instrument. PBMCs were gated using forward / side 
scatter characteristics. NK cells were identified as cells showing strong labeling for CD56 
but negative for CD3 and a second gate was formed around these cells. The amount of 
IFN gamma production produced from these cells was determined by setting a histogram 
marker at <1% of the appropriate isotype control, typically on the first decade of the 4-log 
scale. Five thousand events were acquired per sample and analysed using WinMDI 
software.   
 
2.2.8.5.2    Plasmacytoid Dendritic cell Depletion Assays: 
To determine the contribution of pDCs to any anti-viral or immunostimulatory effects of 
SM360320 on cHCV-PBMCs, whole PBMCs and PBMCs from which BDCA4
+ pDCs had 
been depleted by immunomagnetic separation were stimulated with SM360320 and the 
efficacy compared in the HCV-replicon assay, gene expression analysis, cytokine 
secretion and NK cell activation. 
 
PBMCs were prepared from freshly drawn EDTA-treated venous blood (2.2.1.1). pDC 
were isolated from the PBMCs (2.2.1.3) and the negative and positive fraction retained fro 
use. The % purity of the pDC depletion was assessed by FACS analysis. Whole PBMCs 
and PBMCs from which BDCA
+  pDC were depleted were resuspended at 5.55 x 10
5 in 
culture medium and added to pre-prepared 96 well plate (180uL / well) containing the 
TLR7 agonist and IFNα.  pDCs alone were resuspended at 2.76 x 10
5 and added to the 
same plate (180uL / well). The plate was sealed using a breathable membrane, placed on 
an orbital shaker and incubated for 5 hours at 37
0C / 5% CO2.  
 
After the incubation, the plate was spun (5 minutes at 1200rpm) and the supernatant 
removed and stored in a fresh U bottom 96 well plate. The cell pellets were resuspended 
in 150μl Quagen RLT Lysis buffer (Ambion). All samples were frozen at -80 C pending 
further analysis at Pfizer for gene expression, cytokine analysis, and HCV replicon 
    95  assays. NK cell activation experiments comparing whole PBMCs with pDC deplete 






























    96              Chapter 3 
 
The effects of Ribavirin on dendritic cell maturation and 
cytokine production 




Chronic infection with hepatitis C virus (HCV) is a major cause of liver related morbidity 
and mortality with infection persisting in 80% of patients and is thought to result from a 
failure to sustain an immune response against HCV(35). 
 
Dendritic cells (DCs) are professional antigen presenting cells characterized by their 
exceptional capacity to activate naïve T cells and prime adaptive immunity. DCs play a 
pivotal role linking innate and adaptive immunity(65;67). They recognize pathogens 
through pathogen recognition receptors (PRRs) including toll like receptors (TLRs), 
leading to DC activation and maturation(67). Activated DCs then activate NK cells, thus 
driving the non-specific innate immune response, whilst simultaneously presenting antigen 
to initiate T cell mediated adaptive immunity. 
 
There are two functionally distinct subsets of DCs; mDC and pDC (chapter 1.5.1.1). pDCs 
are the most abundant producer of type-1 interferons in the body which they produce in 
large quantities during viral infections(271). mDCs prime TH1 responses via IL12 
production but also produce TNFα, IL10 and IFN-ß but not IFNα. Monocyte derived 
dendritic cells (MoDCs) are commonly used in vitro as a model of myeloid DCs due to the 
larger numbers that can be obtained and their close resemblance. 
 
Evidence points towards dendritic cell dysfunction in patients with chronic hepatitis C, with 
impaired maturation and impaired ability to stimulate T cells which may compromise their 
capacity to mount, and sustain, an effective antiviral immune response, thus leading to 
viral persistence(118-121;125;127-131;133-136). 
 
    97  The current mainstay of treatment for CHC is ribavirin in combination with Pegylated 
IFNα, leading to sustained viral eradication in 40-80% of infected patients depending on 
the HCV genotype. Ribavirin is a purine nucleoside analogue that is activated or 
metabolised through 5’ phosphylation to the monophosphate (RMP), diphosphate (RDP) 
and biologically active triphosphate (RTP) form. Despite its effective use for the last 40 
years, the mechanisms of action of ribavirin are poorly understood but several hypotheses 
have been proposed(188). These include direct inhibition of viral RNA replication, 
inhibition of the enzyme inosine monophosphate dehydrogenase (IMPDH) and 
mutagenesis causing viral replication error catastrophe. Ribavirin has also been 
suggested to have immunomodulatory effects, shifting the T-helper 1 cytokine balance 
(TH1)/ TH2) toward TH1 from T cells resulting in improved viral clearance.  
 
Ribavirin monotherapy has minimal effect on HCV viraemia but is associated with 
improvements in serum aminotransferases(272) suggesting that it may have an effect on 
inflammation and the host immune response. In combination with IFNα however, ribavirin 
increases the proportion of patients that clear the virus whilst on treatment from 27% with 
IFNα monotherapy(167) to 41% with combination therapy(171). However its most striking 
effect is that it prevents relapse after cessation of treatment. This latter effect is 
unexplained but also plays a significant role in newer treatment regimes that include HCV 





We set out to investigate the immunomodulatory effects of ribavirin on DC function in 
order to elucidate the mechanisms behind the prevention of relapse following treatment. 
Freshly isolated pDCs and cultured MoDCs from both NHDs and CHC patients were 
exposed in-vitro to ribavirin alone or to a combination of ribavirin and a maturation 
stimulus (CD40L, TLR9 agonist TLR7 agonist). The effects on cytokine secretion from 
DCs were studied as well as the expression of DC maturation markers (HLA-DR, HLA-




    98  3.3 Materials  and  Methods: 
 
Blood samples were collected from 21 uninfected normal healthy donors (NHDs) (18 male 
and 3 female, median age 53 years, range 25-67) who had no risk factors for blood borne 
viruses. Ten patients with chronic hepatitis C virus infection (4 female, 6 male, median 
age 54 years, range 37-61 years) were recruited from the hepatology clinics run by 
Southampton University Hospitals National Health Service Trust. All patients had 
detectable HCV RNA (4 genotype 1, and genotype 6 “non-1”). Patients were excluded if 
they had received treatment for HCV within 6 months prior to the study or tested positive 
for other blood borne viruses, including HBV and HIV.  
 
Monocytes and pDCs were purified by positive selection from PBMCs using anti-CD14 
conjugated and BDCA-4 magnetic microbeads respectively, in conjunction with an 
AutoMACS. Monocyte-derived dendritic cells (MoDCs) were generated by culturing 
monocytes in medium supplemented with rhGM-CSF (50ng/mL) and rhIL-4 (1000IU/mL) 
for 5 days. 
 
Immature MoDCs and freshly isolated pDCs were cultured under the following conditions; 
(1) medium alone (2) in a 1:1 ratio with Chinese hamster ovary cells  (hCD40L-CHO 
cells), (3) with 1µM M362, a TLR9 agonist or (4) 250µM loxoribine, a TLR7 agonist each 
with or without different concentrations of ribavirin (4, 20, 100 and 500µM). Cells were 
diluted in complete medium and incubated at 37
0C in 5% CO2. 
 
The cytokines produced by stimulated MoDCs and pDCs were assessed in cell culture 
supernatants after 24 hours of culture using human IFN-α multi-species ELISA and the 
Multiplex Fluorescent Bead Immunoassay (FBI) (IL12p70, IL10, IL8, IL6, IL1β and TNFα, 
IFNg, IL2, IL4, IL5). Three thousand events were acquired using FACSCalibur dual laser 
flow cytometer and analysed using CellQuest software. 
  
After 48 hours and 24 hours of culture, MoDCs and pDCs respectively, were harvested 
and labelled for two-colour flow cytometry to identify their cell surface phenotype  
 
Cell death was determined by FACS analysis with annexin V FITC in combination with 
propidium iodide after pDCs had been cultured in the presence of M362 (1μM) with and 
without ribavirin at different concentration (500uM, 100uM, 20uM and 4uM) for 24 hours. 
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For a full description of the methods, see Materials and Methods chapter. 
 
Statistical Analysis: 
Data was analyzed using GraphPad Prism version 4.0 for windows (GraphPad Software, 
San Diego, CA, USA) with unpaired t-tests and one way ANNOVA test applied with 





3.4.1  Ribavirin has no effect on IFNα production from immature NHD-pDCs: 
Freshly isolated pDCs from NHDs (n = 5) were cultured for 24 hours with; (1) medium 
alone (2) in a 1:1 ratio with CD40L transfectants  (3) with TLR9 agonist, M362 or (4) with 
the TLR7 agonist, loxoribine in the presence or absence of ribavirin at different 
concentrations. Unstimulated pDCs produced negligible amounts of IFNα which were 
unaltered by the addition of ribavirin (Fig. 17A).  
 
3.4.2  Ribavirin suppresses IFNα production from stimulated NHD-pDCs: 
When pDCs (n=5) were stimulated with CD40L, IFNα production was significantly 
increased. However, the addition of ribavirin, at all concentrations, significantly reduced 
the production of IFNα by NHD-pDCs in a dose-dependent manner in response to CD40L 
(fig. 17B). The same effect was observed when either a M362 or loxoribine was used in 
combination with ribavirin (Figs. 17C and D respectively). 
 
3.4.3  Ribavirin suppresses TNFα, IL8 and IL10 from CD40L-stimulated  NHD-pDCs 
Using the Multiplex Fluorescence Bead Immunoassay (FBI), we tested the effects of 
ribavirin on other cytokines (IL12p70, IL10, IL8, IL6, IL1β and TNFα, IFNγ, IL2, IL4, IL5) 
produced by CD40L-stimulated pDCs from NHDs (n=7). Ribavirin was found to reduce the 
production of TNFα, IL8 and IL10 from stimulated NHD-pDCs (Fig. 18). The effects of 




    100  Fig. 17   Effect of ribavirin on IFNα production from pDCs: 
(A) Unstimulated pDCs from NHDs produced negligible amounts of IFNα which were unaltered by 
ribavirin. (B) Ribavirin, at all concentrations tested, significantly reduced the amount of IFNα 
produced by NHD-pDCs in combination with CD40 ligation. When (C) a TLR9 agonist (M362) and 
(D) a TLR7 agonist (loxoribine) were used as alternative stimuli of IFNα production, ribavirin again 













































































































    101  Fig 18.  NHD-pDCs stimulated with CD40L and ribavirin show suppressed production of  














3.4.4  Ribavirin does not cause cell death or apoptosis in ex-vivo pDCs 
To ensure that the suppressive effects of ribavirin on pDC cytokine production were not 
due to induction of apoptosis or cell death, freshly isolated pDCs from NHDs were 
stimulated for 24 hours with M362 in the presence or absence of ribavirin, and then 
stained with annexin V and propidium iodide.  
 
Figure 19A shows that the inclusion of ribavirin, did not result in increased apoptosis or 
cell death. After 24 hours of culture without ribavirin, 20% of pDCs were dead compared 
to 15%, when the highest dose of ribavirin (500µM) was added. The experiment was 
repeated 5 times and ribavirin did not significantly alter the proportions of live, apoptotic or 




































































































    102  Fig 19.  Cytokine changes in NHD-pDCs stimulated with M362 and ribavirin are not 
attributable to increased apotosis or cell death: 
Apoptosis and cell death were assessed by flow cytometric staining for annexin V and PI (A). The 
left lower quadrant shows the number of viable cells (annexin-V and PI negative). The right lower 
quadrant shows the number of cells undergoing apoptosis (annexin-V positive and PI negative). 
The right upper quadrant shows the number of dead cells or those in late stages of apoptosis 
(annexin-V and PI positive). The experiment was repeated 5 times and ribavirin did not significantly 
alter the proportions of live, apoptotic or dead cells (B). 
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    103  3.4.5  Ribavirin upregulates stimulus induced CD86 expression from NHD-pDCS 
To ensure that the suppression of cytokine production from pDCs was not a ubiquitous 
reduction in all proteins, we looked at the effects of ribavirin on cell surface expression of 
CD86 and HLA class 1. Both molecules are normally highly expressed by stimulated 
pDCs. pDCs from NHDs (n = 5) were cultured for 24 hours with M362 (1µM) in the 
presence or absence of ribavirin and cells subsequently stained for two colour flow 
cytometry. We found that in pDCs stimulated with M362, ribavirin further upregulated the 




3.4.6  Ribavirin suppresses IFNα, TNFα, IL8 and IL10 from stimulated CHC-pDCs: 
To investigate if these effects of ribavirin were also demonstrated in CHC-pDCs, freshly 
isolated pDCs from CHC patients (n = 5) were cultured for 24 hours in a 1:1 ratio with 
CD40L and the effects of ribavirin on IFNα and cytokine production were assessed. As 
seen in NHDs, IFNα production by pDCs from CHC patients was significantly reduced at 
500µM,100µM and 20µM of ribavirin (Figure 21) and TNFa, IL8 and IL10 production were 


















    104  Fig 20.  Ribavirin upregulates stimulus induced CD86 expression from NHD-pDCS: 
NHD pDCs (n =5) stimulated with 1µM M362 and ribavirin further upregulated the expression of 
CD86 in a dose dependent manner (Figure 20A) (*p=<0.05) but had no significant effect on HLA 
class I expression (Figure 20B).  







































Fig 21.  Ribavirin suppresses IFNα from stimulated CHC-pDCs: 
pDCs from CHC patients show reduced IFNα production following CD40 ligation in the presence of 
ribavirin as seen in NHD-pDCs (*p=<0.05). 
 
 


































    105  Fig 22.  Ribavirin suppresses TNFα, IL8 and IL10 from stimulated CHC-pDCs: 
In CHC-pDCs stimulated with CD40L (n=5), ribavirin was found to significantly suppress the 






































































































3.4.7  Ribavirin had no effect on unstimulated MoDC maturation: 
MoDCs from NHDs (n= 8) were cultured with ribavirin at different concentrations for 48 
hours without any additional stimulus. Irrespective of the concentration used, ribavirin 
alone had no effect on levels of expression of phenotypic markers CD40, CD86, CD83 
and HLA-DR on MoDCs (data not shown).  
 
3.4.8  Effects of ribavirin on cytokine production from MoDCs: 
MoDCs from NHDs (n =10) were cultured with or without CD40L for 24 hours in the 
presence or absence of ribavirin at different concentrations.  
 
In immature NHD-MoDCs, cultured with medium alone, ribavirin did not significantly alter 
the secretion of any tested cytokine (Fig 23a). When immature MoDC were cultured for 
24hours with CD40L, CD40 transfectants ligation stimulated the production of TNFα, IL8, 
IL6, IL12 and IL10 (Fig 23b) but not that of IL1β, IL2, IL5 or IFNγ. The addition of ribavirin 
at a concentration of 500µM significantly suppressed the production of this CD40L-
induced TNFα production (Fig 23b). The effect of ribavirin was less pronounced at lower 
doses. Ribavirin did not however, significantly alter the CD40L-induced production of the 9 
other cytokines tested.  
 
 
    106  Fig 23.   Effects of ribavirin on cytokine production from MoDCs: 
A) In immature NHD-MoDCs, ribavirin had no effect on secretion of any tested cytokine.  
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    107  3.5 Discussion: 
 
With the clinical effects of ribavirin still largely unexplained, we set out to investigate the 
immunomodulatory effects of ribavirin on dendritic cell function by looking principally at the 
effects on cytokine production.  
 
In this study we have shown that ribavirin modulates dendritic cell cytokine production in 
response to a maturation stimulus. In pDCs from NHDs, ribavirin significantly suppressed 
stimulus-induced IFNα, TNFα, IL8 and IL10 and these findings were mirrored in pDCs 
from CHC patients. In MoDCs from NHDs ribavirin decreased CD40L-induced TNFα 
production but had no effect on other cytokines tested or phenotype. 
 
The ribavirin induced suppression of TNFα and IL8 from MoDC and pDC shown in this 
study may indicate an anti-inflammatory effect of ribavirin and may, in part, explain the 
reported reduction in hepatic inflammation with ribavirin monotherapy. It has been shown 
that ribavirin alone transiently improves biochemical and histological response in the 
absence of significant reduction in HCV load(274).  
 
The reduction of IFNα from ribavirin-treated pDCs may be of particular physiological 
importance since pDCs, unlike MoDCs, are the major source of INFα in the human body 
producing large quantities of type 1 IFN in response to viral infection. Several 
studies(131;133-136) have found pDCs from patients with CHC have impaired production 
of IFNα. This defect will have an impact on both innate and adaptive immunity and favour 
viral persistence. Our finding that ribavirin is unable to stimulate IFNα production from 
pDCs together with the further impairment in IFNα production from pDCs treated with 
ribavirin correlates with the requirement for exogenous IFNα in the effective treatment of 
CHC and may, in part, explain why ribavirin alone has no beneficial effects on HCV viral 
loads. Whether ribavirin is actually exacerbating the IFNα defect in CHC-pDCs needs 
further investigation in larger cohorts to explore the exact mechanisms. It would be 
interesting to investigate whether the addition of exogenous IFNα can overcome the 
suppressive effects of ribavirin on cytokine production from dendritic cells. 
 
The opposing actions of ribavirin and TLR agonists in IFNα production demonstrated in 
this study may have implications if they are to be used in combination in the future 
    108  treatment of CHC. The study undertaken by Coley with Actilon the TLR9 agonist, 
CpG10101(248)
 (currently withdrawn from further drug development at present) looked at 
the effects of this compound alone, in combination with ribavirin or IFNα or all combined 
and found ribavirin combined with CPG10101 was less effective than when combined with 
exogenous IFNα or all 3 together, strengthening the importance of continued use of 
exogenous IFNα in future treatments. 
 
As a purine nucleoside analogue, it has been hypothesized that ribavirin may exert 
immunomodulatory activities via TLR stimulation on dendritic cells(247). Our findings do 
not support this hypothesis, with ribavirin having no effect on either phenotype or cytokine 
production when administered alone to either pDCs or MoDCs. In stimulated DCs, 
ribavirin was still unable to further enhance cytokine production, but in fact reduced the 
production of IFNα, TNFα, IL8 and IL10 from pDCs and TNFα from MoDCs.  
 
To ensure the suppression of cytokine production from ribavirin-treated DCs was not a 
ubiquitous downregulation of all proteins, we looked at the effects of ribavirin on CD86 
and HLA class I expression, both of which are highly expressed on stimulated pDCs. Our 
results show that ribavirin had no significant effect on Class I expression and actually 
enhanced CD86 surface expression. The enhancment of CD86 surface expression was 
interesting and could reflect a subtle maturation effect of ribavirin. This should be explored 
further, looking at the other markers of pDC maturation such as increases in surface 
expression of MHC and co-stimulatory molecules, CD83 and CD80 as well as CD86. The 
expression of these co-stimulatory molecules is essential for effective activation of T 
lymphocytes. In previous studies it has been shown that DCs from CHC patients have 
impaired maturation with an immature phenotype(118-121;125;127-131;133-136). It is 
possible that ribavirin can overcome this effect and thereby restore antigen presentation 
and priming of T cells. In the absence of evidence of any other mechanism whereby 
ribavirin may enhance viral clearance and sustained response to interferon it may be a 
subtle effect on DC maturation that accounts for the profound clinical effects of ribavirin 
when used in conjunction with IFNα in the treatment of HCV infection and further studies 
will need to be carried out. The effect of dendritic cells treated with ribavirin on T cell allo-
stimulation and the consequence for NK cell activation to see if ribavirin has any effect on 
DC antigen presentation function also needs further investigation. 
 
    109  Only one other study has examined the effects of ribavirin on DC maturation and 
function(275) and focused only on MoDCs. Using ribavirin at a physiological concentration 
of 120µM, they found that ribavirin suppressed IL-12 and IL-10 in addition to TNFα when 
co-administered with poly I:C as a stimulus. They assessed cell culture supernatants at 
multiple time points up to 48 hours and the suppression of IL-12 was seen at 32 hours and 
maximal suppression of IL-10 at 36 hours. In our study, supernatants were assessed at 
only one time point, at 24 hours which may be a reason for seeing no effect on IL12 in this 
study. However, they too found that ribavirin had no effect on phenotypic maturation in 
either stimulated or immature MoDCs.  
 
A number of studies in PBMCs have shown that ribavirin has an effect on mitogen-
induced cytokine production, with some studies showing enhancement and others 
inhibition(202-205). Furthermore some studies have shown ribavirin to induce a TH1 
profile(202;205;206), while others showed no impact on cytokine production(276) or 
induction of a TH2 profile. We have shown reduction in both TH1 (TNFα, IL8 and IL6) and 
also TH2 (IL10) and the significance of this remains unexplained.  Some of the inhibitory 
effects of cytokines seen in PBMCs are thought to be secondary to the known 
antiproliferative effects of ribavirin on T cells(203). DCs, however, do not proliferate during 
stimulation so this is unlikely to be the case in this study.  
 
This study is limited by small numbers but has shown that ribavirin is able to modulate 
cytokine production from dendritic cells, in particular suppressing the production of IFNα.  
It is clear from recent trials with protease inhibitors Telaprivir (221;223;277) and 
Bocepravir(226) that ribavirin will continue to be required in future anti-viral regimes to 
improve SVR and prevent relapse. If this is the case, the findings in this study highlight the 
importance of the need for the continued use of IFNα therapy in this combination to 
overcome the suppression we have identified. 
 
The mechanisms underlying the suppression of IFNα by ribavirin and the possible effects 
of ribavirin on pDC maturation should be explored further. By studying a larger cohort of 
CHC patients it may also be possible to assess differences in the effects on cytokine 




    110  Summary of results: 
 
Results from pDCs in NHDs and CHC: 
1. Effects on IFNα production: 
•  Ribavirin had no effect on IFNa production from immature pDCs 
•  Ribavirin suppressed IFNa production from stimulated pDCs in NHDs (stimulated 
with CD40L, TLR9 or TLR7 agonist) 
•  Ribavirin suppressed IFNa production from stimulated pDCs in CHC (stimulated 
with CD40L – not tested with TLR7 or TLR9 agonist) 
 
2. Effects on other cytokines from pDCs: 
•  Ribavirin suppressed TNFa, IL8 and IL10 from stimulated pDCs in NHDs and CHC 
(Stimulated with CD40L – not tested with TLR7 or TLR9 agonist) 
 
3. Suppressive effects were not due to apoptosis or cell death: 
•  Addition of ribavirin to NHD-pDCs stimulated with TLR9 agonist did cause cell 
death or apoptosis. 
 
4. Suppressive effects were not ubiquitous to all proteins: 
•  CD86 expression was found to be enhanced by ribavirin 
 
Results from MoDCs in NHDs: 
1. Effect on MoDC maturation: 
•  Ribavirin had no effect on maturation of unstimulated MoDCs (effect on stimulated 
MoDCs has not yet been assessed) 
 
2. Effect on cytokine production: 
•  Ribavirin had no effect on cytokine secretion from unstimulated MoDCs 
•  Stimulation of MoDCs with CD40L enhanced secretion of IL12, TNFa, IL6 and IL10 
and ribavrin was found to suppress the CD40L-induced TNFa production but did 
not effect the other cytokines 
 
   
 
    111            Chapter 4 
Activation of Human Dendritic Cells and Enhancement of Antigen   
        Specific T Cell Immunity by a Novel Helminth-Derived 
                                     Immunostimulant.  
 
4.1 Introduction: 
With the increasing prevalence of chronic hepatitis C there is a pressing need for safe and 
effective immunotherapies that will drive the hosts immune effector mechanisms towards 
viral clearance. Persistence of the virus is thought to result from failure to mount a 
vigorous and sustained CD4
+ and CD8
+ T cell response with contraction of the range of 
peptide epitopes recognized culminating in the inability to eliminate infection and 
subsequent disease chronicity(163).  
Immunostimulants represent an emerging class of drugs that are designed to effectively 
and appropriately amplify naturally occurring immune responses against infectious 
pathogens and tumor cells. Dendritic cells are professional antigen presenting cells and 
with their exceptional capacity to activate naïve T cells upon maturation, they are the 
prime initiators of acquired immune responses with the production of antigen specific 
effector T cells in response to viral and other pathogens(65). Dendritic cells therefore 
appear to serve as a relevant target of immunostimulants.  
Currently available treatment for HCV, with interferon alpha and ribavirin, leads to a 
sustained viral eradication in only 40-80% of patients depending on the HCV 
genotype(167). Treatment is associated with multiple side effects and complications that 
often result in discontinuation of treatment and a large number not being offered 
treatment. The use of immune stimulators might prove to be an effective treatment either 
alone or in combination with existing or new anti-virals.  
Onchocerca volvulus is a filarial parasite that causes human onchocerciasis, more 
commonly known as river blindness, mainly in West Africa.  
    112  Activation-associated secreted proteins (ASPs) of parasitic nematodes are produced by 
the infective larval stage and are highly immunogenic.  ASPs have been studied as 
potential anti-helminth vaccine components, especially hookworm ASP(278-281).  
Recombinant secreted protein of the helminth Onchocerca volvulus, rOv-ASP-1, is typical 
of nematode ASPs in that it is intrinsically immunogenic(282), highly charged and contains 
highly conserved cysteine rich domain with structural homology to pathogenesis-related 
proteins in plants and also vespid venom antigen 5 (283).  
During the course of experiments evaluating Recombinant Onchocerca volvulus 
activation-associated secreted protein-1 (rOv-ASP-1) as a possible vaccine candidate 
against onchocerciasis in humans, the 25kD protein was also shown to be a potent 
adjuvant for inducing Th2 and Th1-associated antibodies to protein (ovalbumin), 
polypeptide (HIV-1 gp120-CD4 chimera) and small peptide (from SARS-CoV spike 
protein) antigens in vaccinated mice(284).  Unusually for a helminth product, rOv-ASP-1 
as an adjuvant with ovalbumin strongly biased antibody and cellular responses to Th1-
type (IFN γ) in vaccinated mice(284). 
 
4.2 Aims: 
Having shown that rOv-ASP-1 is a potent vaccine adjuvant in mice, the aim of this study 
was to explore the mechanisms of action of rOv-ASP-1 and assess its potential as a 
human therapeutic by testing its ability to stimulate human dendritic cells (DCs), looking at 
the effect of rOv-ASP-1 on expression of DC maturation markers (HLA-DR, CD83, CD86, 
CD40 and BDCA-2) and cytokine secretion using ex vivo- isolated plasmacytoid DCs 
(pDCs) and cultured, monocyte-derived DCs (MoDCs) from normal healthy donors 
(NHDs) and to determine if Ov-ASP-1-treated DCs are capable of enhancing MoDC 
antigen-presenting capacity. If Ov-ASP-1 was able to enhance in vitro responses, it may 




    113  4.3 Materials  and  Methods: 
Blood samples were collected from 20 uninfected normal healthy donors with no known 
risk factors for blood-borne virus infection. 14 were male and 6 were female. The median 
age was 52 (range 26-68). 
 
Monocytes (n=14) and pDCs (n=6) were purified by positive selection from PBMCs using 
anti-CD14 conjugated and BDCA-4 magnetic microbeads respectively, in conjunction with 
an AutoMACS. Monocyte-derived dendritic cells (MoDCs) were generated by culturing 
monocytes in medium supplemented with rhGM-CSF (50ng/mL) and rhIL-4 (1000IU/mL) 
for 5 days. 
 
Immature MoDCs and freshly isolated pDCs were cultured in media alone or in a 1:1 ratio 
with a CD40 ligand-transfected Chinese hamster ovary cells (hCD40L-CHO) with or 
without with 5 μg/ml rOv-ASP-1 or 100 ng/ml LPS, used as a positive control. 
 
After 24 hours of culture, MoDCs and pDCs were harvested and labelled for two-colour 
flow cytometry to identify their cell surface phenotype. 
  
The cytokines produced by stimulated MoDCs and pDCs were assessed in cell culture 
supernatants after 24 hours of culture using ELISA (IFNα) and a cytometric bead assay 
(IL12p70, IL10, IL8, IL6, IL1β and TNFα, IFNg, IL2, IL4, IL5). 
  
To establish if rOv-ASP-1 was able to enhance MoDC antigen-presenting capacity a 
mixed lymphocyte reaction assay was performed and proliferation was measured by H-
thymidine incorporation. 
 
For a full description of the methods see Materials and Methods chapter. 
 
Statistical analysis
Paired t-tests were used to compare means. Analyses were performed using Prism 
version 4·0 for Windows (GraphPad Software, San Diego, CA, USA). 
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4.4.1  rOv-ASP-1 induces phenotypic maturation of monocyte-derived dendritic 
cells from normal healthy donors 
 
It is well known that TLRs activate signal transduction cascades leading maturation of 
DCs that includes expression of co-stimulatory molecules on their surface. To determine if 
rOv-ASP-1 induced DC maturation, MoDCs (n=14) were cultured with or without 
recombinant rOv-ASP-1 at an optimal concentration of 5µg/ml for 48 hours. Using FACS 
analysis we measured expression of surface molecules that are characteristically 
upregulated in DCs after stimulation. As shown in figure 24, all four phenotypic markers 
that were tested increased after treatment with rOv-ASP-1. 
 
Fig 24. Phenotypic maturation by rOv-ASP-1 treated MODCs: Phenotypic maturation by 
rOv-ASP-1 treated MODCs. MoDCs (N = 14) were cultured with or without 5 µg/ml rOv-ASP for 24 hours. 
Using FACS analysis the expression of maturation markers CD40, CD83, CD86 and HLA-DR were measured. 
All four of the maturation markers were significantly upregulated after treatment with rOv-ASP-1. LPS was 
used as a positive control (n=9) 



















































    115  4.4.2  rOv-ASP-1 stimulates proinflammatory cytokines from monocyte-derived 
dendritic cells 
 
MoDCs from NHDs (n=10) were cultured with or without recombinant rOv-ASP-1 at an 
optimal concentration of 5µg/ml for 24 hours and cytokine production was determined. 
rOv-ASP-1 alone was found to stimulate significant amounts of pro-inflammatory 
cytokines, IL6, IL8 and TNFα (fig 25) but not IL-12. However, when MoDCs were co-
stimulated with CD40L, significant enhancement of IL-12 was seen. Co-stimulation with 
CD40L also enhanced the rOv-ASP-1 induced secretion of IL-10 and TNFα. A wide 
variation in response was seen between donors with some secreting much higher levels 
of cytokines than others. There was no significant induction of other cytokines tested IL2, 
IL4, IL5 or IL1ß. 
 
 
Fig 25.  Production of proinflammatory cytokines from rOv-ASP-1 treated MoDCs 
with and without CD40L: MoDCs were cultured with media alone or in a 1:1 ratio with a CD40 ligand-
transfected Chinese hamster ovary cells (hCD40L-CHO) with or without 5µg/ml rOv-ASP. LPS was used as a 
positive control. rOv-ASP alone stimulated significant amounts of pro-inflammatory cytokines, IL-6, IL-8, and 
TNFα but not IL-12. However, when MoDCs were co-stimulated with CD40L, significant enhancement of IL-12 








































































s4.4.3 r Ov-ASP-1 stimulates an anti-inflammatory cytokine from monocyte-derived 
dendritic cells. 
 
MoDCs cultured with rOv-ASP-1 were also found to significantly stimulate the production 
of the anti-inflammatory cytokine, IL-10 (Figure 26). 
 
Fig 26.  Production of IL-10 from rOv-ASP-1 treated MoDCs with and without CD40L: 
MoDCs stimulated with rOv-ASP significantly stimulated the production of the anti-inflammatory cytokine, IL-










































4.4.4  rOv-ASP-1 has no effect on pDC maturation or Interferon alpha production. 
 
pDCs are the major producers of type 1 interferons. We therefore tested the effects of 
rOv-ASP-1 on the production of IFNα from pDC after 24 hours of culture. As shown in 
figure 27, rOv-ASP-1 did not stimulate the production IFNα. rOv-ASP-1 also had no effect 
on levels of expression of phenotypic markers on pDCs (either HLA-DR or co-stimulatory 






    117  Fig 27.  Production of IFNα from rOv-ASP-1 treated pDCs: pDC (n=5) stimulated with 5µg/ml 






































4.4.5 r Ov-ASP enhances the allo-stimulatory function of MoDCs: 
 
To assess if rOv-ASP treatment of MoDCs was also able to enhance their accessory / 
antigen presentation function, we used the mixed lymphocyte reaction (MLR) assay with 
allogeneic antigens. Figure 28 shows the results of the MLR experiments indicating that 
MoDCs treated with 5ug/ml of rOv-ASP enhanced their ability to stimulate proliferation of 
allogeneic CD4












    118  Fig 28.  rOv-ASP-1 treated MoDCs have enhanced allo-stimulatory function: MoDCs 
treated with 5 µg/ml rOv-ASP-1 showed enhanced ability to stimulate the proliferation of allogenic CD4
+ T 
cells. The CD4
+ T cell proliferation (counts per minute) in response to rOv-ASP-1 is shown. Each point 
represents the mean (s.d) of results from 5 individuals *P<0.05 
 
 
rOv-ASP-1 enhances allogeneic stimulation
by human MoDCs













































































    119  4.5 Discussion: 
 
r-Ov-ASP is a novel immunostimmulant derived from Onchocera volvulus, the helminth 
parasite that causes onchocerciasis (river blindness). r-Ov-ASP has previously been 
shown to be a potent vaccine adjuvant in mice(284). In this study we investigated the 
immunostimulatory effects of this protein on human DCs from NHDs and show evidence 
of phenotypic maturation, enhanced cytokine production and enhanced allo-stimulatory 
function from MoDCs. 
 
It has previously been shown that among human PBMCs, rOv-ASP primarily binds to 
monocytes (93-98%) and B cells (41-94%), the major APCs in peripheral blood
11, 
suggesting rOv-ASP may interact with specific receptors presented on the surface of the 
APCs to activate the immune cells. In human PBMCs, rOv-ASP has been shown to be a 
potent inducer of Th1-type pro-inflammatory cytokines (IFNγ and TNF-α) and the 
immunoregulatory (IL-10) cytokine secretion(285).  
 
The effects of the rOv-ASP-1 on DCs, the major antigen presenting cell involved in 
priming T-cell responses, has not been previously described. Dendritic cells recognize 
PAMPS through TLRs. TLRs are important pattern recognition receptors (PPRs) of the 
innate immune system, recognizing various invading pathogens (PAMPS) expressed on 
the cell surface of immune cells. After PAMP recognition by TLRs, signalling pathways are 
activated resulting in recruitment of adaptor proteins such as myeloid differentiation factor 
88 (MyD88) and down stream activation of transcription factors, NFkB and mitogen 
activated protein kinases (MAPK) with production of pro-inflammatory cytokines(93). TLR 
signalling stimulates the activation and maturation of DCs with expression of co-
stimulatory molecules and secretion of cytokines which drive polarization of CD4+ TH1 or 
TH2 cells towards the TH1 or TH2 phenotype. DCs provide a central link between innate 
and adaptive immunity(286). 
 
It is thought from previous studies that rOV-ASP-1 activity is mediated through TLR 
signaling(285) and other human parasite-derived products have also been shown to 
stimulate immune responses via TLR pathways(287;288). In human PBMCs, rOV-ASP-1 
has been shown to activate TLR2 and TLR4 to induce production of pro-inflammatory 
cytokines (IFNγ) with inhibition of IFNγ secretion from human PBMC reported by anti-
TLR2 and anti-TLR4 antibodies(285). rOv-ASP-1 was also found to trigger the activation 
    120  of HEK293 cells transfected with TLR2 and TLR4 but not with TLR9(285). Although TLR2 
and 4 mediate a response to a different set of PAMPs, they share a common activation 
pathway through the TIR signaling domain resulting in activation of NFkB and MAPK. 
 
In this study we have shown that rOV-ASP activities are mediated by its ability to activate 
APCs. We showed phenotypic maturation of rOv-ASP-1 treated MoDCs based on up-
regulation of phenotypic markers (CD40, HLA-DR, CD83 and CD86). rOV-ASP stimulated 
significant amounts of pro-inflammatory cytokine, IL6, IL-8 and TNFα but not IL-12. The 
rOV-ASP induced secretion of IL-12 was found to be CD40-dependant, with significant 
enhancement of IL-12 only being observed after providing MoDCs with co-stimulation 
through the CD40-CD40L pathway. Co-stimulation through the CD40-CD40L pathway 
also enhanced the rOV-ASP-1 induced secretion of IL-10 and TNFα. These results 
provide evidence that rOV-ASP-1 may support DC-induced adaptive immune responses 
by multiple distinct mechanisms. The CD40-CD40L pathway dependant IL-12 production 
by DCs may be important for the development of TH1 responses and cytotoxic T 
lymphocyte generation. IL-12 is primarily produced by myeloid DCs and macrophages and 
T cell and NK cell secretion of IFN γ is mostly induced by IL-12. 
 
rOv-ASP not only enhanced pro-inflammatory cytokine production from MoDCs but also 
significantly stimulated the production of the anti-inflammatory cytokine IL-10. The 
enhanced secretion of IL-10 has previously been seen in rOV-ASP-1 stimulated 
PBMCs(285) and also in vaccinated mice where, despite theoretical presence of Ov-ASP-
1 induced IL-10 in vivo (based on stimulation of normal mouse splenocyte in vitro), the 
protein has potent Th1-inducing immunostimulatory activity(284). IL-10 of DC origin plays 
a central role in the regulation of T-cell responses and is capable of inhibiting synthesis of 
pro-inflammatory cytokines like IFNγ, TNFα and IL2. It is possible that in natural infection 
with O. Volvulus larvae, co-induction of IL-10 helps to limit damaging effects of too potent 
a Th1 response.   
 
Based on the profile of cytokines stimulated by rOv-ASP-1 it has been hypothesized that 
the rOv-ASP-1 protein may contain several Th1 PAMPS that bind to different receptors on 
APCs and activate differently the secretion of Th1 cytokines and IL-10 through distinct 
pathways. Structural homology analyses of rOv-ASP-1 with the crystallized closely-related 
hookworm secreted protein Na-ASP-2 suggested that rOv-ASP-1 has three distinct 
domains(289) each of which could contain distinct bioactive sites. If this is the case and 
    121  different domains induce IL-10 and pro-inflammatory cytokines, then it may be possible to 
express a subunit that stimulates the pro-inflammatory cytokines without concurrent IL-10 
secretion or subunits that differentially activate TLR2 or TLR4 pathways. 
 
We found that rOv-ASP enhanced the ability of MoDCs to stimulate proliferation of 
allogeneic CD4
+ T cells and rOv-ASP-1 primed DCs have been shown to have the ability 
to induce IFNγ secretion from naïve autologous PBMCs. This suggests the protein is able 
to enhance DCs accessory/antigen presentation function and suggests its ability to boost 
the activation of an adaptive immune response. Further studies need to be done looking 
at antigen specific responses. 
 
The observed effects of rOv-ASP on DCs described in this study suggest several potential 
applications for the use of the protein which are discussed below, but in the first instance, 
the subunits of the protein would need to be expressed or synthesized and the 
bioactivities determined. 
 
There has been a recent resurgence of interest in new and improved vaccine adjuvants. 
The interest has been stimulated by the need for new vaccines to combat problematic 
pathogens causing AIDS, SARS, TB, HCV and ‘flu as well as those that could be 
employed as biological weapons in terrorist attacks.  Recombinant protein-based or 
subunit based vaccines with adjuvants as stimulants are becoming more popular as they 
are less broadly immunogenic than traditional live or killed whole organism based 
vaccines. However, finding high potency immunostimulatory adjuvants capable of safely 
boosting both humoral and cellular immune responses is a challenge. At present, alum is 
the only adjuvant approved for human use world-wide but it is mainly associated with Th2 
responses and has little capacity to stimulate cellular (Th1) immune responses(290).  
 
Ov-ASP-1 has previously been shown to stimulate high tires of IgG1 (Th2) and IgG2a 
(Th1) in vaccinated mice which exceeded the efficacy of alum or MPL and TDM 
adjuvants(282;284;291). Unlike alum, it has the ability to stimulate a mixed Th1/Th2 with a 
strong Th1-biased immune response. It has been shown to have potential adjuvanticity in 
inducing immune responses of recombinant subunit-based vaccines, synthetic peptides, 
as well as in improving the immune efficacy of commercial inactivated vaccines 
(haemorragic fever with renal syndrome (HFRS), Influenza and Rabies)(291).  
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this study we have demonstrated that rOv-ASP activates DCs to the same degree as an 
established TLR agonist, LPS. These findings further substantiate the potential of the use 
of rOv-ASP as a novel human innate vaccine adjuvant in humans that can boost the 
activation of an adaptive immune response. It has been shown to stimulate both antibody 
and cellular responses which is an important challenge for vaccine development and 
which few experimental adjuvants are capable. It may be possible to express a subunit 
with optimal Th1 inducing ability without the concurrent IL-10 secretion or one which 
specially activates TLR2 or TLR4 pathways. 
 
The ability of rOv-ASP-1 to stimulate human DCs may enable it to be used as a human 
therapeutic and as a DC activator where DC function is impaired by a pathogen such as 
HCV. In the case of chronic HCV infection, where DC function has been reported to be 
impaired by the virus, rOv-ASP-1, or more likely a subunit, could enhance DC-driven T 
cell anti-HCV responses that would shift the virus-host equilibrium in favor of viral 
clearance. In support of this, recent in vitro evidence showed that rOv-ASP-1 was able to 
enhance and/or induce anti-HCV Core IFNγ responses in patients with chronic HCV 
infection (292)
 Our data have shown that in pDCs treated with rOv-ASP, there was no 
effect seen in either maturation or cytokine production. Human pDCs express TLR7, 8 and 
9 and so these findings support previous findings that rOv-ASP-1 signals through TLR2 
and TLR4. Our findings of an effect of rOv-ASP-1 on MoDCs but not pDCs indicate that 
rOv-ASP-1 could directly activate the closely-related myeloid DC subset in vivo, which 
share at least two of the Toll-like receptors (TLRs) through which rOv-ASP-1 signals 
(TLR2 and TLR4) and not the plasmacytoid compartment.  Although the latter is the most 
abundant and rapid source of IFN-α, other DCs and antigen presenting cells can also 
make this cytokine, albeit in lower amounts.  The liver-resident DC population is mainly 
myeloid in type and could, therefore, be susceptible to activation by rOv-ASP-1 resulting 
in restored or enhanced ability to present antigen.   
 
In a previous study (292) it was shown that rOv-ASP-1 induced IFNγ secretion from 
purified CD56
+ cells but not CD4+ or CD8+ cells. The CD56+ cells were critical to the 
immunostimulatory effect of the protein and dependant on contact between CD56+ and 
CD56- fractions of PBMCs, most likely between APCs, including DCs, in the CD56- 
fraction. It is possible, therefore, that as well as being an adjuvant for acquired immune 
responses, rOv-ASP-1 has possible applications for the direct stimulation of NK cells and 
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appropriate, topically. With respect to the liver, we have not tested the effects of rOV-ASP 
on NKT cells which are abundant in this organ and it is possible that the protein may have 
activating properties on these cells in situ. 
 
The potential therapeutic uses of rOv-ASP-1 are not restricted to pro-inflammatory 
immune stimulation. We found that rOv-ASP-1 also enhances secretion of large amounts 
of IL-10, a potent immunoregulatory cytokine which may also be valuable in limiting 
inflammatory and autoimmune diseases. This would require expressing a subunit that is 
responsible for the induction of IL-10 without pro-inflammatory cytokines and could be 
could particularly useful if administered topically, locally or targeted to an affected organ 
using a tissue-specific antibody. 
 
In conclusion, this study shown the ability of rOv-ASP-1 to stimulate human DCs and 
these findings suggest that the immunostimulatory properties of this protein may be 
mediated by its ability to activate antigen presenting cells, in particular MoDCs. The 
findings extends the immunostimulatory activity of Ov-ASP-1 beyond the previous 
reported findings of the adjuvanticity of the parasite protein for primary immune responses 
in vaccinated mice(282;284) to enhancing human responses. 
 
 
Summary of Findings: 
 
1. Phenotypic maturation of MoDCs 
•  Shown by up-regulation of maturation markers, HLA-DR, CD83, CD86 and CD40 
 
2. Stimulation of Pro-inflammatory cytokines from MoDCs 
•  rOV-ASP1 alone stimulated IL8, IL6 and TNFα but not IL12 
•  IL12 secretion required co-stimulation with CD40L 
•  CD40L co-stimulation also further enhanced TNFα secretion 
 
3. Stimulation of anti-inflammatory cytokine from MoDCs 
•  rOV-ASP alone stimulated IL10 secretion 
•  CD40L co-stimulation further enhanced this IL10 secretion 
 
    124  4. No effect seen on pDCs 
•  No effect on pDC phenotypic maturation as shown by maturation markers, HLA-
DR, BDCA 2, CD83 or CD86 
•  No effect on IFNα secretion from pDCs 
 
5. Enhanced allo-stimulatory function of MoDCS 



























    125  Chapter 5 
 
The TLR7 agonist SM-360320 induces a robust antiviral and 
         immunostimulatory response in chronic hepatitis C infection 
 
5.1 Introduction: 
The current mainstay of treatment for CHC is ribavarin in combination with pegylated 
(PEG)-IFNα, leading to sustained viral eradication in 40-80% of infected patients, primarily 
depending on the HCV genotype(167). The current treatment is associated with significant 
side effects including flu-like symptoms, depression and injection site reactions and is also 
not suitable for a number of patients(178).  Alternative novel strategies for the treatment of 
CHC are therefore required.  
The host’s innate and adaptive cellular immune responses are believed to be critical in 
determining the outcome of HCV infection(161;161;163). The NK cell-mediated innate 
immune response may be both genetically programmed to determine the chance of 
spontaneously resolving acute HCV infection (159) and may be directly modulated by 
HCV itself, leading to impaired NK cell function (293). Dendritic cells (DCs) are 
professional antigen presenting cells characterized by their exceptional capacity to 
activate naïve T cells and prime adaptive immunity. DCs play a pivotal role linking innate 
and adaptive immunity(67). Two functionally distinct subsets of DCs are recognised; 
myeloid (mDC) and plasmacytoid (pDC). pDCs are the most potent producer of type-1 
interferons in the body and release large quantities during viral infections(294).  
In terms of the adaptive immune response, successful viral clearance during acute 
infection has been attributed to a robust HCV-specific CD8
+ T cell effector response and a 
predominantly Th1-polarised CD4
+ anti-HCV response(161). A failure to sustain this early 
anti-HCV T cell response correlates with viral persistence and the development of CHC. 
 
Toll-like receptors (TLRs) are a family of pattern recognition receptors that play a key role 
in innate immunity(93). TLRs are activated by a range of pathogen-associated molecular 
patterns (PAMPs) which are conserved among pathogens. TLRs 3, 7 and 9 are 
intracellular receptors specialized in the recognition of viral nucleic acids and recognize 
ligands in endosomes and lysosomes. TLR3 recognizes double stranded RNA (dsRNA) 
    126  and is expressed on B and T lymphocytes and NK cells. TLR7 recognizes synthetic 
imidazoquinolone-like molecules, guanosine analogues and single-stranded RNA derived 
from viruses while TLR9 recognizes unmethylated 2’-deoxyribo (cytidine-phosphate-
guanosine (CpG) DNA. TLR 7 and 9 are expressed by pDCs and B cells. On binding, they 
induce a signaling cascade resulting in the induction of type I interferons and 
proinflammatory cytokines, which drive an inflammatory response and activate the 
adaptive immune system(94).  
 
TLR agonists have been investigated for the treatment of chronic hepatitis C as a means 
of inducing endogenous IFNα production by stimulating immune cells with efficient 
activation of innate and acquired immunity even in the presence of the immune 
dysfunction induced by CHC infection. Activation of pDCs is important for HCV treatment 
because these activated cells are not only the primary producer of the cytokine IFNα, but 
also present antigen to initiate T cell mediated adaptive immunity. 
 
 In short term monotherapy trials, the TLR7 agonist Isatoribine(241) and TLR9 agonist, 
CpG 10101 (Actilon)(250) have been shown to have clinical efficacy against HCV, 
reducing HCV viral load with evidence of immune modulation as shown by upregulation of 
the interferon-response gene, 2’5’OAS and increased production of IFNα and  IP10 in 
both sudies but also neopterin (a marker of immune activation produced by activated 
macrophages) in the Isatoribine trial.  
 
Figure 29:  Structure of SM-360320:  Selectivity – TLR7 specific 
                  Plasma protein binding (PPB) – 75% 
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The aim of this study was to investigate both the anti-viral and the immunostimulatory 
actions that might be responsible for HCV clearance in vitro. The effects of the TLR7 
agonist, SM-360320 (9-benzyl-8-hydroxy-2-(2-methoxyethoxy)adenine) (295) on innate 
immunity was studied and the responses were compared in blood from NHDs and 
patients with CHC, both treatment naïve and previous non-responders to treatment. 
5.3 Materials  and  Methods: 
Blood samples were collected from chronic hepatitis C patients recruited from the 
hepatology clinics run by Southampton University Hospitals NHS Trust and Royal 
Bournemouth and Christchurch NHS Trust. All patients had detectable HCV RNA 
determined by quantitative PCR (Cobas Amplicor HCV Monitor test, Roche Molecular 
Systems, NJ, USA). Patients were excluded if they had received treatment within 6 
months or less prior to the study or tested positive for other blood bourn viruses, including 
HBV and HIV. 60 patients were Interferon treatment naïve and 20 were previous non-
responders (NR) to treatment. A further 80 uninfected NHDs, who had no risk factors for 
blood borne viruses were also recruited.  
 
Clinical data from all three groups can be seen in table 5. 
 
Stimulating whole blood: 
Aliquots of fresh blood (450μl) collected into sodium citrate were transferred into 24-well 
assay plates containing 50μl pre-prepared agonist, SM-360320, IFNα or no stimulus. Final 
concentrations of SM-360320 were 0.1μM – 10μM and IFNα was 20IU/ml IFNα. The 
plates were sealed, placed on an orbital shaker and incubated for 5 hours at 37
0C. 
Aliquots (4 x 25µl) of the stimulated blood from each well were transferred to 96 well 
plates and mixed with MagMAX lysis/binding solution. 
 
The blood remaining in the 24 well plate was spun (5 min at 500rpm) and plasma 
removed and frozen at -80
0C. The remaining cell pellet was resuspended in the residual 
plasma (~300µl) and 1.3mls RNALater (Ambion) was added to stabilize the samples. 
These samples were also frozen at -80 C pending further analysis for gene expression, 
cytokine analysis, and HCV replicon assays which were undertaken at Pfizer, Sandwich. 
    128  PBMC isolation and storage: 
Blood collected into EDTA containing vacutainers was separated immediately and PBMC 
isolated (see chapter 2.2.1.1) Cells were frozen and stored at -80
0C while awaiting further 
use. 
 
Gene Expression Analysis: 
After thawing, RNA was extracted from blood mixed with MagMAX lysis/binding solution 
using the MagMAX 96 well blood RNA isolation kit according to the manufacturer’s 
instructions. Complementary deoxyribonucleic acid (cDNA) was prepared using high 
capacity cDNA archive kits. 2’5’OAS gene expression was quantified using real time 
taqman QPCR using ‘assay on demand reagents’ (Applied Biosystems, USA) as 
described by the manufacturer. 2’5’ OAS gene expression was maeasured relative to the 
background house keeper gene, β-actin, giving the ‘relative quantitiy’. This was analysed 
using the delta-delta-ct method of analyzing Taqman. (This work was done at Pfizer) 
Cytokine analysis    
Levels of pro-inflammatory cytokines, TNFα, IL-1β, IL-2, IL-6, IL-8, IL-12p70, anti-viral 
cytokines, IFNγ and IFNα and regulatory cytokines, IL-10 and IL-4 were determined in 
plasma using a custom multiplex electrochemiluminescence Enzyme-Linked 
ImmunoSorbent Assay (ELISA) as described by the manufacturer (Meso Scale 
Discovery). (This work was done at Pfizer).                                   
HCV replicon assay 
The presence of soluble factors with anti-viral activities in treated plasma was measured 
by evaluating the ability to inhibit HCV replication in an HCV-replicon system.  
Huh7 1b replicon cells were cultured in flasks. Supernatants (10 uL) from whole blood ex 
vivo experiments were added to the replicon cells and incubated for 48 hours at 37
0C.  
HCV Replicon levels were then quantified using a luciferase reporter assay (270). (This 
work was done at Pfizer). 
NK cell activation & intracellular IFNγ staining 
Previously cryopreserved PBMCs were thawed and rested in incubators for five hours at 
37
0C prior to the assay. Cells were resuspended to 2 x 10
6/ml in RMPI1640 (no phenol). 
900μl PBMCs were plated into duplicate wells of a 24 well plate containing 100μl pre-
    129  prepared agonist per well, 100μl IFNα2b.or 100μl of dilutent only. After 5 hours incubation 
at 37°C, 1μl of Brefeldin-A was added to one well of each duplicate. Cells were then 
incubated for a further 18 hours. After a total culture period of 24 hours, PBMCs were 
harvested and labelled for four-colour flow cytometry to identify activated CD56
+ CD16
+ 
NK cells on the basis of cell surface CD69 expression and cytoplasmic interferon gamma 
(IFNγ) expression by intracellular staining.  
 
pDC Depletion 
For 5 NHDs and 5CHC patients, PBMCs were prepared from freshly drawn blood (se 
Chapter 2.2.1.1). pDCs were isolated from the PBMCs by positive selection (see chapter 
2.2.1.3). Whole PBMCs, PBMCs from which BDCA4
+ pDCs were depleted, and pDCs 
alone were stimulated with SM360320 (10uM-0.01uM) in sealed plates for 5hours at 37
0C 
and gene expression analysis, cytokine production and  NK cell activation was assessed 
as above. The % purity of the pDC depletion was assessed by FACS analysis. 
 
For a full description of the methods, see Materials and Methods chapter 2. 
 
Statistical Analysis: 
All statistical analysis was undertaken by a statistician at Pfizer. GraphPad PRISM (V5) 
and a Pfizer Inc proprietary add-in to Microsoft Excel 2003 were used to perform initial 
data analysis and visualisations.  Statistical analyses were performed using SAS (V8.02), 
GenStat (V10) and Spotfire DecisionSite 9.0.   
In order to satisfy the assumptions of the analysis methods used, the data from the gene 
expression, cytokine and pDC depletion analyses were analysed on the log10 scale and 
data from NK-cell Activation were analysed on the logit scale.  Plots of the data were used 
to check the statistical assumptions and any unusual features such as outliers were 
investigated.  
 
For gene expression, cytokine analyses, NK-cell activation and pDC depletion 
experiments all transformed responses were analysed using a linear mixed model that 
allowed for donor-to-donor variation and investigated differences between the three donor 
groups, the stimuli and the effects of pDC depletion. Specific pairwise comparisons 
between the stimuli and groups were quantified on the transformed scale and back-
transformed to give geometric means, ratios in means, 95% confidence intervals 
    130  (excluding NK-cell activation data) and p-values.  All tests were performed at the 5% 
significance level.   
 
For the HCV replicon assay the distribution of the collected Replicon data did not lend 
itself to the modelling techniques used for the other responses. Therefore the multivariate 
technique K-means clustering was applied to identify similar donor profiles, where a profile 
contains the responses exhibited by a donor across the 6 stimuli.  A number of different 






















    131  Table 5:  Subjects clinical characteristics 
      CHC  NHDs 
      Naive (n=60)  NR (n=20)  n=80 
Age Median  46 45  42 
   Range  27-87 36-70  22-61 
Gender Male  46(77%) 16(80%)  54(68%) 
   Female  14(23%) 4(20%)  26(32%) 
Race Caucasian  57 17  Unknown
   Asian  1 3     
Genotype
a G1  28(47%) 14(70%)  N/A 
   G2/3  28(47%) 5(25%)     
   G4  1(1%) 1(5%)     
   Unknown  3(5%) 0(0%)     
Viral load
b Median  7.91E+05 5.52E+06  N/A 
   Range  (7.02E+02-2.32E+07) (7.25E+05-2.06E+07)     
Disease Severity
c Mild  19(32%) 5(25%)  N/A 
   Moderate  14(23%) 1(5%)     
   Severe  14(23%) 7(35%)     
   No Biopsy  13(22%) 7(35%)     
ALT (IU/L) (10-40)  Median  62 58.5  N/A 
   Range  10-169 22-252     
Risk for HCV  IVDU  33 7  N/A 
   Blood Product  14 9     
   Other  11 4     
Alcohol intake
d Low  33(55%) 16(80%)  N/A 
   Moderate  11(18%) 3(15%)     
   Heavy  16(27%) 1(5%)     
 
a HCV genotype determined using CPA accredited PCR-based ‘Genotyping for Treatment Assay’ (iQur Ltd, 
UK). 
b Viral load determined by quantitative PCR (Cobas Amplicor HCV Monitor test, Roche Molecular Systems, 
USA) quoted as copies/ml.   
c Based on histological analysis of biopsies for inflammation and fibrosis. In the 
absence of histological evidence, disease status was determined by clinical criteria including physical 
examination, diagnostic imaging and laboratory indices.    
 
d Low, <7 units/week; Moderate, 7-14 units/week; Heavy, >14 units/week 
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5.4.1 Induction  of  2’5  OAS Gene Expression: 
2’5’OAS gene expression is shown as ‘relative quantity’ The ‘relative quantity’ of 2’5’OAS 
is relative to the background house keeper gene, β-actin, analyzed using the delta-delta-ct 
method of analyzing Taqman rather than analyzing arbitrary copy number. The β-actin 
levels were not found to be reduced by either treatments. 
Culture of whole blood, from all three groups, with 20IU/ml IFNα or SM-360320 at dose of 
1µM significantly induced 2’5’OAS gene expression (p=<0.01; Fig 30). The magnitude of 
the response was higher in blood from NHD compared to CHC (p=<0.01). However, in the 
CHC patients, a larger variation in the induction of 2’5’ OAS was observed across the 
samples compared to NHDs with some patients giving a 100-fold induction. There was no 
significant difference observed between treatment naïve and NR patient groups.  
 
Fig. 30:   Expression of 2’5 OAS:  SM-360320 (10μM and 1μM) and IFNα (20IU/ml) enhanced 
expression of 2’5’OAS in all 3 patient groups. Expression was significantly less in the CHC groups 






































































































    133  5.4.2  Induction of Cytokine Production: 
1μM SM-360320 stimulated secretion of all the antiviral, anti-inflammatory and regulatory 
cytokines tested (p=<0.001) in whole blood from NHDs and CHC patients with a dose 
response clearly shown. A wider range of secretion of individual cytokines was noted from 
CHC patients as compared to NHDs (Figure 31). It enhanced the secretion of IP-10, IFNγ 
and IL6 to the highest levels.  
 
20IU/ml IFNα and was found to stimulate significant amounts of IFNα, IFNγ, IL-6, IP-10 
and IL-12 (p=<0.001) in blood from CHC patients and IFNα, IL-6, IP-10 and IL-1β in blood 
from NHDs but had no effect on the other cytokines tested (IL-1β, IL-8, TNFα, IL-4 and IL-
10 in CHC patients and IFNγ, TNFα, IL-12, IL-8, IL-4 and IL-10 in NHDs) 
 
SM-360320 enhanced secretion of TNFα, IL-6 and IL-1β to higher levels than were 
observed from NHD- blood and CHC-blood on incubation with IFNα. In contrast, similar 
levels of endogenous IFNα and IP-10 were secreted on incubation with both compounds, 
although the MSD assay may be detecting the exogenous IFNα making this data difficult 
to interpret. 
 
On average, naïve CHC-blood induced higher levels of the cytokines when stimulated with 
either compound as compared to non-responder CHC-blood, however this did not reach 
statistical significance (p=>0.10) 
 
The untreated levels of all the cytokines secreted was higher from CHC-blood than NHD-











    134  Fig 31.   Cytokine secretion: Secretion of anti-viral, pro-inflammatory and regulatory cytokines 
by PBMCs treated with TLR7 agonist SM360320 and IFNα. * indicate significant enhancement of 




































































































































































































































































NHDs Naive CHC NR CHC
 




























































































































































































































































NHDs Naive CHC NR CHC
 
 
    136  Table 5: Induction of cytokine production: Cytokines were induced in all 3 subject groups. Data  
presented here showing mean responses and significance over untreated  for 10 cytokines tested in NHD,  
















IP-10  NHD Untreated  10.4  -  -  - 
     SM   1803.0  <0.001  174.2  (148.3, 204.6) 
      IFNα  529.7 <0.001 51.2  (43.6,  60.1) 
   Naïve  Untreated  83.6  -  -  - 
      SM   4036.5  <0.001  48.3  (37.4, 62.4) 
      IFNα  1749.8 <0.001  20.9  (16.2,  27.0) 
   NR  Untreated  66.5  -  -  - 
      SM   3372.9  <0.001  50.7  (33.2, 77.4) 
      IFNα  1566.8 <0.001  23.6  (15.4,  36.0) 
IFNα (2a)  NHD Untreated  1.7  -  -  - 
     SM   94.4  <0.001  54.5  (43.6, 68.0) 
      IFNα  81.1 <0.001 46.8  (37.5,  58.4) 
   Naïve  Untreated  12.0  -  -  - 
      SM   338.8  <0.001  28.2  (19.8, 40.3) 
      IFNα  241.0 <0.001 20.1  (14.1,  28.7) 
   NR  Untreated  6.0  -  -  - 
      SM  269.2  <0.001  45.2  (25.0, 81.5) 
       IFNα  205.1 <0.001 34.4  (19.1,  62.1) 
TNFα  NHD Untreated  1.9  -  -  - 
     SM  185.8  <0.001  99.8  (86.9, 114.6) 
      IFNα  1.5 <0.01 0.8  (0.7,  0.9) 
   Naïve  Untreated  13.4  -  -  - 
      SM  179.5  <0.001  13.4  (10.5, 17.2) 
      IFNα  12.1 NS 0.9  (0.7,  1.2) 
   NR  Untreated  10.4  -  -  - 
      SM  141.3  <0.001  13.5  (9.0, 20.4) 
      IFNα  8.8 NS 0.8 (0.6,  1.3) 
IL-12p70  NHD Untreated  2.8  -  -  - 
     SM  7.2  <0.001  2.6  (2.2, 3.0) 
    137        IFNα  2.3 <0.05 0.8  (0.7,  0.9) 
   Naïve  Untreated  27.2  -  -  - 
      SM  357.3  <0.001  13.2  (10.1, 17.2) 
      IFNα  161.4 <0.001  5.9  (4.5,  7.8) 
   NR  Untreated  15.7  -  -  - 
      SM  311.9  <0.001  19.8  (12.7, 30.8) 
      IFNα  125.3 <0.001  8.0  (5.1,  12.4) 
IL-1β  NHD Untreated  0.5  -  -  - 
     SM  43.8  <0.001  96.7  (81.6, 114.6) 
      IFNα  0.3 <0.001 0.7  (0.6,  0.8) 
   Naïve  Untreated  5.6  -  -  - 
      SM  86.9  <0.001  15.5  (11.2, 21.3) 
      IFNα  6.2 NS 1.1 (0.8,  1.5) 
   NR  Untreated  4.8  -  -  - 
      SM  45.7  <0.001  9.5  (5.5, 16.5) 
      IFNα  4.0 NS 0.8 (0.5,  1.4) 
IL-4  NHD Untreated  1.2  -  -  - 
     SM  2.4  <0.001  2.1  (1.8, 2.4) 
      IFNα  0.6 <0.001 0.5  (0.5,  0.6) 
   Naïve  Untreated  8.2  -  -  - 
      SM  31.8  <0.001  3.9  (2.9, 5.2) 
      IFNα  8.3 NS 1.0 (0.8,  1.3) 
   NR  Untreated  4.7  -  -  - 
      SM  23.7  <0.001  5.0  (3.1, 8.2) 
      IFNα  5.8 NS 1.2 (0.8,  2.0) 
IL-6  NHD Untreated  4.5  -  -  - 
     SM  1419.1  <0.001  317.0  (257.5, 390.1) 
      IFNα  13.6 <0.001 3.0  (2.5,  3.8) 
   Naïve  Untreated  32.5  -  -  - 
      SM  1306.2  <0.001  40.2  (28.5, 56.7) 
      IFNα  61.2 <0.001 1.9  (1.3,  2.7) 
   NR  Untreated  17.3  -  -  - 
      SM  1137.6  <0.001  65.8  (37.3, 116.1) 
      IFNα  35.5 <0.001 2.1  (1.2,  3.6) 
IL-8  NHD Untreated  9.8  -  -  - 
     SM  40.7  <0.001  4.2  (3.6, 4.8) 
      IFNα  3.2 <0.001 0.3  (0.3,  0.4) 
    138     Naïve  Untreated  55.8  -  -  - 
      SM  87.5  <0.001  1.6  (1.2, 2.0) 
      IFNα  17.2 <0.001 0.3  (0.2,  0.4) 
   NR  Untreated  39.0  -  -  - 
      SM  43.9  NS  1.1  (0.7, 1.7) 
      IFNα  11.4 <0.001 0.3  (0.2,  0.4) 
IL-10  NHD Untreated  0.9  -  -  - 
     SM  1.6  <0.001  1.7  (1.5, 2.0) 
      IFNα  0.6 <0.001 0.6  (0.6,  0.7) 
   Naïve  Untreated  17.1  -  -  - 
      SM  46.3  <0.001  2.7  (2.2, 3.3) 
      IFNα  16.5 NS 1.0  (0.8,  1.2) 
   NR  Untreated  13.6  -  -  - 
      SM  33.7  <0.001  2.5  (1.8, 3.5) 
      IFNα  11.7 NS 0.9  (0.6,  1.2) 
 
 
5.4.3 Inhibition  of  HCV Replication: 
Plasma derived from blood derived from treatment naïve and NR patients that had been 
incubated with 10µM and 1μM SM-360320 significantly inhibited replication of HCV 
replicons in Huh-7 cells (p=<0.05) shown by reduction of reduce luciferase reporter 
expression to baseline levels in an HCV replicon assay (Fig 32). This is consistent with 
the high levels of IFNα found in the plasma (338.8pg/ml-naive and 269pg/ml-NR) (Fig 31). 
The antiviral activity of plasma from IFNα treated blood was lower than that of SM-360320 
treated blood (median = 73% inhibition vs 99% inhibition) possibly due to degradation of 
exogenous IFNα and/or lower induction of endogenous IFNα. Some antiviral activity was 
observed in plasma derived from untreated blood. In the naïve CHC patients, two distinct 
groups were identified by K-means clustering, with some patients reaching maximal 
inhibition at a lower concentration of agonist than others. When comparing naïve and 
N.Rs, some naïve patients gave replicon responses that were more consistent with the 
N.R group than others. 
Blood from NHDs has not been analysed in the replicon assay.  
 




Fig. 32  Inhibition of HCV replication – Plasma from SM-360320 (10µM and 1µM) treated 
PBMCs significantly inhibited replication of HCV replicons in Huh-7 cells (p=<0.05).The antiviral 
potential of plasma from IFNα treated blood was less effective. 
























































5.4.4 Induction  of  NK Cell Activation: 
 
NK cells were identified by FACS as CD3-CD56+ and the percentage of these cells 
expressing CD69 (as a marker of activation) or containing intracellular IFNγ was 
determined. Surface expression of CD69 was studied on cells that had not been exposed 
to Brefaldin-A. In all 3 subject groups, the TLR7 agonist resulted in a dose-dependent 
increase in NK cell activation (Fig. 33). CD69 expression and IFNγ production were 
significantly enhanced by both 10µM and 1µM SM-360320 (p=<0.001) in all subject 
groups and also 0.01μM in NHDs. IFNα also enhanced CD69 expression in all subject 
groups (p=<0.001) but was less effective than the highest concentrations of SM-360320 
(p=<0.05) and did not significantly enhance IFNγ production (p=>0.1). 
 
Comparing the 3 groups treated with 10µM SM-360320, CD69 expression by treatment 
naïve CHC-NK cells was significantly lower than that seen in NHD-NK cells (p=<0.05). A 
similar trend was also seen between NHD-NK cells and NR CHC-NK cells but this was not 
statistically significant (p=>0.1) 
 
 
    140  Fig. 33    Induction of NK cell activation: TLR7 agonist enhanced NK cell activation in all 3 















































































































































































































































































5.4.5  The Role of pDCs: 
To investigate the role of pDCs in IFNα production and 2’5 OAS gene expression the 
effect of depleting  pDCs from PBMCs prior to exposure to the agonist, was studied in a 
subset of patients (NHD n=5, CHC n=5). Secretion of IFNα and 2’5’ OAS expression from 
whole NHD-PBMCs was induced on incubation with SM-360320 (10µM and 1µM) or 
20IU/ml IFNα (p=<0.05). Levels of IFNα induction were reduced on depletion of pDCs 
from the NHD-PBMCs stimulated with SM360320 (p=<0.05), confirming the importance of 
this cell type for TLR7 agonist responses. However, no significant difference in 2’5’ OAS 
expression was seen with pDC depletion (Fig. 34A). In the CHC group there was a wide 
variation of responses in the untreated samples of the whole PBMCs making the results 
from pDC depletion difficult to interpret for IFNα secretion. However, on depletion of pDCs 
from CHC-PBMCs, there was a significant reduction in 2’5’ OAS expression with 
SM360320 (10μM and 1μM) and 20IU/ml IFNα (p=<0.001) (Fig 34B). The efficiency of 
depletion of pDCs from PBMCs was 68% on average.  
    141   
To investigate whether NK cell activation was occurring indirectly in response to agonist-
induced IFNα production by plasmacytoid DCs (pDCs), or directly in response to the 
agonist, the effect of depleting pDCs from PBMCs prior to exposure to the agonist, was 
studied and cells stained for CD69 expression and intracellular IFNγ production. In 
preliminary experiments in the uninfected subject group, NK cell activation (assessed by 
CD69 expression and IFNγ production) was induced by the top doses of TLR7 agonist 
and was partially impaired by pDC depletion with reduced IFNγ secretion.  
 
Fig 34.    Effect of pDC depletion on IFNα production and 2’5’ OAS expression:  
A. In NHDs a reduced secretion of IFNα was seen from PBMC depleted of pDCs stimulated with 
SM360320. No significant change was seen in 2’5’ OAS expression when pDCs were depleted 
B. In CHC patients untreated levels of IFNα secretion in whole PBMCs were highly variable making 
interpretation on pDC depletion difficult. However, reduced expression of 2’5’ OAS was seen on 
depletion of pDCs. 
* indicate statistically significant enhancement or inhibition of IFNα production from untreated levels 
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    143  5.5 Discussion: 
The need to overcome immune dysfunction seen in HCV and induce strong HCV-specific 
T-cell responses to clear the virus has prompted evaluation of immunomodulators in CHC 
treatment. The aim of this study was to investigate both the antiviral and 
immunostimulatory actions of the TLR7 agonist, SM-360320 on cells derived from the 
blood of CHC -patients. We have shown that SM-360320 was able to induce a robust ex 
vivo innate immune response in blood from treatment naïve and NR-CHC-patients.  
On average blood from naïve-CHC patients produced higher levels of all cytokines 
compared to NRs but no differences were observed in the cytokines secreted. In the 
replicon assay, blood from some of the naïve patients showed responses more like the 
NR-patients which may indicate they will be non-responders to treatment. CD69 
expression on NK-cells was higher in NHDs than CHC-patients with no significant 
difference between naïve and NRs. There were no differences observed in 2’5’OAS 
expression between the patient groups. 
TLR7 expression is limited to certain tissues (296) and a restricted set of human immune 
cells, notably pDCs and B cells. TLR7 agonists are not thought to have direct antiviral 
effects (297) but following TLR engagement induce pDCs to produce large quantities of 
type 1 IFNs and more modest amounts of various other cytokines e.g. IL-6 and TNFα. 
Induction of type 1 IFNs through activation of TLRs on pDCs is a crucial part of the host’s 
innate immune response to viral infection which results in the production
 of a wide range 
of downstream antiviral effector molecules such as interferon stimulated genes: 2’5’OAS,
 
RNase-L, MxA, and signaling chemokines such as IP-10. As a consequence of the 
secretion of type 1 IFNs, a number of secondary effects are also induced such as 
stimulation of NK-cells as well as maturation of pDCs to potent antigen-presenting cells, 
augmenting their ability to stimulate T-cells and thus activating both the innate and 
adaptive immune responses. 
In this study we investigated the antiviral effects of SM-360320 by looking at the induction 
of 2’5OAS, induction of cytokines and the antiviral activity of plasma from treated blood in 
HCV replicon cells. 
 
    144  Plasma from blood treated with SM-360320 inhibited replication of HCV-replicons in Huh-
7 cells reducing luciferase reporter expression to baseline levels. This may indicate the 
potential of TLR7 agonists to reduce viral load mediated by the antiviral activities of 
agonist-induced IFNα. The expression 2’5’OAS was found to be increased with TLR7 
treatment and secretion of antiviral cytokines, IFNα and IFNγ and pro-inflammatory 
cytokines from whole blood were significantly enhanced. In vivo this would be predicted to 
promote a Th1 immune response and favour viral clearance. 
NK-cells play an important part in the first line of defence against viral infections, rapidly 
recognising and killing virus-infected cells and also secreting inflammatory cytokines, such 
as IFNγ which have direct antiviral effects as well as activating and polarising Th1 and 
cytotoxic lymphocyte responses (298;299). Therefore they provide a pivotal link between 
innate and adaptive immunity. Several groups have shown
 that TLR7 agonists induce NK-
cell activation (CD69 expression and IFNγ production) and enhance their cytotoxic
 effector 
function (300-303). In this study we found that SM-360320 was able to significantly 
upregulate NK-cell activation and was more effective than IFNα treatment. The effect of 
SM-360320 on NK-cells was lower in CHC-patients than NHDs.   
 
NK-cells express TLR 2, 3, 5 and 6 but little TLR 4, 7, 8 and 9 (300). It is not clear 
therefore if NK-cell activation by TLR7 agonists is caused by direct activation of TLR7 
receptor in NK-cells or if they act indirectly and secondary to activation of other cells, in 
particular pDCs, and cytokines produced by these cells. It has previously been observed 
that TLR7-induced NK-cell activation is crucially dependant on contact with cytokines (e.g. 
IFNα or IL-12) produced by accessory cells in the blood (301-303). 
 
To explore this further, we depleted pDCs, the main IFNα producing cells, from PBMCs 
and assessed the effects of the TLR7 agonist on NK-cell activation. In preliminary 
experiments it has been shown that NK-cell activation was partially impaired supporting 
evidence of an indirect effect and dependence on cytokines from accessory cells in the 
peripheral blood.  
To determine the contribution of pDCs to any antiviral or immunostimulatory effects of SM-
360320, the effects of pDC depletion on cytokine secretion and 2’5’OAS induction were 
assessed. As would be expected, depletion of pDCs from NHD-PBMCs resulted in a 
reduction of IFNα secretion however a corresponding reduction in 2’5’OAS induction was 
    145  not found to be significant. In CHC-PBMCs, 2’5’OAS induction was found to be decreased 
but the IFNα data is difficult to interpret due to large variability in the whole PBMC group. 
Defects in CHC-pDC IFNα production have been described in a number of studies 
(136;304-309) and it would be interesting to explore the effects of the TLR7 agonist 
directly on pDCs to see if it has the ability to induce pDC maturation and reverse the 
defects described. 
 
Current treatment for CHC is based on the combination of PEG-IFNα and ribavirin. Both 
appear to possess antiviral and some immunomodulatory activities (310;311). When 
comparing IFNα, at a concentration representative of plasma levels typically found during 
IFN therapy, to the TLR7 agonist in this study we show that, SM-360320 at 1µM induced 
pro-inflammatory cytokines and 2’5’OAS to higher levels than IFNα, was more effective in 
the replicon assay and induced NK-cell activation to significantly higher levels based on 
percentage of circulating NK cells expressing CD69, which has also been shown with a 
TLR9 agonists (312). Therefore, comparison of immunostimulatory and antiviral activities 
show that SM-360320 may provide similar or better antiviral effects and modulation of the 
innate immune response. Irrespective of the efficacy of SM-360320 in vitro it must be 
recognized that preclinical and clinical trials may reveal adverse effects that may make the 
compound impractical or less attractive than IFNα. 
  
Clinical studies with TLR7/8 agonists (313-316) have shown a modest reduction in viral 
replication in HCV infected patients as well as induction of the immune response with 
enhanced secretion of IFNα, IP-10, neopterin and enhanced expression of ISGs, 2’5’ OAS 
and ISG15. They were also shown to functionally activate NK cells in vitro and conditioned 
media from the TLR treated PBMCs inhibited HCV replication in a replicon system 
(317).The virological response correlated with the induction of the ISGs indicating that 
they induce their anti-HCV effect through induction of an immune response. These 
findings are therefore similar to what I have shown in this study.  
 
While stimulating TLRs could re-establish an appropriate immune response to infection, 
caution must be taken as inappropriate stimulation can lead to inflammation and 
autoimmunity with unwanted stimulation of cytokines causing side effects.  In general side 
effects of TLR agonists have been mild, with far fewer problems than less subtle immune 
stimulators such as IFNs (318), however, development of several TLR7 agonists have 
    146  been halted due to intense immune stimulation found in 13 week toxicology studies .  In 
this study the effective in vitro dose of SM-360320 was found to be 1μM.  
 
Although direct-acting HCV-specific drugs (e.g. protease inhibitors) may provide superior 
antiviral effects, a probable advantage of TLR agonists is the relatively low emergence of 
drug resistance that is a particular challenge in HCV with its high genetic diversity and 
mutation rate. Drug resistance is less likely because the molecular target of these agents 
is the host receptor rather than a virally encoded target. Furthermore, because TLR7 
activation initiates a broad immune response, including both innate and adaptive 
responses, it is likely that multiple aspects of viral replication are simultaneously attacked. 
 
In summary, the TLR7 agonist, SM-360320 has been shown to possess effective antiviral 
and immunostimulatory effects on whole blood from CHC donors and might provide 
complementary and additional HCV therapies making it a promising novel treatment. It is 
likely that HCV therapy will continue to require the presence of an effective 
immunomodulatory agent and TLR7 provides a candidate target mechanism for this role. 
 
Summary of findings: 
Induction of 2’5’OAS: 
• SM360320  (10μM and 1μM) and IFNα induced 2’5’OAS expression in NHD and 
CHC patients 
•  A higher response was seen in NHDs compared with CHC patients 
•  No difference was seen between NR and naïve CHC patients 
 
Induction of cytokine production: 
•  SM360320 stimulated secretion of all cytokines tested (10μM and 1μM) in NHD 
and CHC patients 
• IFNα stimulated secretion of IFNα, IFNγ, IL-6, IP-10 and IL-12 in CHC patients and 
IFNα, IL-6, IP-10 and IL-1β in NHDs 
•  Higher levels of IL-1β and IL-6 were produced from SM360320 treated blood 
compared to IFNα treated blood 
•  Naïve CHC blood induced higher levels of cytokines than NR CHC blood 
•  Untreated levels of all cytokines were higher from CHC patient blood 
 
    147  Inhibition of HCV replication: 
•  SM360320 treated blood inhibited replication of HCV replicons in Huh-7 cells 
•  SM360320 treated blood had a higher antiviral activity than IFNα treated blood 
 
Induction of NK cell activation: 
•  SM360320 enhanced CD69 expression and IFNγ production in a dose dependant 
manner 
• IFNα was less effective at enhancing CD69 expression than SM360320  
• INFα did not enhance INFγ production 
•  NHDs enhanced CD69 expression greater than naïve CHC patients  
 
The role of oDCs: 
• SM360320  and  IFNα enhanced secretion of IFNα and expression of 2’5’OAS from 
whole PBMCs from NHDs 
•  In NHDs, secretion of IFNα was reduced when pDCs were depleted while 2’5’OAS 
expression remained unchanged 
•  IN CHC patients, 2’5OAS expression was reduced when pDCS were depleted 



















Chronic infection with hepatitis C virus (HCV) is a major cause of liver related morbidity 
and mortality. It has infected 180 million people worldwide. Infection is spread parenterally 
and persists in 80% of patients. Substantial evidence has emerged to support the role of 
the host immune response in the outcome and pathogenesis of acute and chronic HCV 
infection. It has been accepted that successful viral clearance by the host is largely 
attributable to induction of innate immune responses with robust induction of type I IFN, 
antiviral cellular effectors and NK cells(159;319-321) and also the development of broad 
and sustained adaptive T cell responses directed to HCV antigenic determinants. 
 
Dendritic cells (DCs) are professional antigen presenting cells characterized by their 
exceptional capacity to activate naïve T cells and prime adaptive immunity. DCs play a 
pivotal role linking innate and adaptive immunity(65;67). They recognize pathogens 
through pathogen recognition receptors (PRRs) including toll like receptors (TLRs), 
leading to DC activation and maturation. Activated DCs then activate NK cells, thus 
driving the non-specific innate immune response, whilst simultaneously presenting antigen 
to initiate T cell mediated adaptive immunity. DC dysfunction has been implicated as a 
mechanism that enables persistent viral infection via impaired priming of naïve T cells and 
subsequent adaptive immune response. 
 
NK cells play an important part in the first line of defence against viral infections, rapidly 
recognising and killing virus-infected cells via perforin release, by induction of apoptosis 
and also by secreting inflammatory cytokines, such as IFNγ, which have direct antiviral 
effects, inhibiting viral replication as well as activating and polarizing Th1 and cytotoxic 
lymphocyte responses(80;81). Therefore they provide a pivotal link between innate and 
adaptive immunity. The phenotypes and/or functional activities of
 various populations of 
these cells have been reported to be
 impaired in patients with chronic HCV infection (140-
146). 
 
    149  I set out to explore the how current and novel treatments for hepatitis C are able to 
modulate the immune response looking specifically at their effects on dendritic cells, NK 
cells and their ability to stimulate T cells and an adaptive immune response in both NHDs 
and CHC patients. 
 
In the following sections, the findings made during the course of the project are 
summarized and discussed in relation to the future direction of treatment for CHC. 
  
 
6.2 Summary  of  Findings: 
 
6.2.1  Effect of ribavirin on DC maturation and cytokine production  
 
The current mainstay of treatment for CHC is ribavirin in combination with PEG- IFNα. 
Ribavirin is a purine nucleoside analogue which continues to remain critical in the 
treatment of CHC. Despite its effective use for the last 40 years, its mechanisms of action 
are still poorly understood but several hypotheses have been proposed (188). These 
include immunomodulatory effects, shifting the T-helper 1 cytokine balance (TH1)/ TH2) 
toward TH1 resulting in improved viral clearance.  
 
Some studies have previously shown suppressive effects of ribavirin on PBMCs but only 
one study has examined the effects of ribavirin on dendritic cells and focused on moncyte 
derived DCs that represent a model of myeloid DCs(322). They found that ribavirin 
suppressed IL-12, TNFα and IL-10 secretion when co-administered with poly I:C as a 
stimulus but had no effect on phenotypic maturation.  
 
In this thesis, I set out to investigate further the immunomodulatory effects of ribavirin and 
looked at its effects on pDCs freshly extracted from blood, which have not previously been 
evaluated. pDCs are the main producers of IFNα in the body. I explored the effects of 
ribavirin on pDC function and cytokine production.  
 
I have shown that ribavirin is able to modulate cytokine production from dendritic cells in 
response to a maturation stimulus, in particular suppressing the production of IFNα from 
pDCS from both CHC and NHD patients but also TNFα, IL8 and IL10. In MoDCs from 
    150  NHDs, I have shown that ribavirin decreased CD40L-induced TNFα production but had no 
effect on other cytokines tested following this stimulus, or on DC phenotype. 
 
The finding that ribavirin is unable to stimulate IFNα production from pDCs together with 
the further impairment in IFNα production from pDCs treated with ribavirin correlates with 
the requirement for exogenous IFNα in the effective treatment of CHC and may, in part, 
explain why ribavirin alone has little beneficial effect on HCV viral loads.  
 
At present it seems likely that ribavirin will continue to be needed in the future treatment of 
CHC alongside newer anti-virals, to achieve SVR and prevent relapse, as suggested in 
recent HCV protease inhibitor trials (206; 208; 256). The findings in this thesis suggest 
that exogenous IFNα therapy will be required if ribavirin is continued to be used as part of 
a combination therapy. Furthermore, the opposing actions of ribavirin and TLR agonists in 
IFNα production demonstrated in this study may have implications if they are to be used in 
combination in the future treatment of CHC. Finally, the ribavirin induced suppression of 
TNFα and IL8 from MoDC and pDC shown in this study may indicate an anti-inflammatory 
effect of ribavirin and may, in part, explain the previously reported reduction in hepatic 
inflammation with ribavirin monotherapy. 
 
6.2.1.1   Future Work: 
 
- Further investigation into the suppression of IFNα by Ribavirin using a larger cohort of 
patients and with exploration into the mechanisms underlying this defect. 
 
- Explore any possible maturation defect of pDCs caused by ribavirin by looking at the 
effects on CD86, CD80 and HLA-DR expression.  
 
- Explore if ribavirin has any effect on DC antigen presentation by looking at the effect of 
ribavirin treated DCs on T cell allo-stimulation and the effect on NK cell activation. 
 
- Comparison of effects of ribavirin on sustained responders and previous non-responders 
to treatment. 
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Specific T Cell Immunity by a Novel Helminth-Derived 
Immunostimulant.  
Current treatment for CHC leads to sustained viral eradication in 40-80% of infected 
patients depending on the HCV genotype and is associated with multiple side effects and 
complications. These often result in discontinuation of treatment and account for a large 
proportion of patients not being offered treatment. With the increasing prevalence of 
chronic hepatitis C there is a pressing need for safe and effective immunotherapies that 
will drive the host’s immune effector mechanisms towards viral clearance.  
Immunostimulants represent an emerging class of drugs that are designed to effectively 
and appropriately amplify naturally occurring immune responses against infectious 
pathogens. 
Onchocerca volvulus is a filarial parasite that causes human onchocerciasis (River 
Blindness). Recombinant secreted protein of the helminth Onchocerca volvulus, rOv-ASP-
1, is typical of nematode ASPs in that it is intrinsically immunogenic(282). rOv-ASP-1 has 
been shown to stimulate murine immunocytes in earlier work (274). 
In this study, I assessed the potential of rOv-ASP-1 as a human therapeutic by testing its 
ability to stimulate human dendritic cells from NHDs looking at its effect on DC phenotype 
and cytokine production and I investigated if it is able to enhance DC antigen presentation 
capacity by using proliferation assays. 
 
I have shown that rOv-ASP-1 activities are mediated by its ability to activate APCs. I have 
shown evidence of phenotypic maturation, based on up-regulation of phenotypic markers 
(CD40, HLA-DR, CD83 and CD86) and enhanced proinflammatory cytokine production 
(IL-6, IL-8 and TNFα). rOv-ASP-1 not only enhanced pro-inflammatory cytokine 
production from MoDCs but also significantly stimulated the production of the anti-
inflammatory cytokine IL-10. The rOv-ASP-1 induced secretion of IL-12 was found to be 
CD40-dependant and co-stimulation through the CD40-CD40L pathway also enhanced 
the rOV-ASP-1 induced secretion of IL-10 and TNFα. These results provide evidence that 
rOV-ASP-1 may initiate DC-induced adaptive immune responses by multiple distinct 
mechanisms.  
 
    152  I also found that rOv-ASP-1 enhanced the ability of MoDCs to stimulate proliferation of 
allogeneic CD4
+ T cells suggesting the protein is able to enhance DCs accessory/antigen 
presentation function. 
 
With the findings of the effects of rOv-ASP-1 on DCs shown in this study, there are 
several potential applications for the use of the protein including use as a novel innate 
vaccine adjuvant that can boost the activation of an adaptive immune response. The key 
property of adjuvants is their ability to induce DC maturation and activation which I have 
shown in this study. rOv-ASP-1 has also previously been shown to stimulate a mixed Th1/ 
Th2 with a strong Th1-biased immune response which is an important challenge for 
vaccine development and which few experimental adjuvants are capable. 
 
The ability of rOv-ASP-1 to stimulate human DCs may enable it to be used as a human 
therapeutic and as a DC activator where DC function is impaired by a pathogen. In the 
case of chronic HCV infection, where DC function has been reported to be impaired by the 
virus, rOv-ASP-1, or more likely a subunit, may potentially be used to boost antigen-
specific responses and favor viral clearance. 
 
Finally, the findings that rOv-ASP-1, enhances secretion of large amounts of IL-10, a 
potent immunoregulatory cytokine may also be valuable in inflammatory and autoimmune 
diseases. This would require expressing a subunit that is responsible for the induction of 
IL-10 without pro-inflammatory cytokines and be could particularly useful if administered 
topically, locally or targeted to an affected organ using a tissue-specific antibody. 
 
6.2.2.1     Future Work: 
 
- Investigate the antigen specific responses of rOv-ASP to recall antigens (influenza 
haemagglutinin, tetanus toxoid) and recombinant HCV antigens (core and NS3, from a 
genotype 1b isolate) measured by 
3H-thymidine incorporation. 
 
- Explore the effects of Ov-ASP-1 in CHC patients. 
 
 
    153  6.2.3  Evaluating the antiviral and immunostimulatory actions of a 
                 TLR7 agonist in chronic hepatitis C infection 
 
TLR agonists have been investigated in the treatment of chronic hepatitis C as a means of 
inducing endogenous IFNα production and efficient activation of innate and acquired 
immunity. The potential ability of TLR agonists to stimulate immune cells even in the 
presence of the immune dysfunction induced by CHC infection makes them important 
therapeutic targets with the aim that they could be used to activate pDCs to enhance 
endogenous IFNα production to clear HCV infection.  
 
In this study, I investigated both the anti-viral and the immunostimulatory actions of TLR7 
agonist, SM-360320 on the innate immunity, looking at its effects on 2’5’ OAS gene 
expression, HCV replicon inhibition, cytokine production and NK cell activation and 
comparing the effect of the agonist on blood from treatment naïve CHC patients, previous 
NRs to treatment and NHDs.  
 
I have shown that SM-360320 induces 2’5’OAS gene expression, inhibits replication of 
HCV replicons in Huh 7 cells and stimulates secretion of anti-viral and pro-inflammatory 
cytokines, all suggesting a potential mechanism for enhanced viral clearance through 
increased IFNα production and promotion of a Th1 immune response. 
 
I have also shown that SM-360320 is able to up-regulate NK cell activation as shown by 
enhanced CD69 expression and IFNγ secretion. NK cells play an important part in the first 
line of defence against viral infections, with direct cytotoxicity of virus infected cells and 
secretion of cytokines, such as IFNγ which have direct antiviral effects as well as 
activating and polarizing a Th1 immune response and again favouring viral clearance. 
 
I investigated the effects of pDC depletion on cytokine secretion and 2’5 OAS induction to 
explore the contribution of pDCs to any anti-viral or immunostimulatory effects of 
SM360320. Depletion of pDCs from NHD-PBMCs resulted in a reduction of IFNα 
secretion suggesting activation of pDCs through TLR7. However, in CHC patients the 
results were difficult to interpret and needs to be explored further with a larger number of 
patients. 
 
    154  The effects of SM-360320 on whole blood and NK cell activation were found to be greater 
than IFNα suggesting that SM-360320 may provide similar or better antiviral effects and 
modulation of the innate immune response than IFNa. 
 
The findings in this study suggest that SM-360320 might access complementary and 
additional mechanisms of action to current HCV therapies making it a promising novel 
treatment. However, irrespective of the efficacy of SM-360320 in vitro it must be 
recognized that preclinical and clinical trials may reveal adverse or differing effects that 
may make the compound impractical or less attractive than IFNα. 
 
6.2.3.1    Future work: 
- Explore the effects on the TLR7 agonist on purified pDCs from CHC patients to 
determine if it has sufficient potency to reverse the defect in CHC-pDC IFNα production 
reported in a number of studies. Determine if it has the ability to induce pDC maturation 
with upregulation of HLA-DR, CD80, CD86 and CD40. 
 
-  To assess the immunostimulatory effects of SM360320 on acquired immunity by looking 
at T cell proliferation in response recall antigens (influenza haemagglutinin, tetanus 
toxoid) and recombinant HCV antigens (core and NS3, from a genotype 1b isolate) 
measured by 
3H-thymidine incorporation to demonstrate if the agonist increases the 
capacity of antigen presenting cells to induce reactive T cells and promote antigen specific 
T helper type 1 cell-mediated immune response.  
 
-  Further explore the effect of pDC depletion in IFNα production and 2’5’ OAS expression 
in CHC patients with a larger cohort of patients. 
 
- Take TLR7 agonist, SM-360320 through preclinical testing, pharmo-toxicology studies 







    155  6.3 Conclusions: 
 
HCV remains a significant global healthcare challenge. The host’s immune response is 
pivotal in the natural clearance of infection, in disease pathogenesis of CHC and in 
response to treatment. 
 
The current mainstay of treatment for CHC is PEG-IFNα in combination with ribavirin, 
relying on immune stimulation from the IFNα while the mechanism of action of ribavirin 
remains poorly understood.  Work in this thesis has done little to advance the 
understanding of these mechanisms beyond showing a reduced production of IFNα from 
pDCs and explaining possible reasons behind the failure of monotherapy and 
dependence on co-administration of IFNα in treatment regimens. 
 
IFNα alone is only modestly effective and toxic, promoting the search for other therapeutic 
agents. Here we have shown that TLR7 agonists have the potential to reproduce many of 
the effects of exogenous IFNα with evidence of inhibition of viral replication and immune 
modulation. TLR7 agonists may have a role in replacing IFN and may be used in 
conjunction with directly acting antivirals. Used alone, they may have an advantage over 
direct antiviral agents such as protease inhibitors with the risk of drug resistance that is a 
particular challenge in HCV with its high genetic diversity and mutation rate. The 
molecular target of these agents is the host receptor rather than a virally encoded target 
making drug resistance less likely. 
 
The novel helminth-derived protein, rOv-ASP-1, investigated in this thesis has also shown 
promise as an effective immunostimulant to boost antigen specific responses or as a 
vaccine adjuvant.  
 
Further investigation of these compounds is therefore warranted due to their potential 
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Background: Ribavirin, in combination with interferon alpha (IFNα), is the current 
treatment for chronic hepatitis C (CHC). However, the mechanisms of ribavirin’s action are 
still poorly understood.  
Aim:  We investigated the immunomodulatory effects of ribavirin on dendritic cells which 
are potent antigen presenting cells playing a pivotal role linking innate and adaptive 
immunity. 
Methods: Using freshly isolated plasmacytoid DCs (pDCs) and cultured, monocyte-
derived DCs (MoDCs) the effect of ribavirin alone or in combination with the maturation 
stimuli CD40L, TLR9 agonist or TLR7 agonist was tested. The expression of DC 
    181  maturation markers (HLA-DR, CD83, CD86 & CD40) and cytokine secretion by normal 
healthy donors (NHDs) and CHC patients was examined. 
Results:  In pDCs, ribavirin upregulated the expression of CD86 (p=<0.05) but had no 
effect on HLA class I expression. Production of IFNα by NHD and CHC was significantly 
reduced by ribavirin at all concentrations (p=<0.05) following pDC stimulation with CD40L, 
TLR9 or TLR7 agonists. Ribavirin also caused a significant reduction in IL8 (p=<0.05) and 
TNFα (p=<0.05). The suppressive effects of ribavirin on cytokine production were not due 
to induction of pDC apoptosis or cell death. In MoDCs, ribavirin had no effect on 
maturation but was found to significantly suppress the production of TNFα (p=0.05). 
Conclusions:  The suppression of TNFα production from MoDCs and pDCs treated with 
ribavirin may contribute to the reduction in hepatic inflammation seen with ribavirin 
monotherapy. Ribavirin’s suppression of endogenous IFNα production from activated pDC 




Chronic infection with hepatitis C virus (HCV) is a major cause of liver related morbidity 
and mortality affecting 170 million people worldwide. Infection persists in 80% of patients 
and is thought to result from a failure to sustain an immune response against HCV
1. 
 
Dendritic cells (DCs) are professional antigen presenting cells characterized by their 
exceptional capacity to activate naïve T cells and prime adaptive immunity. DCs play a 
pivotal role linking innate and adaptive immunity
2,3. They recognize pathogens through 
pathogen recognition receptors (PRRs) including toll like receptors (TLRs), leading to DC 
activation and maturation
3. Activated DCs then activate NK cells, thus driving the non-
specific innate immune response, whilst simultaneously presenting antigen to initiate T 
cell mediated adaptive immunity. 
 
There are two functionally distinct subsets of DCs; myeloid (mDC) and plasmacytoid 
(pDC). pDCs are the most abundant producer of type-1 interferons in the body which they 
produce in large quantities during viral infections
4. Myeloid DCs produce IL12 to prime TH1 
responses. Monocyte derived dendritic cells (MoDCs) are commonly used in vitro as a 
model of myeloid DCs due to the larger numbers that can be obtained and their close 
resemblance. 
 
    182  Evidence points towards dendritic cell dysfunction in patients with chronic hepatitis C, with 
impaired maturation and impaired ability to stimulate T cells which may compromise their 




Ribavirin is a purine nucleoside analogue that is activated or metabolised through 5’ 
phosphylation to the monophosphate (RMP), diphosphate (RDP) and biologically active 
triphosphate (RTP) form. Despite its effective use for the last 40 years, the mechanisms of 
action of ribavirin are poorly understood but several hypotheses have been proposed
19,20. 
These include direct inhibition of viral RNA replication, inhibition of the enzyme inosine 
monophosphate dehydrogenase (IMPDH) and mutagenesis causing viral replication error 
catastrophe as well as  immunomodulatory effects, shifting the T-helper 1 cytokine 
balance (TH1)/ TH2) toward TH1 from T cells resulting in improved viral clearance.  
 
Ribavirin monotherapy has minimal effect on HCV viraemia but is associated with 
improvements in serum aminotransferases
21 suggesting that it may have an effect on 
inflammation and the host immune response. In combination with IFNα however, ribavirin 
increases the proportion of patients that clear the virus whilst on treatment from 27% with 
IFNα monotherapy
22 to 41% with combination therapy
23. However its most striking effect is 
that it prevents relapse after cessation of treatment. This latter effect is unexplained but 
also plays a significant role in newer treatment regimes that include HCV protease 
inhibitors with pegylated interferon and ribavirin
24-26. 
 
We set out to investigate the immunomodulatory effects of ribavirin on DC function in 
order to elucidate the mechanisms behind the prevention of relapse following treatment. 
Freshly isolated pDCs and cultured MoDCs from both NHDs and CHC patients were 
exposed in-vitro to ribavirin alone or to a combination of ribavirin and a maturation 
stimulus (CD40L, TLR9 agonist TLR7 agonist). These data show that ribavirin does 







    183  Materials and Methods:
 
Human subjects: 
Ethical approval was obtained from Southampton and South-West Hampshire Joint 
Research Ethics Committee and all patients gave informed consent in writing prior to 
participating in the study. 
 
Blood samples were collected from 21 uninfected NHD (18 male and 3 female, median 
age 53 years, range 25-67) who had no risk factors for blood borne viruses. Ten patients 
with CHC virus infection (4 female, 6 male, median age 54 years, range 37-61 years) 
were recruited from the hepatology clinics run by Southampton University Hospitals 
National Health Service Trust. All patients had detectable HCV RNA (4 genotype 1, and 
genotype 6 “non-1”). Patients were excluded if they had received treatment for HCV within 
6 months prior to the study or tested positive for other blood borne viruses, including HBV 
and HIV.  
 
Purification of plasmacytoid DCs from peripheral blood: 
Freshly drawn blood was obtained from NHD and CHC subjects in 300ml and 100ml 
volumes respectively. Blood was collected into K3  ethylenediamine tetraacetic acid 
(EDTA). PBMCs were prepared immediately using Lymphoprep density gradient 
centrifugation (Robbins Scientific, Solihull, UK). Plasmacytoid DCs (pDCs) were isolated 
from the PBMCs by positive selection with MACS BDCA-4 Blood Dendritic Cell Isolation 
Kit (Miltenyi Biotec, Bisley, UK), according to the manufacturer’s recommended protocol, 
in conjunction with an AutoMACS machine (Miltenyi Biotec). 
 
Generation of immature MoDCs: 
50mls of freshly drawn blood was obtained from NHD subjects and collected into EDTA 
and PBMCs prepared immediately using Lymphoprep density gradient centrifugation. 
Monocytes were isolated by positive selection with anti-CD14 conjugated magnetic MACS 
beads (Miltenyi Biotec), using an AutoMACS. 
Monocytes (1 x 10
6cells/ml) were cultured in 6 well plates (Greiner Bio-One, Stonehouse, 
UK) in 3ml per well of complete medium [RMPI-1640 without phenol red (Invitrogen, 
Paisley, UK), with 2 mmol/l L-glutamine, 100U/ml penicillin, 100μg/ml streptomycin 
(Sigma, Poole, UK) and 10% heat-inactivated fetal calf serum (FCS)  
(Hyclone, Perbio Science UK Ltd, Tattenhall, UK)], containing 50ng/ml recombinant  
    184  human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) and 1000 IU/ml 
rhIL4 (both from R&D Systems, Abingdon, UK). After 2 and 5 days 0.5ml of culture 
medium was replaced with fresh medium containing cytokines. 
 
Stimulation of MoDCs and pDC with ribavirin 
Day 5 immature MoDCs were plated into 24 well (500µL / well) cell culture plates (Greiner 
Bio-One) at a concentration of 2 x 10
5/ml. MoDCs were cultured with medium alone or in a 
1:1 ratio with CD40 ligand-transfected Chinese hamster ovary cells (hCD40L-CHO) ), (gift 
from Professor M. Glennie, Tenovus Laboratories, Southampton, UK) with or without 
different concentrations of ribavirin (4, 20, 100 and 500µM) (provided by iQur Ltd, 
Southampton, UK). 
 
Freshly isolated pDCs were plated into 96 well (200µl /well) cell culture plates at a 
concentration of 2 x 10
4 / ml. pDCs were cultured under the following conditions; (1) 
medium alone (2) in a 1:1 ratio with hCD40L-CHO cells, (3) with 1µM M362, a TLR9 
agonist (InvivoGen, San Diego, CA) or (4) 250µM loxoribine, a TLR7 agonist (InvivoGen) 
each with or without different concentrations of ribavirin (4, 20, 100 and 500µM). Cells 
were diluted in complete medium and incubated at 37
0C in 5% CO2
 
Determination of DC maturation: 
After 24 hours and 48 hours of culture, pDCs and MoDCs respectively were harvested 
and labelled for two-colour flow cytometry to identify their cell surface phenotype. 
 
Briefly, cells were resuspended in PBS containing 0.1% Sodium Azide (Sigma), 1% 
BSA (Sigma) and 100µg / ml human IgG (Jackson Immunoresearch, Suffolk, UK) and 
blocked on ice for 30 minutes. MoDCs were then stained using allophycocyanin (APC) - 
conjugated monoclonal antibodies against CD40, CD86 and CD83 (all from BD 
Biosciences, Oxford, UK) or fluorescein isothiocyanate (FITC)-labeled anti-human HLA-
DR (BD Biosciences). pDCs were stained using APC- conjugated monoclonal antibodies 
against HLA class 1 or FITC-labeled CD86 all diluted to their optimal concentrations or 
with equivalent concentrations of APC- or FITC- labelled isotype controls (murine IgG1 
and IgG2b; BD Biosciences). After staining, cells were washed, fixed in 1% 
paraformaldehyde and stored on ice in the dark pending data analysis using a 
FACSCalibur flow cytometer with Cell Quest software (BD Biosciences).  
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The cytokines produced by stimulated MoDCs and pDCs were isolated by centrifugation 
(300xg) as cell culture supernatants after 24 hours of culture.  
Production of IFNα from pDCs was determined using a human IFN-α multi-species 
Enzyme-Linked Immunosorbent Assay (ELISA), following the ‘extended range’ protocol of 
the manufacturer (PBL Biomedical Laboratories, NJ, US). This recognizes 13 of 14 IFN-α 
isoforms, the exception being IFN-αF. 
 
Concentrations of IL12p70, IL10, IL8, IL6, IL1β and TNFα, IFNγ, IL2, IL4, IL5 in MoDC 
and pDC culture supernatants were simultaneously quantified using the Multiplex 
Fluorescent Bead Immunoassay (FBI), according to the manufacturer’s instructions 
(Bender MedSystems). 3000 events were acquired using a FACSCalibur dual laser flow 




Determination of cell death and apoptosis: 
Freshly isolated pDCs were plated into 96 well cell culture plates at a concentration of 2 x 
10
4/ml in complete medium in the presence of 1μM M362 with or without ribavirin at 
different concentrations (500µM, 100µM, 20µM and 4µM) for 24 hours. Cell death was 
determined by FACS analysis with annexin V FITC in combination with propidium iodide, 
used according to the instructions of the manufacturer (BD Pharmingen).  
 
Statistical Analysis: 
Data was analyzed using GraphPad Prism version 4.0 for Windows (GraphPad Software, 
San Diego, CA, USA) with unpaired t-tests and one way ANNOVA test applied with 
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Results from pDCs: 
Ribavirin has no effect on IFNα production from immature NHD-pDCs: 
Freshly isolated pDCs from NHDs (n = 5) were cultured for 24 hours with; (1) medium 
alone (2) in a 1:1 ratio with CD40L transfectants  (3) with TLR9 agonist, M362 or (4) with 
the TLR7 agonist, loxoribine in the presence or absence of ribavirin at different 
concentrations. Unstimulated pDCs produced negligible amounts of IFNα which were 
unaltered by the addition of ribavirin (Fig. 1A).  
 
Ribavirin suppresses IFNα production from stimulated NHD-pDCs: 
When pDCs (n=5) were stimulated with CD40L, IFNα production was significantly 
increased. However, the addition of ribavirin, at all concentrations, significantly reduced 
the production of IFNα by NHD-pDCs in a dose-dependent manner in response to CD40L 
(fig. 1B). The same effect was observed when either a M362 or loxoribine was used in 
combination with ribavirin (Figs. 1C and D respectively). 
 
Ribavirin suppresses TNFα,  IL8, IL10 and IFNα from CD40L-stimulated  NHD-pDCs 
Using the Multiplex Fluorescence Bead Immunoassay (FBI), we tested the effects of 
ribavirin on other cytokines (IL12p70, IL10, IL8, IL6, IL1β and TNFα, IFNγ, IL2, IL4, IL5) 
produced by CD40L-stimulated pDCs from NHDs (n=7). Ribavirin was found to reduce the 
production of TNFα, IL8 and IL10 from stimulated NHD-pDCs (Fig. 2). The effects of 
ribavirin on production of these cytokines by loxoribine or M362 has not been studied. 
 
Ribavirin does not cause cell death or apoptosis in ex-vivo pDCs 
To ensure that the suppressive effects of ribavirin on pDC cytokine production were not 
due to induction of apoptosis or cell death, freshly isolated pDCs from NHDs were 
stimulated for 24 hours with M362 in the presence or absence of ribavirin, and then 
stained with annexin V and propidium iodide.  
 
Figure 3A shows that the inclusion of ribavirin, did not result in increased apoptosis or cell 
death. After 24 hours of culture without ribavirin, 20% of pDCs were dead compared to 
15%, when the highest dose of ribavirin (500µM) was added. The experiment was 
repeated 5 times and ribavirin did not significantly alter the proportions of live, apoptotic or 
dead cells at any of the test doses (Fig. 3B). 
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To ensure that the suppression of cytokine production from pDCs was not a ubiquitous 
reduction in all proteins, we looked at the effects of ribavirin on cell surface expression of 
CD86 and HLA class 1. Both molecules are normally highly expressed by stimulated 
pDCs. pDCs from NHDs (n = 5) were cultured for 24 hours with M362 (1µM) in the 
presence or absence of ribavirin and cells subsequently stained for two colour flow 
cytometry. We found that in pDCs stimulated with M362, ribavirin further upregulated the 
expression of CD86 (Figure 4A) (*p=<0.05) but had no effect on HLA class I expression 
(Figure 4B). 
 
Ribavirin suppresses IFNα, TNFα, IL8, IL10 and IFNα from stimulated CHC-pDCs: 
To investigate if these effects of ribavirin were also demonstrated in CHC-pDCs, freshly 
isolated pDCs from CHC patients (n = 5) were cultured for 24 hours in a 1:1 ratio with 
CD40L and the effects of ribavirin on IFNα and cytokine production were assessed. As 
seen in NHDs, IFNα production by pDCs from CHC patients was significantly reduced at 
500µM,100µM and 20µM of ribavirin (Figure 5) and TNFa, IL8 and IL10 production were 
also significantly suppressed (Fig. 6).  
 
Effects on MoDCs 
Ribavirin had no effect on unstimulated MoDC maturation: 
MoDCs from NHDs (n= 8) were cultured with ribavirin at different concentrations for 48 
hours without any additional stimulus. Irrespective of the concentration used, ribavirin 
alone had no effect on levels of expression of phenotypic markers CD40, CD86, CD83 
and HLA-DR on MoDCs (data not shown).  
 
Effects of ribavirin on cytokine production from MoDCs: 
MoDCs from NHDs (n =10) were cultured with or without CD40L for 24 hours in the 
presence or absence of ribavirin at different concentrations.  
 
In immature NHD-MoDCs, cultured with medium alone, ribavirin did not significantly alter 
the secretion of any tested cytokine (Fig 7a). When immature MoDC were cultured for 
24hours with CD40L, CD40 transfectants ligation stimulated the production of TNFα, IL8, 
IL6, IL12 and IL10 (Fig 7b) but not that of IL1β, IL2, IL5 or IFNγ. The addition of ribavirin 
at a concentration of 500µM significantly suppressed the production of this CD40L-
induced TNFα production (Fig 7b). The effect of ribavirin was less pronounced at lower 
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other cytokines tested.  
 
Discussion: 
With the clinical effects of ribavirin still largely unexplained, we set out to investigate the 
immunomodulatory effects of ribavirin on dendritic cell function by looking principally at the 
effects on cytokine production.  
 
In this study we have shown that ribavirin modulates dendritic cell cytokine production in 
response to a maturation stimulus. In pDCs from NHDs, ribavirin significantly suppressed 
stimulus-induced IFNα, TNFα, IL8 and IL10 and these findings were mirrored in pDCs 
from CHC patients. In MoDCs from NHDs ribavirin decreased CD40L-induced TNFα 
production but had no effect on other cytokines tested or phenotype. 
 
The ribavirin induced suppression of TNFα and IL8 from MoDC and pDC shown in this 
study may indicate an anti-inflammatory effect of ribavirin and may, in part, explain the 
reported reduction in hepatic inflammation with ribavirin monotherapy. It has been shown 
that ribavirin alone transiently improves biochemical and histological response in the 
absence of significant reduction in HCV load
21.  
 
The reduction of IFNα from ribavirin-treated pDCs may be of particular physiological 
importance since pDCs, unlike MoDCs, are the major source of INFα in the human body 
producing large quantities of type 1 IFN in response to viral infection. Several studies
14-18 
have found pDCs from patients with CHC have impaired production of IFNα. This defect 
will have an impact on both innate and adaptive immunity and favour viral persistence. 
Our finding that ribavirin is unable to stimulate IFNα production from pDCs together with 
the further impairment in IFNα production from pDCs treated with ribavirin correlates with 
the requirement for exogenous IFNα in the effective treatment of CHC and may, in part, 
explain why ribavirin alone has no beneficial effects on HCV viral loads. Whether ribavirin 
is actually exacerbating the IFNα defect in CHC-pDCs needs further investigation in larger 
cohorts to explore the exact mechanisms. It would be interesting to investigate whether 
the addition of exogenous IFNα can overcome the suppressive effects of ribavirin on 
cytokine production from dendritic cells. 
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this study may have implications if they are to be used in combination in the future 
treatment of CHC. The study undertaken by Coley with Actilon the TLR9 agonist, 
CpG10101
28 (currently withdrawn from further drug development at present) looked at the 
effects of this compound alone, in combination with ribavirin or IFNα or all combined and 
found ribavirin combined with CPG10101 was less effective than when combined with 
exogenous IFNα or all 3 together, strengthening the importance of continued use of 
exogenous IFNα in future treatments. 
 
As a purine nucleoside analogue, it has been hypothesized that ribavirin may exert 
immunomodulatory activities via TLR stimulation on dendritic cells
29. Our findings do not 
support this hypothesis, with ribavirin having no effect on either phenotype or cytokine 
production when administered alone to either pDCs or MoDCs. In stimulated DCs, 
ribavirin was still unable to further enhance cytokine production, but in fact reduced the 
production of IFNα, TNFα, IL8 and IL10 from pDCs and TNFα from MoDCs.  
 
To ensure the suppression of cytokine production from ribavirin-treated DCs was not a 
ubiquitous downregulation of all proteins, we looked at the effects of ribavirin on CD86 
and HLA class I expression, both of which are highly expressed on stimulated pDCs. Our 
results show that ribavirin had no significant effect on Class I expression and actually 
enhanced CD86 surface expression. The enhancement of CD86 surface expression was 
interesting and could reflect a subtle maturation effect of ribavirin. This should be explored 
further, looking at the other markers of pDC maturation such as increases in surface 
expression of MHC and co-stimulatory molecules, CD83 and CD80 as well as CD86. The 
expression of these co-stimulatory molecules is essential for effective activation of T 
lymphocytes. In previous studies it has been shown that DCs from CHC patients have 
impaired maturation with an immature phenotype
5-18. It is possible that ribavirin can 
overcome this effect and thereby restore antigen presentation and priming of T cells. In 
the absence of evidence of any other mechanism whereby ribavirin may enhance viral 
clearance and sustained response to interferon it may be a subtle effect on DC maturation 
that accounts for the profound clinical effects of ribavirin when used in conjunction with 
IFNα in the treatment of HCV infection and further studies will need to be carried out. The 
effect of dendritic cells treated with ribavirin on T cell allo-stimulation and the 
consequence for NK cell activation to see if ribavirin has any effect on DC antigen 
presentation function also needs further investigation. 
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Only one other study has examined the effects of ribavirin on DC maturation and 
function
30 and focused only on MoDCs. Using ribavirin at a physiological concentration of 
120µM, they found that ribavirin suppressed IL-12 and IL-10 in addition to TNFα when co-
administered with poly I:C as a stimulus. They assessed cell culture supernatants at 
multiple time points up to 48 hours and the suppression of IL-12 was seen at 32 hours and 
maximal suppression of IL-10 at 36 hours. In our study, supernatants were assessed at 
only one time point, at 24 hours which may be a reason for seeing no effect on IL12 in this 
study. However, they too found that ribavirin had no effect on phenotypic maturation in 
either stimulated or immature MoDCs.  
 
A number of studies in PBMCs have shown that ribavirin has an effect on mitogen-
induced cytokine production, with some studies showing enhancement and others 
inhibition
31-34. Furthermore some studies have shown ribavirin to induce a TH1 
profile
31,34,35, while others showed no impact on cytokine production
36 or induction of a TH2 
profile. We have shown reduction in both TH1 (TNFα, IL8 and IL6) and also TH2 (IL10) and 
the significance of this remains unexplained.  Some of the inhibitory effects of cytokines 
seen in PBMCs are thought to be secondary to the known antiproliferative effects of 
ribavirin on T cells
32. DCs, however, do not proliferate during stimulation so this is unlikely 
to be the case in this study.  
 
This study is limited by small numbers but has shown that ribavirin is able to modulate 
cytokine production from dentritic cells, in particular suppressing the production of IFNα. 
The findings in this study therefore highlight the importance of the continued use of 
exogenous IFNα therapy if ribavirin is used and the recent trials of HCV protease inhibitor 
Telaprivir
24-26 and Bocepravir
27 have indicated that ribavirin will continue to be required in 
future anti-viral regimes to achieve SVR and prevent relapse. The mechanisms underlying 
the suppression of IFNα by ribavirin and the possible effects of ribavirin on pDC 
maturation should be explored further. By studying a larger cohort of CHC patients it may 
also be possible to assess differences in the effects on cytokine production from sustained 
viral responders and non-responders to treatment. 
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Fig. 1  (A) Unstimulated pDCs from NHDs produced negligible amounts of IFNα which 
were unaltered by ribavirin. (B) Ribavirin, at all concentrations tested, significantly reduced 
the amount of IFNα produced by NHD-pDCs in combination with CD40 ligation. When (C) 
a TLR9 agonist (M362) and (D) a TLR7 agonist (loxoribine) were used as alternative 
stimuli of IFNα production, ribavirin again reduced IFNα production 
*p=<0.05; **p=<0.01 
 
Fig 2. NHD-pDCs stimulated with CD40L and ribavirin show suppressed production of 
TNFα, IL8 and IL10. 
 
Fig 3. Cytokine changes in NHD-pDCs stimulated with M362 and ribavirin are not 
attributable to increased apotosis or cell death. Apoptosis and cell death were assessed 
by flow cytometric staining for annexin V and PI (A). The left lower quadrant shows the 
number of viable cells (annexin-V and PI negative). The right lower quadrant shows the 
number of cells undergoing apoptosis (annexin-V positive and PI negative). The right 
upper quadrant shows the number of dead cells or those in late stages of apoptosis 
(annexin-V and PI positive).  
The experiment was repeated 5 times and ribavirin did not significantly alter the 
proportions of live, apoptotic or dead cells (B). 
 
Fig 4. NHD pDCs (n =5) stimulated with 1µM M362 and ribavirin further upregulated the 
expression of CD86 in a dose dependent manner (Figure 4A) (*p=<0.05) but had no 
significant effect on HLA class I expression (Figure 4B).  
MFI; mean fluorescence intensity; bars show mean. 
 
Fig 5. pDCs isolated from CHC patients also show reduced IFNα production following 
CD40 ligation in the presence of ribavirin as seen in NHD-pDCs (*p=<0.05). 
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Fig 6. In CHC-pDCs stimulated with CD40L (n=5), ribavirin was found to significantly 
suppress the production of TNFα, IL8 and IL10 by pDCs, mirroring the effects seen in 
NHDs.  
 
Fig 7. In immature NHD-MoDCs, ribavirin had no effect on secretion of any tested 
cytokine (7a). When MoDCs were cultured with CD40L, CD40 transfectants ligation 
stimulated the production of TNFa, IL8, IL6, IL12 and IL10 (fig 7b). Inclusion of ribavirin at 
a concentration of 500uM was found to significantly suppress CD40L-induced TNFa 
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    201  Abstract 
We previously reported that rOv-ASP-1, a recombinant Onchocerca volvulus activation 
associated protein-1, was a potent adjuvant for recombinant protein or synthetic peptide-
based antigens. In this study, we further evaluated the adjuvanticity of rOv-ASP-1 and 
explored its mechanism of action. Consistently, recombinant full-length spike protein (rS) 
of SARS-CoV or its receptor-binding domain (rRBD) in the presence of rOv-ASP-1 could 
effectively induce a mixed but Th1-skewed immune response in immunized mice. It 
appears that rOv-ASP-1 primarily bound to the antigen-presenting cells (APCs) among 
human peripheral blood mononuclear cells (PBMCs) and triggered Th1-biased pro-
inflammatory cytokine production probably via the activation of monocyte-derived dendritic 
cells (DCs) and the toll-like receptor TLR2 and TLR4, thus suggesting that rOv-ASP-1 is a 
novel potent innate adjuvant.  
 
Keywords: Onchocerca volvulus, innate adjuvant, vaccine, antigen-presenting cells, TLR-
2; TLR-4, SARS-CoV  
 
Introduction 
Recently, recombinant proteins and synthetic peptides have been considered as 
alternative approaches for vaccine development, but their poor immunogenicity 
emphasizes a major unmet need for immunostimulatory adjuvants capable of safely 
boosting both humoral and cellular immune responses. Currently, alum remains the only 
adjuvant approved for human use in the majority of countries worldwide. Although alum is 
able to induce a good antibody (Th2) response, it has little capacity to stimulate strong 
cellular (Th1) immune responses which are so important for protection against many 
pathogens (1). In addition, alum has the potential to cause severe local and systemic side-
effects that limit its wide application for various vaccines in humans.  
Protozoan and helminth parasites have proven to be a source of molecules which 
have potent regulatory and, sometimes, stimulatory effects on the immune systems of 
their mammalian hosts (1-4). Some of these molecules were shown to contain pathogen 
associated molecular patterns (PAMP) that bind to endocytic-pattern recognition receptors 
(PRRs) on antigen-presenting cells (APCs). Several helminth products were also reported 
to act as adjuvants in experimental vaccine models, but they preferentially induced Th2-
type immune responses (5-8). For example, proteins secreted by adult Nippostrongylus 
brasiliensis (NES) induced strong Th2 responses in mice immunized with hen egg 
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surface of the eggs of a human parasite, Schistosoma mansoni, acted as a Th2 adjuvant 
for human serum albumin when injected intranasally, subcutaneously or intraperitonealy 
into mice (6, 7). In a recent report, a 19 aa synthetic peptide (GK-1) from Taenia  
crassiceps cysticerci was shown to also have a capacity of an adjuvant (8). When it was 
co-administered with the inactivated anti-influenza vaccine in both young and aged mice, 
it induced increased levels of anti-influenza antibodies in aged mice before and after 
infection, reduced the local inflammation that accompanied influenza vaccination itself and 
favored virus clearance after infection in both young and aged mice. 
Activation-associated secreted proteins (ASP) of parasitic nematodes are highly 
immunogenic and have been extensively studied as potential vaccine components against 
their corresponding parasites, with the ASPs from hookworms being the major vaccine 
candidates tested in human trials (9-15). Like other filarial nematodes, Onchocerca 
volvulus worms secrete a large number of immunoregulatory molecules to subvert the 
immune responses and minimize severe pathology and thus enabling their ability to 
establish a chronic infection in humans that can last more than 15 years (16). The native 
ASP-1 protein of O. volvulus (Ov-ASP-1) is located in the secretory granules of the 
glandular oesophagus of the infective third-stage larvae (L3) and is predicted to have 
multiple immunoregulatory functions (2, 17).  Our previous studies demonstrated that 
recombinant Ov-ASP-1 (rOv-ASP-1) is not only a protective antigen in vaccinated mice 
against O. volvulus L3s, but also a potent adjuvant for bystander proteins (2, 17-19). In 
ovalbumin (OVA)-immunized mice, rOv-ASP-1 exceeded the efficacy of alum or 
MPL+TDM adjuvants in terms of end-point total IgG or IgG1 and IgG2a antibody titers 
(18). Interestingly, IgG isotype responses to OVA were of a mixed Th1/Th2-associated 
antibody profile but with a Th1 dominance and the spleen cell cytokines were exclusively 
of the Th1-type (18). We have also shown that although rOv-ASP-1 induced similar level 
of IgG1 responses as alum when formulated with HBsAg as the bystander vaccine 
protein, it clearly induced significantly higher levels of IgG2a and IFN-g-producing T cell 
responses against HBsAg than alum. Furthermore, Ov-ASP-1 improved both IgG1 and 
IgG2a responses to three commercial inactivated vaccines ((haemorrhagic fever with 
renal syndrome (HFRS), Influenza and Rabies) when used separately or in combination 
(20). In comparison with the other helminth-derived adjuvants shown to be strong inducers 
of Th2 responses to bystander proteins in vaccines (5-7, 21), the property of rOv-ASP-1 to 
induce both Th1 and Th2-associated antibody responses and depending on the antigen 
also a Th1-biased antibody and cellular responses highlights its potential utility as an 
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protective responses are of the Th1 type.  
In this study, we further evaluated the adjuvanticity of rOv-ASP-1 and explored its 
mechanism of action. Consistently, rOv-ASP-1  effectively boosted recombinant SARS-
CoV spike protein (rS) or its receptor-binding domain (rRBD) to induce a mixed but Th1-
skewed immune response in the immunized mice.  It appears that rOv-ASP-1 bound 
primarily to the APCs among human peripheral blood mononuclear cells (PBMCs) and 
triggered Th1 biased pro-inflammatory cytokines probably via the activation of monocyte-
derived dendritic cells (MoDCs) and the toll-like receptor TLR2 and TLR4, thus suggesting 
that rOv-ASP-1 is a novel potent innate adjuvant. 
 
Materials and Methods 
Preparation of recombinant Ov-ASP-1 
The recombinant Ov-ASP-1 protein (rOv-ASP-1) was expressed as a histidine-tagged 
protein in E-coli and purified as previously described (18). The purified rOv-ASP-1 was 
tested negative in a Limulus amoebocyte lysate assay. A quantitative LPS testing by 
Cambrex Bio Science (Baltimore, MD, USA) showed that purified rOv-ASP-1 contained 
less than 0.25 endotoxin units per milligram of the protein (25 pg endotoxin/mg). We 
considered it as an LPS-free stock and used it in all described experiments.  
Immunization of mice  
Mouse animal protocols were approved by the Institutional Animal Care and Use 
Committee at the New York Blood Center. The recombinant full-length S protein (rS) and 
its receptor-binding domain (rRBD) of SARS-CoV Urbani (accession number AY278741) 
were expressed by recombinant baculovirus system as previously described (22). Four 
BALB/c mice or five C57BL/6 (6 wks old) per group were subcutaneously immunized with 
20 μg of rS or rRBD resuspended in PBS plus 25 μg rOv-ASP-1 or MLP+TDM adjuvant as 
recommended (Sigma, Saint Louis, MO) and boosted with 10 μg of the same antigen with 
the corresponding adjuvant or PBS at 3-wk intervals. In a previous study (18) we found 
that 2.5 ￿g/mouse of rOv-ASP-1 adjuvant was not significantly active for antibody 
responses, 10 ￿g/mouse gave adjuvanticity intermediate to the final dose that we have 
chosen to use (25 ￿g/mouse) and 50 ￿g/mice was not better than 25 ￿g/mouse. The 
source of rOv-ASP-1 in this study is the same as that used in our previous studies and 
therefore we also used 25 ￿g/mice in this study. Pre-immune sera were collected prior to 
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before use.  
Enzyme-linked immunosorbent assay (ELISA)  
The reactivity of mouse antisera with rS protein was determined by ELISA. Briefly, 1 μg/ml 
rS protein was used to coat 96-well microtiter plates (Corning Costar, Acton, MA) in 0.1 M 
carbonate buffer (pH 9.6) at 4 ￿ overnight. After blocking with 2% non-fat milk, serially 
diluted mouse sera were added and incubated at 37 ￿ for 1 h, followed by four washes 
with PBS containing 0.1% Tween 20. Bound antibodies were detected with goat anti-
mouse IgG, IgG1, IgG2a, IgG2b or IgG3 antibodies (Sigma) as previously described (18). 
Then, biotinylated rabbit anti-goat IgG and extravidin peroxidase conjugate (both from 
Sigma, 1:2000 dilution for 1 h at 37￿) were added sequentially. After washes, the reaction 
was visualized by addition of the substrate 3,3’,5,5’-tetramethylbenzidine (TMB) and the 
absorbance at 450 nm was measured by an ELISA plate reader (Tecan US, Research 
Triangle Park, NC). 
 
SARS pseudovirus and neutralization assay 
A SARS-CoV pseudovirus system was developed in our laboratory as previously 
described (23, 24). In brief, HEK293T cells were co-transfected with a plasmid encoding 
the S protein corresponding to SARS-CoV Tor2 isolate and a plasmid encoding Env-
defective, luciferase-expressing HIV-1 genome (pNL4-3.luc.RE) by using FuGENE 6 
reagents (Boehringer Mannheim). Supernatants containing SARS pseudovirus were 
harvested 48 h post-transfection and used for single-cycle infection of human or civet 
ACE2-transfected 293T (293T/ACE2) cells. Briefly, 293T/ACE2 cells were plated in 96-
well tissue-culture plates at 10
4 cells/well and grown overnight. The supernatants 
containing SARS pseudovirus were preincubated with serially diluted antisera from 
vaccinated mice at 37 ￿ for 1 h before adding to the 293T/ACE2 cells. The cultures were 
fed with fresh medium 24 h later and then incubated for an additional 48 h. The cells were 
washed with PBS and lysed using lysis reagent included in a luciferase kit (Promega, 
Madison, WI). Aliquots of cell lysates were transferred to 96-well Costar flat-bottom 
luminometer plates (Corning Costar, Corning, NY), followed by addition of luciferase 
substrate (Promega). Relative light units (RLU) were determined immediately in the Ultra 
384 luminometer (Tecan US). Values are presented as the antibody titers that provide 
50% neutralization of rS binding to ACE2. 
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Spleens were harvested from the immunized mice and single-cell suspensions of 
splenocytes were obtained from the pooled spleens by mincing through cell strainers. 
Erythrocytes were lysed with ammonium chloride solution. Splenocytes were resuspended 
in complete RPMI 1640 medium to 1 X 10
6 cell/ml and 0.2 X10
5 were plated to 96-well U 
bottom plates for culture. The cells were stimulated with 1 μg/ml rRBD protein for 24 h. 
Cell culture supernatants were collected after stimulation and mouse cytokines (IL-2, IL-4, 
IL-5, IL-6, IL-10, IFN-γ, and TNF-α) were quantified by Cytometric Bead Array (CBA) kit 
(BD Biosciences, San Jose, CA) according to the manufacturer’s protocol.  
IFN-γ  ELISPOT assay 
Specific IFN-γ -producing cells from the splenocytes of vaccinated mice were detected by 
BD™ ELISPOT Mouse IFN-γ ELISPOT Set according to the manufacturer’s protocol (BD 
Biosciences). In brief, 96-well ELISPOT plates were coated with anti-IFN-γ monoclonal 
antibody (mAb) overnight at 4 ￿, and blocked by the Blocking Solution (RPMI-1640 
containing 10% FBS). Single-cell suspensions prepared from the spleens of vaccinated 
mice were added to the wells at the concentration of 2 x 10
5 cells/well. Cells were 
incubated for 24 h in the presence or absence of the rRBD (1μg/ml), followed by washes 
with PBS. The cells were sequentially incubated with biotinylated anti-mouse IFN-γ mAb 
for 2 h at room temperature (RT), streptavidin-conjugated horseradish peroxidase (HRP) 
for 1 h at RT and 3,3’,5,5’-tetramethylbenzidine (TMB) substrate solutions for around 15 
min, with extensive washes between incubations. The spots of IFN-γ  producing cells were 
counted by ELISPOT reader system. 
Flow cytometry-based binding assay 
rOv-ASP-1 and a similarly expressed control protein, chloramphenicol acetyl transferase 
(CAT), were labeled with biotin using the FluoReporter® Mini-biotin-XX Protein Labeling 
Kit (Molecular Probes). Fresh healthy donor PBMCs (N = 4) were isolated by density 
gradient centrifugation over Ficoll (Sigma). Five μg of biotinylated rOv-ASP-1 or CAT were 
then incubated with 1x10
6 human PBMCs at 37 ￿ for 30 min. After washing the cells at 
4￿
  the cells were incubated with streptavidin FITC (Amersham Pharmacia Biotech, 
Uppsala, Sweden) for 20 min followed by 30 min incubation with PE or APC-labeled 
antibodies (BD Pharmingen) directed against surface markers on PBMCs (T-cells, 
monocytes, natural killer (NK) cells and B cells). As controls for non-specific binding, rOv-
ASP-1-biotin labeled cells were incubated with appropriate APC or PE labeled isotype and 
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buffer and analyzed using 2-3 color FACS analysis using a Becton Dickinson FACS 
CANTO flow cytometer and the DiVa software (NYBC FACS facility services). 
Stimulation of human naïve PBMCs by rOv-ASP-1  
Fresh human naïve PBMCs were isolated by density gradient centrifugation over Ficoll 
(Sigma). For cytokine production, PBMCs (N =14) were cultured in quadruplicate in round-
bottomed 96-well culture plates at 4 x 10
5/well in RPMI-1640 medium containing 10% 
FBS, 25 mM HEPES, 2 mM L-glutamine, 100 units/ml of penicillin and 100 μg/ml of 
streptomycin (all from Sigma). The cells were cultured for 5 days in the presence of rOv-
ASP-1 (5 μg/ml) with or without polymyxin B at 37 ￿ in a humidified 5% CO2 incubator. In 
preliminary experiments, 5 μg/ml of LPS-free rOv-ASP-1 was established as an optimal 
dose for cytokine stimulation.  For control purposes, we also treated PBMCs with 
recombinant CAT (5 μg/ml). In previous studies we have established that CAT and other 
recombinant  O. volvulus proteins expressed similarly in E. coli did not have any 
immunostimulatory activity. Cytokines (IFN-γ, TNF-α, IL-4, IL-5, IL-10) in the cell culture 
supernatants were measured using a human Th1/Th2 CBA kit (BD Biosciences) 
according to the manufacturer’s protocol. To examine the potential involvement of the 
TLRs on the immunostimulatory activity of rOv-ASP-1 on PBMCs, we tested the inhibitory 
activity of anti-TLR antibodies (TLR2 and TLR4) on the IFN-γ secretion from PBMCs 
stimulated by rOv-ASP-1. PBMCs were pre-incubated with 10 μg/ml of Goat anti-TLR2, -
TLR4 or -IL-4 antibodies (eBiosciences) at 37￿ for 1 hr before adding rOv-ASP-1 (5 
μg/ml) to each treated well. Anti-IL-4 antibodies served as unrelated control antibody and 
untreated wells served as the positive control for maximum IFN-γ secretion in the 
presence of rOv-ASP-1. The concentration of IFN-γ in the culture supernatants was tested 
by ELISA (25).  Amounts of secreted cytokine are expressed in pg/ml per cultured wells. 
Stimulation of MoDCs with rOv-ASP-1 
Blood samples were collected from uninfected normal healthy donors (NHD) with no 
known risk factors for blood-borne virus infection (11 were male and 3 were female and 
the median age was 52). Ethical approval was obtained from Southampton and South-
west Hampshire Joint Research Ethics Committee and all volunteers gave informed 
consent in writing prior to participating in the study. Fifty ml of freshly drawn blood was 
obtained from 14 NHD subjects. Blood was collected into K3-ethylenediamine tetraacetic 
acid (EDTA) and separated immediately by centrifugation over Lymphoprep (Robbins 
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MACS CD14
+ isolation kit (Miltenyi Biotec, Bisley, UK), according to the manufacturer's 
recommended protocol. CD14
+ cells were positively selected from PBMC using an 
AutoMACS machine (Miltenyi Biotec). Monocytes (10
6 cells/ml) were cultured in six-well 
plates (Greiner Bio-One, Stonehouse, UK) in 3 ml per well of complete RPMI medium 
[RPMI-1640 without phenol red (Invitrogen, Paisley, UK), with 2  mM L-glutamine, 
100 U/ml penicillin, 100 µg/ml streptomycin (Sigma, Poole, UK) and 10% heat-inactivated 
fetal calf serum (FCS) (Hyclone, Perbio Science UK Ltd, Tattenhall, UK)], containing 
50 ng/ml recombinant human granulocyte–macrophage colony-stimulating factor (rhGM-
CSF) and 1000 IU/ml rhIL-4 (both from R&D Systems, Abingdon, UK). After 2 days and 
5 days 0.5 ml of culture medium was replaced with fresh cytokines. The day 5 immature 
DCs (2 x 10
5) were then cultured in complete media [RPMI-1640 without phenol red 
(Invitrogen, Paisley, UK), with 2  mM L-glutamine, 100  U/ml penicillin, 100  µg/ml 
streptomycin (Sigma, Poole, UK) and 10% heat-inactivated fetal calf serum (FCS) 
(Hyclone, Perbio Science UK Ltd, Tattenhall, UK)] alone or with 5 μg/ml rOv-ASP or 100 
ng/ml LPS in 48-well cell culture plates. After 24hrs of stimulation, DCs were stained for 
two-color flow cytometry (FACSCalibur dual laser flow cytometer, BD Biosciences) and 
analyzed using CellQuest software (BD Biosciences) and the supernatants were measure 
for cytokine secretion. For each condition, cells were resuspended and incubated on ice 
for 30  min in 50  µl wash buffer [phosphate-buffered saline (PBS)/0·05% NaN3/0·5% 
bovine serum albumin (BSA)] containing 100  µg/ml human Fcγ fragments (Jackson 
ImmunoResearch Laboratories, West Grove, PA, USA) (‘blocking buffer’). Cells were then 
stained with 50  µl of antigen-presenting cell (APC)-labeled anti-human CD83, CD86, 
CD40 (BD Biosciences) or CD303-APC (BDCA2; Milltenyi Biotec Bisley, UK) or 
fluorescein isothiocyanate (FITC)-labeled anti-human HLA-DR (BD Biosciences), all 
diluted to their optimal concentrations in blocking buffer or APC- or FITC-labelled isotype 
controls (murine IgG1 and IgG2b; BD Biosciences) at equivalent dilutions. After staining 
cells were washed, then fixed in 1% formaldehyde and stored on ice in the dark pending 
analysis. Using two-color analysis, the presence of the surface markers, HLA-DR, CD83, 
CD86 and CD40 on immature and mature MoDCs was determined by collecting ≥ 40 000 
events in the total cell population. All positive staining was compared with appropriate 
isotype controls. Multiple cytokines in the 24 h culture supernatants from the stimulated 
MoDCs were also measured using a human Th1/Th2 Cytometric Bead Array (BD 
Biosciences, San Jose, CA).  
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5 washed immature or 
TNF-α-matured MoDCs were added to 2 × 10
5 human CD40 ligand-transfected Chinese 
hamster ovary cells (hCD40L-CHO) or wild-type cells (wt-CHO) (both gifts from Professor 
M. Glennie, Tenovus Laboratories, Southampton, UK) adhering to the wells of 48-well cell 
culture plates in a final culture volume of 0.5 ml complete RPMI-1640 medium with or 
without 5 μg/ml rOv-ASP or 100 ng/ml LPS. Further wells contained MoDCs, hCD40L-
CHO or wt-CHO cells alone. After 24 h, supernatants were harvested and centrifuged for 
10 min at 2500 g, then frozen pending further analysis using a human Th1/Th2 Cytometric 
Bead Array as described above.  
Mixed lymphocyte reaction assay (MLR) 
To establish if rOv-ASP was able to enhance MoDC antigen-presenting capacity a mixed 
lymphocyte reaction assay (MLR) was performed and proliferation was measured by H-
thymidine incorporation. Day 5 MoDCs isolated from 5 NHDs were cultured (1 x 10
5) in 
complete medium supplemented with IL-4 and GM-CSF with or without rOv-ASP (5μg/ml) 
for 24-48 h. DCs were then thoroughly washed before adding to naive CD4
+ T cells to 
ensure all rOv-ASP was washed off. As a result, the T cell response will be detected if 
presented by the stimulated DCs. As responder cells in the MLR, naive CD4
+ T cells were 
isolated by negative selection from 5 allogeneic normal healthy donors using a CD4
+ T 
cell Isolation Kit II (Miltenyi Biotec), according to the manufacturer's recommended 
protocol. Purified CD4
+ T cells (2 x 10
5) were co-cultured in triplicates with MoDCs at 
various DC:T cell ratios (1:20—1:80) in U bottom 96-well plates in complete RMPI-1640 
for 5 days at 37 ￿, 5% CO2. During the last 18 h of incubation, the cultures were pulsed 
with 1 μCi/ml 
3H-thymidine. Cells were then harvested and the incorporated tritium 
thymidine was measured on a β plate reader (Topcount, Packard, Groningen, 
Netherlands) to determine induction of the allogeneic naive CD4 T cell proliferation. 
TLR2, TLR4 and TLR9 activation 
Stable lines of human embryonic kidney cells (HEK) 293 expressing surface toll-like 
receptor (TLR) constructs (TLR2, TLR4 or TLR9) were obtained under Material Transfer 
Agreement from Dr. D. Golenbock (University of Massachusetts Medical School, 
Worchester, MA). These HEK cells naturally lack TLR2, TLR4, TLR9 expression and 
genetic complementation with TLR constructs renders the cells responsive to the 
respective TLR ligands (323;324). The cells were maintained in Dulbecco’s modified 
Eagle medium (GIBCO Invitrogen, Carlsbad, USA) supplemented with 10 % fetal calf 
serum, 100 U/ml penicillin (PAA, Pasching, Austria), 0.1 μg/ml streptomycin (PAA) and 
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were plated at 5 x 10
4 cells per well in flat bottom 96-well tissue-culture plates and 
incubated for 3 h to allow adhesion. Cells were then stimulated with rOv-ASP-1 or control 
TLR ligands (Pam3CysK4; a bacterial lipoprotein analog for TLR2; LPS for TLR4; or the 
synthetic DNA analog CpG-ODN2216 for TLR9) at 37￿ for 18 h. The culture supernatants 
were collected for quantitation of IL-8 production using commercial ELISA kit (R&D 
systems). Values are expressed in pg/ml per well. 
NF-κB-dependent reporter gene assay 
HEK293 cells, either with or without stable transfection with hCD14, were maintained in 
media including sodium pyruvate and supplemented with 10 % fetal calf serum (FCS; 
Biochrom, Berlin, Germany), 100 U/ml penicillin (PAA, Pasching, Austria), 0.1 μg/ml 
streptomycin (PAA) and 200 mM L-glutamine (Gibco Invitrogen). Transient transfection of 
HEK293 cells was performed using FuGENE 6 Transfection Reagent (Roche Diagnostics, 
Mannheim, Germany) following the manufacturer’s instruction. Cells were plated in 12-
well plates with 1 x 10
5 cells per well. When cultures reached 50% to 80% confluence, 
they were incubated overnight with plasmids containing NF-κB reporter luciferase (120 ng) 
and, to control for differences in transfection efficiency, with RSV-β-galactosidase (40 ng). 
Cells were co-transfected either with hTLR4 (2 ng) and hMD2 (40 ng), or with hTLR2 (40 
ng). After 24 h, cells were stimulated with various amounts of rOv-ASP-1 or control 
ligands in DMEM with 100 U/ml penicillin, 0.1 mg/ml streptomycin and 200 mM L-
glutamine. The control ligands for TLR2 were: Triacylated lipopeptides (Pam3CSK4; LP3) 
and diacylated lipopeptides (Pam2CSK4; LP2) (EMC Microcollections, Tübingen, 
Germany) as previously described (26). LPS (Sigma) was used as the ligand for TLR4. 
After 20 h of stimulation, luciferase activity was measured in cell extracts with the 
Luciferase Reporter Gene Assay kit (Roche Diagnostics) according to the manufacturer’s 
instruction. Luciferase and β-galactosidase activity were estimated with 
chemiluminescence assays (Luciferase and β-Gal Reporter Gene Assay (Roche 
Diagnostics) and results were expressed as the ratio of luciferase to β-galactosidase and 
graphed as the mean +/- SD of triplicate experiments. 
Statistical analysis 
Paired t-tests and, where appropriate, Mann–Whitney tests were used to compare means. 
Analyses were performed using Prism version 4·0 for Windows (GraphPad Software, San 
Diego, CA, USA). 
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rOv-ASP-1 potentiates both Th1 and Th2-associated IgG2a and IgG1 responses  
The adjuvanticity of rOv-ASP-1 was firstly evaluated by using recombinant SARS-CoV S 
protein (rS) as a model antigen. Four Balb/C mice were immunized four times with the rS 
in the absence or presence of rOv-ASP-1 or with a control adjuvant, MLP+TDM. As 
shown in Fig. 1A, both adjuvants, rOv-ASP-1 and MLP+TDM, augmented the IgG 
antibody responses to rS protein versus (vs.) rS alone in terms of total IgG titers. Further 
comparison between the rOv-ASP-1 and MLP+TDM-induced responses by IgG isotypes 
(Table 1) shows: 1) similar IgG1 (1:656,100); and 2) three-fold higher IgG2a (656,100 vs. 
218,700) and three-fold higher IgG2b (218,700 vs. 72,900) end point titers in the presence 
of rOv-ASP-1. Each adjuvant/antigen model performed differently depending on the 
adjuvant – a skewed Th2 response with MLP+TDM (IgG1/IgG2a=3), but a mixed Th1/Th2 
(IgG1/IgG2a=1) response with rOv-ASP-1 with a dominance of Th1 antibodies (IgG2a and 
IgG2b). These results indicate that rOv-ASP-1 induced a more Th1 skewing antibody 
response than MLP+TDM. Moreover, when the neutralizing activities of the antibodies 
were analyzed (Fig. 1B), it appeared that the antisera from the mice immunized with rS in 
the presence of rOv-ASP-1 contained similar levels of the neutralizing antibodies against 
infection by SARS pseudovirus (1/29,096) as those from the mice administered with rS 
plus MLP+TDM adjuvant (1/33,960). Therefore, rOv-ASP-1 is a potent adjuvant for SARS-
CoV rS protein and can induce functional antiviral antibodies. 
rOv-ASP-1 effectively induced both humoral and Th1- dominant cellular immune 
responses against the rRBD of SARS-CoV S protein 
We have previously shown that the RBD of SARS-CoV is a major target of neutralizing 
antibodies (22, 27-29) and that recombinant RBD-based vaccines can induce protective 
immunity in the immunized animals (23, 30-33). Here, the recombinant RBD was further 
used to test the adjuvanticity of rOv-ASP-1 in comparison with the MLP+TDM adjuvant in 
C57BL/6 mice. As shown in Fig. 1C, both immunization protocols elicited similar high titers 
of antibodies against the rS protein after three vaccinations. The pooled splenocytes from 
each group of immunized mice were stimulated with the rRBD (1 μg/ml) as a recall 
antigen and the production of cytokines were measured by CBA kit (Table 2). In previous 
vaccines studies using rOv-ASP-1 as the adjuvant and rS or rRBD as the bystander 
antigen (32, 34), we found that the variation between individual mice was very low and 
therefore we are confident that that the results we obtained using the pooled spleens are 
a good representation of what would have been the outcome if we have had used 
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boosting the production of Type I proinflammatory cytokines (IL-2, IFN-γ, TNF-α, and IL-
6). Secretion of the Th1/regulatory cytokine IL-10 was elevated but less than that induced 
by MPL+TDM. There was no significant recall induction of the IL-4 or IL-5 cytokines by 
rRBD. The highly dominant IFN-γ recall response was further supported by enumerating 
the number of the IFN-γ producing cells in splenocytes from the vaccinated mice cultured 
for 24 h post-in the presence of rRBD.  As shown in Fig. 2, RBD/ASP-1 vaccination 
induced significantly a higher frequency of the IFN-γ-producing cells than those of 
RBD/MPL+TDM and PBS groups (P<0.01). These results suggested that rOv-ASP-1 is a 
potent adjuvant inducing not only strong humoral response but also an RBD specific Th1-
biased cellular response.  
rOv-ASP-1 binds primarily to antigen-presenting cells among human PBMCs 
Our data have clearly demonstrated that  rOv-ASP-1 is a potent vaccine adjuvant that 
induces a Th1-dominant cellular response and depending on the bystander antigen we 
also found that it can elicit a dominant Th1-associated antibody response (18, 20).  To 
explore the possible mechanism of rOv-ASP-1 adjuvanticity, we analyzed first the binding 
profile of biotinylated rOv-ASP-1 with human PBMCs (N = 4) by flow cytometry (Fig. 3). 
We found that biotin-labeled rOv-ASP-1 bound mostly to monocytes (93-98% of CD14+ or 
87-90% of CD3-CD4+
 low) and to B cells (41-94% of CD19+). A small fraction of other cells 
also bound rOv-ASP-1: 1-3% CD4+ (CD3+CD4+
high), 3.9-8% of CD8
+ T cells and 0.5-9% 
of NK cells. As a control, biotinylated-CAT did not bind to more than 2% of any leukocyte 
population (data not shown). These results demonstrated that rOv-ASP-1 primarily binds 
to the APCs, monocytes and B cells, among human PBMCs, suggesting that rOv-ASP-1 
may interact with the specific receptors presented on the surface of the APCs to activate 
the immune cells. 
rOv-ASP-1 stimulated human PBMCs to produce  proinflammatory cytokines  
We then determined whether rOv-ASP-1 can trigger cytokine production of human 
PBMCs from normal healthy donors. As shown in Fig. 4, rOv-ASP-1 protein stimulated 
significant production of Th1-type cytokines, IFN-γ and TNF-α, and the immunoregulatory 
T cell cytokine, IL-10.  No significant Th2 cytokines (IL-4 or IL-5) were detected in the 
PBMC culture supernatants,  although the IL-5 response was somewhat increased. 
Inhibition of LPS activity using polymyxin B (20 μg/ml) had no effect on the bioactivity of 
rOv-ASP-1 on human PBMCs (Fig. 4F). In contrast, it appeared that the activity of the 
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inducing activity could be abolished by polymyxin B. Therefore, the rOv-ASP-1 protein 
appears to be a potent inducer of pro-inflammatory (IFN-γ and TNF-α) and 
immunoregulatory (IL-10) cytokine secretion from the normal human PBMCs. 
rOv-ASP-1 induces phenotypic maturation of MoDCs and stimulates the secretion of 
proinflammatory and anti-inflammatory cytokines 
It is well known that TLRs activate signal transduction cascades leading to expression of 
co-stimulatory molecules on DCs and the secretion of IL-12 following recognition of their 
respective ligands (35). To determine if rOv-ASP-1 induced DC maturation, MoDCs from 
NHD (N = 14) were cultured with or without rOv-ASP-1 at 5 µg/ml for 24 h. Using FACS 
analysis we measured expression of surface molecules that are characteristically 
upregulated in DCs after stimulation. As shown in Figure 5, all four phenotypic markers 
that were tested increased after treatment with rOv-ASP-1. MoDCs from NHDs (N = 9-10) 
were then cultured with or without rOv-ASP-1 (5 µg/ml) for 24 h and cytokine production 
was determined. Notably, rOv-ASP-1 stimulated significant amounts of the 
proinflammatory cytokines, IL-6, IL-8, IL-2 and TNF-α but not IL-12 (Fig. 6). There was no 
significant induction of other cytokines tested IL-2, IL-4, IL-5 or IL-1ß but the MoDCs 
cultured with rOv-ASP-1 significantly stimulated also the production of the anti-
inflammatory cytokine, IL-10. Notably, the rOv-ASP-1 induced secretion of IL-12 was 
CD40-dependent; significant enhancement of IL-12 secretion was observed only after 
providing the MoDCs with co-stimulation through the CD40-CD40L pathway (i.e. by 
including CD40L-expressing CHO cells). Co-stimulation through the CD40-CD40L 
pathway also enhanced the rOv-ASP-1 induced secretion of IL-10 and TNF-￿(Fig. 6; 
immature + CD40L vs. rOv-ASP-1 + CD40L). These results provide evidence that rOv-
ASP-1 may initiate DC-induced adaptive immune responses by multiple distinct 
mechanisms. 
To assess if rOv-ASP-1 treatment of MoDCs was also able to enhance their 
accessory/antigen presentation function, we used the mixed lymphocyte reaction (MLR) 
assay with allogeneic antigens. Figure 7A shows the results of the MLR experiments 
indicating that MoDCs treated with 5ug/ml of rOv-ASP-1 enhanced their ability to stimulate 
proliferation of allogeneic CD4
+ T cells. Moreover, rOv-ASP-1 primed DCs were able to 
induce IFN-γ secretion from naïve PBMCs (Fig. 7B). The ability of rOv-ASP to stimulate 
human DCs further substantiates the prospect of its use as an innate vaccine adjuvant in 
humans that can boost the activation of an adaptive immune response.  
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Previous studies have indicated that signaling from TLR on APCs after ligand binding can 
induce subsequently the production of pro-inflammatory cytokines from T cells and NK 
cells and provide help to B cells, and thus this mechanism is thereby thought to contribute 
considerably to the enhanced antibody and cellular-enhancing
 effects of innate vaccine 
adjuvants (36, 37). The secretion of IFN-￿ by T cells and NK cells is mostly induced by IL-
12, which is primarily produced by DCs and macrophages (38-40). Therefore, we 
investigated whether rOv-ASP-1 can activate TLR2 and/or TLR4 presented on the surface 
of APCs and thereby result  in  pro-inflammatory cytokine production. To test this 
hypothesis, PBMCs from three healthy donors were treated with rOv-ASP-1 in the 
absence or presence of anti-TLR2, anti-TLR4 or anti-IL-4 antibodies, and the secretion of 
IFN-γ was then measured by ELISA.  As shown in Fig. 8, the IFN-γ secretion was 
significantly inhibited with both anti-TLR2 and anti-TLR4 antibodies and not with anti-IL-4 
antibodies, suggesting that the rOv-ASP-1-induced IFN-γ secretion from human PBMCs is 
TLR2 and TLR4 dependent.  
rOv-ASP-1 triggered cellular activation via TLR2 and TLR4 
The above results suggest that the rOv-ASP-1-induced  pro-inflammatory cytokine 
production from human PBMCs might be dependent on TLR2 and TLR4 activation. We 
then used the stable lines of HEK293 cells expressing TLR2, TLR4 or TLR9 to test its 
potential to activate TLR directly. Each of the cell lines was respectively incubated with 
rOv-ASP-1 at the indicated amounts and the TLR activation was expressed by human IL-8 
production. As shown in Fig. 9, the specific control ligands for TLR2, TLR4 or TLR9 
stimulated the cells expressing the appropriate receptors, while rOv-ASP-1 activated both 
TLR2 and TLR4-expressing cells at dose-dependent manners but not TLR9. The wild-type 
HEK293 cells, which do not expression TLR2 and TLR4, were unresponsive to the rOv-
ASP-1 (data not shown) in the IL-8 release assay.  
The rOv-ASP-1 cellular activation via TLR2 and TLR4 was further determined by a 
more sensitive NF-κB-dependent reporter gene assay. Consistently, rOv-ASP-1 strongly 
induced luciferase activity in the TLR2 or TLR4-transfected HEK293 cells in a dose-
dependent manner (Fig. 10). These data strongly support the view that both TLR2 and 
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The identification of new adjuvants that stimulate both antibody and cellular responses is 
an important challenge for vaccine development. In particular, there is a demand for safe 
and non-toxic adjuvants able to stimulate cellular (Th1) immunity for fighting against the 
existing and emerging pathogens. We have previously shown that rOv-ASP-1 has potent 
adjuvant effects for several vaccine antigens including recombinant proteins, synthetic 
peptides and commercial inactivated vaccines (18, 20). Importantly, rOv-ASP-1 could 
induce a mixed Th1/Th2 response with a Th1-biased antibody profile against some of the 
bystander antigens in the immunized mice. In the present work, the adjuvanticity of rOv-
ASP-1 was further evaluated in comparison with MPL+TDM adjuvant using the 
recombinant SARS-CoV S and RBD proteins, which have been shown to induce in the 
presence of the MLP+TDM adjuvant potent neutralizing antibodies and have thereby been 
considered as an ideal SARS vaccine candidates (22, 30).  Our present study has shown 
that rOv-ASP-1 also was highly effective in eliciting functional antibody responses in 
immunized mice. Its adjuvanticity to the SARS-CoV S protein exceeded the MPL+TDM 
adjuvant, especially in the induction of Th1 associated IgG2a and IgG2b antibody isotype 
responses. Furthermore, we have demonstrated that Ov-ASP-1 is a potent adjuvant also 
for the induction of Th1-biased cellular response. Impressively, immunization with the 
rRBD protein and rOv-ASP-1 significantly promoted the IFN-γ and TNF-￿ production in 
the immunized mice. These results further confirmed that rOv-ASP-1 can be used as a 
potent vaccine adjuvant for the recombinant protein-based vaccine antigens which are 
generally far less immunogenic than old fashion vaccines consisting of live or killed whole 
organisms.  
The molecular mechanism underlying adjuvant activity has been poorly 
understood for a long time, but this field has been rapidly evolving since the discovery of 
the TLR family of proteins and their corresponding innate ligands. TLRs are prominent 
pattern recognition receptors (PRR) of the innate immune system recognizing various 
invading pathogens through conserved motif named PAMPs (36). Interaction of PAMPs 
with TLR on the surface of APCs initiates a signaling cascade resulting in the recruitment 
of adaptor proteins such as the myeloid differentiation factor 88 (MyD88) and the 
downstream activation of NF-κB and mitogen-activated protein kinases (MAPK) (35). 
Consequently, the TLR signaling stimulates the activation and maturation of APCs 
including the regulated presentation of antigens, up-regulation of costimulatory molecules 
and secretion of proinflammatory chemokines and cytokines. These events mediate not 
only innate but ultimately also adaptive immunity (37, 41). Vaccinations with adjuvants 
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across the entire spectrum of innate and adaptive immunity. Therefore, innate immune 
signals mediated by TLRs
 have been thought to contribute significantly to the antibody-
enhancing
 effects of vaccine adjuvants as well as their ability to elicit cellular protective 
immunity. Previous studies have demonstrated that human parasite-derived products can 
also stimulate the immune responses via the TLR pathways. For example, a schistosome-
specific phosphatidylserine was shown to activate TLR2 and affect DCs such that mature 
DCs gained the ability to induce the development of IL-10-producing regulatory T cells 
(42). The T. gondii profilin activate DCs through TLR11, which was required for parasite-
induced IL-12 production and optimal resistance to infection in vivo (1). Furthermore, the 
adjuvant candidate lacto-N-fucopentaose III (LNFPIII) from S. mansoni acted as an innate 
Th2 adjuvant via TLR4 signaling (43, 44). 
To explore the mechanism of rOv-ASP-1 adjuvanticity, we initially analyzed the 
binding profile of rOv-ASP-1 with normal human PBMCs by a flow cytometry-based assay. 
It was found that rOv-ASP-1 binds primarily to the human monocytes and B cells, the 
major APCs in the peripheral blood. Significantly, rOv-ASP-1 stimulated human PBMCs to 
produce Th1-type pro-inflammatory cytokines (IFN-γ and TNF-α) and the 
immunoregulatory IL-10 cytokine. It has been known that IFN-γ is mainly released by 
activated Th1 cells and NK cells while TNF-α is mainly produced by macrophages but 
also by a broad variety of other cell types including Th1 cells. Both cytokines are involved 
in the regulation of the immune and inflammatory responses. Recently, we have shown 
that rOv-ASP-1 induced IFN-γ secretion from purified CD56+ cells but not from CD4+ or 
CD8+ cells (25). Moreover, this immunostimulatory effect was dependent on contact 
between CD56+ and CD56- fractions of PBMC, most likely between APCs, including DCs, 
in the CD56- fraction.  
Interestingly, rOv-ASP-1 also induced significant IL-10 secretion from naïve human 
PBMCs. This cytokine is mainly expressed by monocytes and Th2 cells and is capable of 
inhibiting synthesis of proinflammatory cytokines like IFN-γ,  IL-2,  TNF-α and GM-CSF 
made by cells such as macrophages and the Th1 cells. As rOv-ASP-1 could not stimulate 
human PBMCs to produce Th2-type IL-4 and IL-5 cytokines, it is possible that a 
monocytes subpopulation is responsible for the secretion of IL-10. Initial studies of 
PBMCs vs. monocytes have indicated that monocytes secrete IL-10 in the presence of 
rOv-ASP-1 through an unknown as yet mechanism. Based on the profile of cytokines 
stimulated by rOv-ASP-1 we hypothesize that the Ov-ASP-1 protein (~23 kDa) may 
contain few putative Th1 PAMPs that bind to different receptors on APCs that activates 
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recognition of PAMP signals APCs, typically human monocyte-derived dendritic cells 
(DCs), to express costimulatory molecules and secrete cytokines, which drive the 
polarization of naïve CD4+ Th type 1 and type 2 cells toward the Th1 or Th2 phenotype 
(45). Th1 cells express IFN-γ and TNF-α that instruct B cells to produce antigen-specific 
IgG2a, whereas Th2 cells produce IL-4, IL-5 and IL-13 to promote IgG1 and IgE class 
switching.  
Human monocyte-derived DCs treated with the parasite protein rOv-ASP-1 have 
shown evidence of phenotypic maturation, enhanced cytokine production and enhanced 
allo-stimulatory function. These findings confirm the immunostimulatory properties of this 
protein are mediated by its ability to activate APC population. The ability of rOv-ASP to 
stimulate human DCs further substantiates the prospect of it use as an innate vaccine 
adjuvant in humans that can boost the activation of an adaptive immune response. The 
ability of rOv-ASP-1 to stimulate human DCs may enable it to be used as a human 
therapeutic. In the case of chronic HCV infection, where DC function has been reported to 
be impaired by the virus, rOv-ASP-1 could enhance DC-driven T cell anti-HCV responses 
that would shift the virus-host equilibrium in favor of viral clearance. In support of this, 
recent in vitro evidence showed that rOv-ASP-1 was able to enhance and/or induce anti-
HCV Core IFN-γ responses in patients with chronic HCV infection (25). 
The adjuvant activity of rOv-ASP-1 appears to be mediated by TLR signaling 
presented on the APCs.  In agreement with this hypothesis, the IFN-γ secretion from 
human PBMCs could be significantly inhibited by both anti-TLR2 and anti-TLR4 
antibodies. Consistently, rOv-ASP-1 also triggered the activation of HEK293 cells 
transfected with TLR2 and TLR4 but not with TLR9 in dose-dependent manners. Previous 
studies indicate that each TLR mediates the response to specific PAMPs shared by a set 
of molecular structures (41). Among the TLRs, TLR2 mediates the response to the most 
diverse set of molecular structures including lipoproteins, peptidoglycan and lipoteichoic 
acids, while it is generally accepted that TLR4 mainly responds to LPS from Gram-
negative bacteria. But, they share a common activation pathway mediated through their 
Toll-IL-1R (TIR) signaling domain resulting in activation of NF-κB and MAPK. Previous 
results have also demonstrated that a number of pathogen-derived PAMPs-containing 
ligands could simultaneously activate TLR2 and TLR4 (46-48), such as the major surface 
protein of Wolbachia  endosymbionts in filarial nematodes (325) and the 
glycosylphosphatidylinositols derived from T. gondii (46). Structural homology analyses of 
Ov-ASP-1 with the crystallized closely-related hookworm secreted protein Na-ASP-2 
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distinct subdomains of Ov-ASP-1 may contain distinct bioactive sites. If this is in case, we 
may be able to express a subunit that stimulates IFN-γ without concurrent IL-10 secretion 
or specially activates TLR2 or TLR4 pathways. To further corroborate the involvement of 
TLR2 and TLR4 in rOv-ASP-1 bioactivities and thus back our indirect studies of anti-TLR2 
and anti-TLR4 antibodies, additional studies using TLR2 and TLR4 knockout mice are 
needed. These would include testing if the adjuvanticity of rOv-ASP-1 is lost in these mice 
and if innate cytokines production and DC maturation is reduced.  
In conclusion, rOv-ASP-1 has potential to be developed as a novel innate vaccine 
adjuvant since it can bind to APCs, matures and activates DCs and subsequently induces 
proinflammatory cytokines leading to a Th1-dominant immune response, potentially via 
TLR2 and TLR4 activation. 
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Fig. 1. Antibody responses of mice immunized with recombinant SARS-CoV S protein or 
its RBD in the absence or presence of the rOv-ASP-1 or the MLP+TDM adjuvant. (A) 
Reactivity of mouse antisera with rS protein. The antisera were collected from mice before 
immunization and 7 days after each boost and tested by ELISA at 1/1000 dilution. (B) 
Neutralization of SARS pseudovirus infection by mouse antisera from each rS 
immunization group. Infection of 293T/ACE2 cells by SARS pseudovirus was determined 
in the presence of antisera at a series of 2-fold dilutions, and 50% neutralization was 
calculated for each sample. * indicate P<0.01 compared to the group of rS alone. (C) 
Titers of anti-rS antibodies from the rRBD-immunized mice. The antisera were tested by 
ELISA at a series of dilution. 
 
Fig. 2. Detection of IFN-γ-producing cells by ELISPOT. Splenocytes from vaccinated mice 
were stimulated with SARS-CoV rRBD. Frequencies of IFN-γ-producing cells are 
expressed as mean ± SE of cytokine spot-forming cells (SFC)/10
6 cells of 5 independent 
experiments. * indicates P<0.05 compared to RBD/MPL+TDM or PBS group. 
 
Fig. 3. Binding of biotinylated rOv-ASP-1 to human PBMC as determined by flow 
cytometry. Cells were gated on lymphocytes (R1) (a). The isotype specific antibodies to 
IgG-PE or IgG-APC were used as control (b and c). Cells were stained with rOv-ASP-1 
biotin-Streptavidin FITC and for T cells with CD3/CD4/CD8(d-f), for monocytes with CD14 
(g), for B-cells with CD19 (h) and for NK cells with CD56 (i). Figure 4 is a representative of 
the binding profile of PBMCs from one normal individual.  
 
Fig. 4. Cytokine secretion of human PBMCs stimulated by rOv-ASP-1. Human PBMCs 
were collected from normal healthy donors (n=14), and treated with or without rOv-ASP-1 
(5  μg/ml) for 5 days. The culture supernatants were tested by human CBA kits for 
cytokines (a) IFN-γ; (b) TNF-α; (c) IL-4; (d) IL-5; (e) IL-10. * indicate P<0.01 compared to 
untreated control wells.  (f) IFN-γ and IL-10 secretion of human PBMCs triggered by rOv-
ASP-1 or recombinant CAT in the presence or absence of polymycin B (20 μg/ml). The 
rOv-ASP-1 induced cytokine secretion was not inhibited by polymycin B. 
 
    222  Fig. 5. Phenotypic maturation of MoDCs treated by rOv-ASP-1. MoDCs (N = 14) were 
cultured with or without 5 µg/ml rOv-ASP for 24 hours. Using FACS analysis the 
expression of maturation markers CD40, CD83, CD86 and HLA-DR were measured. All 
four of the maturation markers were upregulated after treatment with rOv-ASP-1. LPS was 
used as a positive control. 
 
Fig. 6.  Cytokine production from rOv-ASP-1 treated MoDCs with and without CD40L. 
MoDCs  (N = 9-10) were cultured for 24 hours with media alone or in a 1:1 ratio with a 
CD40 ligand-transfected Chinese hamster ovary cells (hCD40L-CHO) with or without 5 
µg/ml rOv-ASP. LPS was used as a positive control. rOv-ASP alone stimulated significant 
amounts of pro-inflammatory cytokines, IL-6, IL-8, IL-2 and TNF-α but not IL-12. However, 
when MoDCs were co-stimulated with CD40L, significant enhancement of IL-12 secretion 
was seen. MoDCs stimulated with rOv-ASP significantly stimulated the production of the 
anti-inflammatory cytokine, IL-10 and this was further enhanced when MoDCs were co-
stimulated with CD40L.  
 
Fig 7.  rOv-ASP-1 treated MoDCs have enhanced allo-stimulatory function. (A) MoDCs 
treated with 5 µg/ml rOv-ASP-1 showed enhanced ability to stimulate the proliferation of 
allogenic CD4
+ T cells. The CD4
+ T cell proliferation (counts per minute) in response to 
rOv-ASP-1 is shown. Each point represents the mean (+ s.d.) of results from 5 individuals. 
*P<0.05. (B) rOv-ASP-1-primed human DCs induced IFN-γ secretion from naïve PBMCs. 
MoDCs were treated with 2 µg/ml rOv-ASP-1 and then washed and co-cultured (1 × 
10
4/well) with autologous normal PBMCs (2 × 10
5/well) in round-bottomed 96-well plate for 
5 days. The level of IFN-γ secretion was determined by ELISA. Streptolysin O (SLO) 
served as a positive immunopotentiator. 
 
Fig. 8. Inhibition of rOv-ASP-1-induced IFN-γ secretion from human PBMC (n=4) by anti-
TLR antibodies. The PBMCs were pre-incubated with anti-TLR2, anti-TLR4 or IL-4 
antibodies (10 μg/ml) at 37°C for 1 hr before adding 5 μg/ml rOv-ASP-1 for stimulation 
over a 5 day period. The concentration of IFN-γ in the culture supernatants was tested by 
ELISA. *indicate P<0.05 when compared to the rOv-ASP-1 untreated cells.  
 
Fig. 9. Activation of TLR2 and TLR4 by rOv-ASP-1 in a dose-dependent manner. Human 
HEK293 cells expressing TLR2 (A), TLR4 (B) or TLR9 (C) were stimulated with 1 μg or 5 
μg/ml of rOv-ASP-1 for  18h and the activation was measured by human IL-8 secretion.  
    223  TLR control ligands (Pam3CSK4 for TLR2, LPS for TLR4, and ODN2216 for TLR9) 
activated the secretion of IL-8 from the appropriate cell lines as expected. 
 
Fig. 10. The rOv-ASP-1-induced cellular activation as determined by NF-κB-dependent 
reporter gene assay. HEK293 cells were co-transfected with an NF-κB-dependent 
luciferase reporter construct and the expression plasmids for TLR2 (A) or TLR4/MD2 (B). 
The cells were challenged with increasing amounts of rOv-ASP-1. The control ligands for 
TLR2 were Pam3CSK4 (LP3) and Pam2CSK4 (LP2); LPS was used as a ligand for TLR4. 

































































































    230  Table 1. Isotyping of antibodies against SARS rS protein after the second boost* 
 
 
                                                     Immunization protocol 
 
     Isotype                  rS alone              rS/rOv-ASP-1                  rS/MPL+TDM 
 
 
     IgG1                     72,900                      656,100                             656,100 
     IgG2a                     2,700                      656,100                             218,700 
     IgG2b                     2,700                      218,700                               72,900 
     IgG3                          300                          8,100                                 2,700 
 
* The end-point titers are the mean of 4 mice per group. As induction of high titer of IgG1 
is considered indicative of a Th2-type immune response, high IgG2a, IgG2b and IgG3 
titers are typical of a Th1-type response. Apparently, rS alone induced a Th2 dominant 




Table 2. Cytokine secretion from mouse splenocytes stimulated ex vivo by rRBD 
 
                                                                        Immunization protocol 
 
Cytokine (pg/20,000 cells)        rRBD/PBS      rRBD/rOv-ASP-1     rRBD/MPL+TDM 
 
    IL-2                                         40.6                      108.0                                24.9 
    IL-4                                           0.0                           5.3                                  6.3 
    IL-5                                           1.6                           6.8                                20.8 
IFN-γ                                      75.5                       950.9                               267.6 
TNF-α                                    16.8                         66.9                                 24.3 
IL-6                                           9.2                         90.4                                 18.6 









    231  Appendix 3 
The TLR7 agonist SM-360320 induces a robust antiviral and   
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Background and Aims: Toll-like receptor 7 (TLR7) agonists offer therapeutic potential in 
chronic hepatitis C (CHC). Their antiviral activity is mediated through induction of innate 
and stimulation of adaptive immune responses. We compared responses in-vitro using 
blood from normal healthy donors (NHDs) and patients with CHC who were treatment 
naïve (TN) or non-responders (NR) to interferon.  
Methods: Peripheral blood from 60 TN, 20 NR CHC patients and 80 NHDs was 
stimulated in-vitro with the TLR7 agonist, SM-360320 or Interferon-α (IFNα). Cytokine 
secretion, antiviral gene expression, Hepatitis C virus (HCV) replicon inhibition, and NK 
cell activation were quantified.  
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Results: Basal cytokine levels were higher in CHC than NHD blood with TN-CHC higher 
than NR-CHC.  SM-360320 and IFNa induced expression of all tested cytokines in all 
groups. Both treatments increased expression of 2'5'OAS in all groups; NHDs were 
highest. SM-360320 treated CHC blood plasma reduced HCV replication to baseline and 
was more effective than IFNα. SM-360320 enhanced NK-cell activation in all groups 
(p=<0.001) and was more effective than IFNα (p=< 0.05). CD69 expression was lower on 
CHC NK cells than NHDs. Depletion of pDCs from NHD- PBMCs reduced IFNα 
production on incubation with SM-360320 and IFNα.  
Conclusions: SM-360320 induced innate immune responses in blood from CHC patients 
suggesting the potential use of TLR7 agonists in treatment of CHC. The lower response in 




Chronic infection with hepatitis C virus (CHC) is a major cause of liver related morbidity 
and mortality. Infection persists in 80% of patients and is thought to result from a failure to 
sustain an immune response against HCV (35). The current standard of care for Hepatitis 
C (HCV) pegylated (PEG)-Interferon-α (IFNα) with Ribavirin, leading to viral clearance in 
40-80% of patients, primarily depending on genotype (167). Current treatment is 
associated with significant side effects including flu-like symptoms, depression and 
injection site reactions (178).  Novel strategies for the treatment of CHC are therefore 
required.  
The host’s innate and adaptive cellular immune responses are believed to be critical in 
determining the outcome of HCV (161;161;163). The natural killer (NK) cell-mediated 
innate immune response may be genetically programmed to determine the chance of 
spontaneously resolving acute HCV infection (159) and directly modulated by HCV itself, 
leading to impaired NK-cell function (326). Dendritic cells (DCs) are professional antigen 
presenting cells characterised by their exceptional capacity to activate naïve T-cells and 
prime adaptive immunity. DCs play a pivotal role linking innate and adaptive immunity 
(67). Two functionally distinct subsets of DCs have been described; myeloid (mDC) and 
plasmacytoid (pDC). pDCs are the most potent producer of type-1 interferon’s in the body 
and release large quantities during viral infections (327).  
    233  In terms of the adaptive immune response, successful viral clearance during acute 
infection has been attributed to a robust HCV-specific CD8
+ T-cell effector response and a 
predominantly Th1-polarised CD4
+ anti-HCV response (161). A failure to sustain this early 
anti-HCV T-cell response correlates with viral persistence and development of CHC. 
Toll-like receptors (TLRs) are a family of pattern recognition receptors that play a key role 
in innate immunity (93). TLRs are activated by a range of pathogen-associated molecular 
patterns conserved among pathogens. TLR3, 7 and 9 are intracellular receptors 
specialized for recognition of viral nucleic acids, recognizing double stranded-RNA, 
synthetic imidazoquinolone-like molecules, guanosine analogues and single-stranded-
RNA derived from viruses and unmethylated 2’-deoxyribo cytidine-phosphate-guanosine 
(CpG) DNA respectively. TLR7 and 9 are expressed by pDCs and B cells. On binding, 
they induce a signalling cascade which induces type I interferon’s and pro-inflammatory 
cytokines, which drive inflammatory responses and activate the adaptive immune system 
(94).  
 
TLR agonists have been investigated for the treatment of CHC as a means of inducing 
endogenous IFNα even in the presence of the immune dysfunction induced by CHC 
infection. Activation of pDCs is important for HCV treatment because these activated cells 
not only primarily produce IFNα, but also present antigen to initiate T-cell mediated 
adaptive immunity. 
 
In short term monotherapy trials, the TLR7 agonist Isatoribine (241), TLR7 agonist 
Resiquimod (1) (328)and the TLR9 agonist, CpG 10101 (Actilon) (250) have been shown 
to have clinical efficacy against HCV with reduced viral load and evidence of immune 
modulation.  
 
The aim of this study was to investigate the antiviral and the immunostimulatory actions 
that might be responsible for HCV clearance in vitro. The effects of the TLR7 agonist, SM-
360320 (9-benzyl-8-hydroxy-2-(2-methoxyethoxy)adenine) (TLR7 specific and 75% bound 
in human plasma) (295) and IFNα on innate immunity was studied. Responses were 
compared in blood from normal healthy donors (NHDs) and patients with CHC, both 
treatment naïve (TN) and previous non-responders (NR) to treatment.  
 
    234  Materials and Methods 
Study subjects: 
Ethical approval was obtained from Southampton and South-West Hampshire Joint 
Research Ethics Committee and all patients gave informed consent in writing prior to 
participating in the study 
 
Whole blood was collected from CHC-patients recruited from hepatology clinics run by 
Southampton University Hospitals and Royal Bournemouth and Christchurch NHS Trusts. 
All patients had detectable HCV-RNA determined by quantitative PCR (Cobas Amplicor 
HCV Monitor test, Roche Molecular Systems, USA). Patients were excluded if they had 
treatment within 6 months prior to the study or tested positive for other blood borne 
viruses, including HBV and HIV. Sixty patients were treatment naïve and 20 were previous 
NR to treatment. A further 80 uninfected NHDs, without risk factors for blood borne 
viruses were recruited internally within Pfizer. Clinical data from the groups is in Table 1. 
 
Whole Blood Stimulation 
Fresh blood collected in sodium citrate vacutainers was aliquoted (450μl for CHC and 
180µl for NHDs) into 24 or 96 well assay plates respectively containing 50μl or 20µ pre-
prepared, SM-360320, IFNα or no stimulus. Final concentrations of SM-360320 were 
0.1μM – 10μM (1µM for NHDs) and IFNα was 20IU/ml.  Plates were sealed, placed on an 
orbital shaker and incubated for 5 hours at 37
0C. Aliquots of 25µl (n=4 CHC and n=1 
NHDs) of the stimulated blood from each well were transferred into 96 well plates and 
mixed with 130µl of MagMAX lysis/binding solution (Ambion) in a 1:1 ratio with 
isopropanol.  
The remaining blood was spun (5 min at 500rpm), plasma removed and frozen at -80
0C. 
The remaining cell pellet for the CHC-blood was re-suspended in the residual plasma 
(~300µl) and 1.3ml RNALater (Ambion) was added to stabilize the samples. These 
samples were also frozen at -80 C pending further analysis. 
 
PBMC isolation and storage: 
Blood collected into EDTA containing vacutainers was separated immediately by 
centrifugation over Lymphoprep (Robbins Scientific, Solihull, UK). Peripheral blood 
mononuclear cells (PBMCs) were recovered from the interface, cells counted using trypan 
    235  blue and then cryopreserved in 90% FCS and 10% sterile culture grade dimethyl sulfoxide 
(DMSO, HybriMAX, Sigma) and stored at -80
0C while awaiting further use. 
 
Gene Expression Analysis 
After thawing, RNA was extracted from blood/MagMAX lysis/binding mixture using the 
MagMAX 96-well blood RNA isolation kit (Ambion) according to the manufacturer’s 
instructions. Complementary deoxyribonucleic acid (cDNA) was prepared using high 
capacity cDNA archive kits (Applied Biosystems, USA) using 10μl RNA in 20μl reactions 
(2µl reverse transcriptase (RT) buffer, 0.8µl deoxyribonucleotide-triphosphate mix, 2µl 
random primers, 1µl Multiscribe RT and 4.2µl RNase free water). 2’5’OAS gene 
expression was quantified using real time taqman QPCR using ‘assay on demand 
reagents’ (Applied Biosystems, USA) as described by manufacturer. QPCR amplification 
reactions were performed on a 7900 real time PCR machine (Applied Biosystems) over 40 
cycles (annealing 60ºC for 45secs, primer extension 72ºC for 1min and denaturation 94ºC 
for 20sec). 2’5’OAS gene expression was measured relative to the house keeper gene, β-
actin. Data were analysed using the delta-delta-ct method for relative quantity (329).  
 
Cytokine analysis    
Levels of pro-inflammatory cytokines, TNFα, IL-1β, IL-2, IL-6, IL-8, IL-12p70, antiviral 
cytokines, IFNγ and IFNα and regulatory cytokines, IL-10 and IL-4 were determined in 
aliquots of 25 µl plasma from the whole blood assays using a custom ultrasensitive 10-
plex electrochemiluminescence ELISA as described by the manufacturer (Meso Scale 
Discovery, USA). Values were calculated within the standard curve.                          
HCV replicon assay 
The presence of soluble factors with antiviral activities in treated plasma was measured in 
an HCV-replicon system. Huh7 1b replicon cells were cultured in flasks. Supernatants 
(10µl) from whole blood ex vivo experiments were added to the replicon cells and 
incubated for 48 hours at 37
°C. Replicon levels were quantified using a luciferase reporter 
assay (270).  
 
NK-cell activation & intracellular IFNγ staining 
Cryopreserved PBMCs were thawed and rested for 5 hours at 37
°C prior to assay. Cells 
were resuspended to 2 x 10
6/ml in RMPI[1640] (no phenol). PBMCs (900µl) were plated 
    236  into duplicate wells of a 24 well plate containing 100μl SM-360320, IFNα or diluent only 
per well. After 5 hours, 1μl of Brefeldin-A (Sigma, UK) was added to one well of each 
duplicate. Cells were incubated for a further 18 hours. After 24 hours, PBMCs were 
harvested and labelled to identify activated CD56
+ CD16
+ NK-cells for cell surface CD69 
expression and cytoplasmic IFNγ expression by intracellular staining. Antibodies (CD56-
APC, CD4-FITC, CD69-FITC, CD3-PE from BD Biosciences) and their isotypes (IgG1-
APC, -FITC, -PE) were diluted with FACS block to optimal concentrations for flow 
cytometry and 50µl of appropriate antibody added 1:1 with FACs block in the well. Cells 
were incubated on ice for 30 minutes, washed, then fixed in 1% formaldehyde and stored 
on ice in the dark pending analysis. 
 
pDC Depletion 
From 5 NHDs (from Southampton) and 5 CHC-patients, PBMCs were prepared from 
blood as above. pDCs were isolated from PBMCs by positive selection using a MACS 
BDCA-4 blood dendritic cell isolation kit (Miltenyi Biotec, UK), according to the 
manufacturer’s instructions, in conjunction with an AutoMACS (Miltenyi Biotec). Whole 
PBMCs, PBMCs depleted of pDCs, and pDCs alone were stimulated with SM-360320 
(10µM-0.01µM; Pfizer, Sandwich) in sealed plates for 5 hours at 37
°C and gene 
expression analysis, cytokine production and NK-cell activation was assessed as above. 
The % purity of the pDC depletion was assessed by FACS analysis. 
 
Statistical Analysis 
GraphPad PRISM (V5) and a Pfizer Inc proprietary add-in to Microsoft Excel 2003 were 
used to perform initial data analysis and visualisations.  Statistical analyses were 
performed using SAS (V8.02), GenStat (V10) and Spotfire DecisionSite 9.0.   
In order to satisfy the assumptions of the analysis methods used, the data from the gene 
expression, cytokine and pDC depletion analyses were analysed on the log10 scale and 
data from NK-cell Activation were analysed on the logit scale.  Plots of the data were used 
to check the statistical assumptions and any unusual features such as outliers were 
investigated.  
 
For gene expression, cytokine analyses, NK-cell activation and pDC depletion 
experiments all transformed responses were analysed using a linear mixed model that 
allowed for donor-to-donor variation and investigated differences between the three donor 
groups, the stimuli and the effects of pDC depletion. Specific pairwise comparisons 
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transformed to give geometric means, ratios in means, 95% confidence intervals 
(excluding NK-cell activation data) and p-values.  All tests were performed at the 5% 
significance level.   
 
For the HCV replicon assay the distribution of the collected Replicon data did not lend 
itself to the modelling techniques used for the other responses. Therefore the multivariate 
technique K-means clustering was applied to identify similar donor profiles, where a profile 
contains the responses exhibited by a donor across the 6 stimuli.  A number of different 




Induction of 2’5’OAS  
IFNα (20IU/ml) and SM-360320 (1µM) significantly induced 2’5’OAS in whole blood from 
all 3 groups (p=<0.01 for all; Figure 1). The level of the response with both stimuli was 
higher in blood from NHD compared to CHC (p=<0.001 for all). However, in CHC-patients, 
a larger variation in 2’5’OAS induction was observed across the samples compared to 
NHDs with some patients giving a 100-fold induction. No significant difference was 
observed between treatment naïve and NR-patient groups (p=>0.10).  
 
Induction of Cytokines 
SM-360320 (1μM) stimulated secretion of all cytokines tested in whole blood from NHDs 
and CHC-patients (p=<0.001 for all at 1µM; Figure 2 and Table 2) in a dose response 
manner. A wider range of secretion of individual cytokines was noted from CHC-patients 
compared to NHDs.   
 
IFNα (20IU/ml) stimulated significant amounts of IFNα, IFNγ, IL-6, IP-10 and IL-12p70 
(p=<0.001 for all) in blood from CHC-patients and IFNα, IL-6 and IP-10 in blood from 
NHDs (p=<0.001 for all). No effect was observed with IFNα on IL-1β, IL-8, TNFα, IL-4 and 
IL-10 in CHC-patients and IFNγ, TNFα, IL-12, IL-8, IL-4 and IL-10 in NHDs. 
 
Higher levels of IL-1β and IL-6 were observed from NHD-blood and CHC-blood with 1µM 
SM-360320 compared to IFNα. In contrast, similar levels of endogenous IFNα and IP-10 
    238  were secreted on incubation with both compounds, although exogenous IFNα may have 
been detected making interpretation difficult. 
 
On average, naïve-CHC blood induced higher levels of the cytokines compared to NR-
CHC blood with either compound; however this did not reach statistical significance 
(p=>0.10). The untreated levels of all cytokines was higher in CHC-blood than NHD-blood 
(p=<0.001 for all).  
 
Inhibition of HCV Replication 
Plasma derived from blood treated with SM-360320 (10µM and 1μM) from CHC-naïve and 
CHC-NR patients inhibited replication of HCV replicons in Huh-7 cells shown by reduction 
of luciferase reporter expression to baseline levels (Figure 3). This is consistent with the 
high levels of IFNα found in the plasma (338.8pg/ml-naive and 269pg/ml-NR) (Table 2). 
The antiviral activity of plasma from IFNα treated blood was lower than that with SM-
360320 (medians 73% vs. 99% inhibition) possibly due to degradation of exogenous IFNα 
and/or lower induction of endogenous IFNα. Some antiviral activity was observed in 
plasma derived from untreated blood. In naïve CHC-patients, two distinct groups were 
identified by K-means clustering, with some patients reaching maximal inhibition at a 
lower concentration of agonist than others. Some naïve patients gave replicon responses 
that were more consistent with the NR group than others (Figure 3). Blood from NHDs has 
not been analysed in the replicon assay.  
NK-cell Activation 
CD3-CD56+ NK-cells were identified by FACS and % expression of CD69 (as a marker of 
activation) or intracellular IFNγ was determined. Surface expression of CD69 was studied 
on cells without Brefeldin-A exposure. In all 3 subject groups, the TLR7 agonist resulted in 
a dose-dependent increase in NK-cell activation (Figure 4). CD69 expression and IFNγ 
production were significantly enhanced by both 10µM and 1µM SM-360320 in all subject 
groups (p=<0.001) and CD69 in NHDs by 0.01μM (p=<0.001). IFNα also enhanced CD69 
expression in all subject groups (p=<0.001) but was less effective than the highest 
concentrations of SM-360320 (p=<0.05) and did not significantly enhance IFNγ production 
(p=>0.1). 
Comparing treatment with 10µM SM-360320, CD69 expression in naïve NK-cells was 
significantly lower than that in NHD NK-cells (p=<0.05 for all). A similar trend was also 
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(p=>0.1) 
 
The Role of pDCs 
Secretion of IFNα and 2’5’OAS expression was observed with 1µM SM-360320 or 
20IU/ml IFNα in whole NHD-PBMCs (p=<0.01). IFNα induction was reduced on depletion 
of pDCs from NHD-PBMCs stimulated with SM-360320 (p=<0.05 for all), confirming the 
importance of this cell type for TLR7 agonist responses. However, no significant 
difference in 2’5’OAS expression was seen with pDC depletion (Figure 5.). In the CHC 
group there was a wide variation of responses in the untreated samples of the whole 
PBMCs making the results from pDC depletion difficult to interpret for IFNα secretion. 
However, on depletion of pDCs from CHC-PBMCs, there was a significant reduction in 
2’5’OAS expression with 1μM SM-360320 and 20IU/ml IFNα (p=<0.001 for all). The 
efficiency of depletion of pDCs from PBMCs was 68% on average.  
 
To investigate whether NK-cell activation was occurring indirectly in response to agonist-
induced IFNα production by plasmacytoid DCs (pDCs), or directly in response to the 
agonist, the effect of depleting pDCs from PBMCs prior to exposure to the agonist, was 
studied and NK assessed as above. In preliminary experiments in NHDs, NK-cell 
activation was induced by the top doses of SM-360320 and was partially impaired by pDC 
depletion with reduced IFNγ secretion (data not shown).  
Discussion 
The need to overcome immune dysfunction seen in HCV and induce strong HCV-specific 
T-cell responses to clear the virus has prompted evaluation of immunomodulators in CHC 
treatment. The aim of this study was to investigate both the antiviral and 
immunostimulatory actions of the TLR7 agonist, SM-360320 on cells derived from the 
blood of CHC -patients. We have shown that SM-360320 was able to induce a robust ex 
vivo innate immune response in blood from treatment TN and NR-CHC-patients.  
Blood from TN-CHC patients produced higher levels of all cytokines compared to NRs but 
no differences were observed in the cytokines secreted. In the replicon assay, blood from 
some of the TN patients showed responses more like the NR-patients which may indicate 
they will be non-responders to treatment. CD69 expression on NK-cells was higher in 
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no differences observed in 2’5’OAS expression between the patient groups. 
 
TLR7 expression is limited to certain tissues (18) and a restricted set of human immune 
cells, notably pDCs and B cells. TLR7 agonists are not thought to have direct antiviral 
effects (19) but following TLR engagement induce pDCs to produce large quantities of 
type 1 IFNs and more modest amounts of various other cytokines e.g. IL-6 and TNFα. 
Induction of type 1 IFNs through activation of TLRs on pDCs is a crucial part of the host’s 
innate immune response to viral infection which results in the production
 of a wide range 
of downstream antiviral effector molecules such as interferon stimulated genes: 2’5’OAS,
 
RNase-L, MxA, and signaling chemokines such as IP-10. As a consequence of the 
secretion of type 1 IFNs, a number of secondary effects are also induced such as 
stimulation of NK-cells as well as maturation of pDCs to potent antigen-presenting cells, 
augmenting their ability to stimulate T-cells and thus activating both the innate and 
adaptive immune responses. 
In this study we investigated the antiviral effects of SM-360320 by looking at the induction 
of 2’5OAS, induction of cytokines and the antiviral activity of plasma from treated blood in 
HCV replicon cells. 
Plasma from blood treated with SM-360320 inhibited replication of HCV-replicons in Huh-
7 cells reducing luciferase reporter expression to baseline levels. This may indicate the 
potential of TLR7 agonists to reduce viral load mediated by the antiviral activities of 
agonist-induced IFNα. The expression 2’5’OAS was found to be increased with TLR7 
treatment and secretion of antiviral cytokines, IFNα and IFNγ and pro-inflammatory 
cytokines from whole blood were significantly enhanced. In vivo this would be predicted to 
promote a Th1 immune response and favour viral clearance. 
NK-cells play an important part in the first line of defence against viral infections, rapidly 
recognising and killing virus-infected cells and also secreting inflammatory cytokines, such 
as IFNγ which have direct antiviral effects as well as activating and polarising Th1 and 
cytotoxic lymphocyte responses (20;21). Therefore they provide a pivotal link between 
innate and adaptive immunity. Several groups have shown
 that TLR7 agonists induce NK-
cell activation (CD69 expression and IFNγ production) and enhance their cytotoxic
 effector 
function (22-25). In this study we found that SM-360320 was able to significantly 
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SM-360320 on NK-cells was lower in CHC-patients than NHDs.   
 
NK-cells express TLR 2, 3, 5 and 6 but little TLR 4, 7, 8 and 9 (22). It is not clear therefore 
if NK-cell activation by TLR7 agonists is caused by direct activation of TLR7 receptor in 
NK-cells or if they act indirectly and secondary to activation of other cells, in particular 
pDCs, and cytokines produced by these cells. It has previously been observed that TLR7-
induced NK-cell activation is crucially dependant on contact with cytokines (e.g. IFNα or 
IL-12) produced by accessory cells in the blood (23-25). 
 
To explore this further, we depleted pDCs, the main IFNα producing cells, from PBMCs 
and assessed the effects of the TLR7 agonist on NK-cell activation. In preliminary 
experiments it has been shown that NK-cell activation was partially impaired supporting 
evidence of an indirect effect and dependence on cytokines from accessory cells in the 
peripheral blood.  
To determine the contribution of pDCs to any antiviral or immunostimulatory effects of SM-
360320, the effects of pDC depletion on cytokine secretion and 2’5’OAS induction were 
assessed. As would be expected, depletion of pDCs from NHD-PBMCs resulted in a 
reduction of IFNα secretion however a corresponding reduction in 2’5’OAS induction was 
not found to be significant. In CHC-PBMCs, 2’5’OAS induction was found to be decreased 
but the IFNα data is difficult to interpret due to large variability in the whole PBMC group. 
Defects in CHC-pDC IFNα production have been described in a number of studies (26-32) 
and it would be interesting to explore the effects of the TLR7 agonist directly on pDCs to 
see if it has the ability to induce pDC maturation and reverse the defects described. 
 
Current treatment for CHC is based on the combination of PEG-IFNα and Ribavirin. Both 
appear to possess antiviral and some immunomodulatory activities (33;34). When 
comparing IFNα, at a concentration representative of plasma levels typically found during 
IFN therapy, to the TLR7 agonist in this study we show that, SM-360320 at 1µM induced 
pro-inflammatory cytokines and 2’5’OAS to higher levels than IFNα, was more effective in 
the replicon assay and induced NK-cell activation to significantly higher levels (also been 
shown with a TLR9 agonist) (35). Therefore, comparison of immunostimulatory and 
antiviral activities show that SM-360320 may provide similar or better antiviral effects and 
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vitro it must be recognized that preclinical and clinical trials may reveal adverse effects 
that may make the compound impractical or less attractive than IFNα. 
  
Clinical studies with TLR7/8 agonists (13;36-38) have shown a modest reduction in viral 
replication in HCV infected patients. While stimulating TLRs could re-establish an 
appropriate immune response to infection, caution must be taken as inappropriate 
stimulation can lead to inflammation and autoimmunity.  In this study the effective in vitro 
dose of SM-360320 was found to be 1μM.  
 
Although direct-acting HCV-specific drugs (e.g. protease inhibitors) may provide superior 
antiviral effects, a probable advantage of TLR agonists is the relatively low emergence of 
drug resistance that is a particular challenge in HCV with its high genetic diversity and 
mutation rate. Drug resistance is less likely because the molecular target of these agents 
is the host receptor rather than a virally encoded target. Furthermore, because TLR7 
activation initiates a broad immune response, including both innate and adaptive 
responses, it is likely that multiple aspects of viral replication are simultaneously attacked. 
 
In summary, the TLR7 agonist, SM-360320 has been shown to possess effective antiviral 
and immunostimulatory effects on whole blood from CHC donors and might provide 
complementary and additional HCV therapies making it a promising novel treatment. It is 
likely that HCV therapy will continue to require the presence of an effective 
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Figure / table Legends: 
 
Table 1: Clinical characteristics of CHC-Naïve, and CHC-NR and information on 
NHDs.  
 
Table 2: Cytokines were induced in all 3 subject groups. Mean responses and 
significance over untreated for 10 cytokines tested in NHD, Naive and NR groups. The 
ratio of geometric means and 95% confidence intervals are also presented.  
 
Figure 1: SM-360320 (10μM and 1μM) and IFNα (20IU/ml) enhanced expression of 
2’5’OAS in all groups. Expression was significantly less in the CHC-patients compared 
to NHD (p<0.01).  
 
    246  Figure 2:  Cytokines secreted by PBMCs treated with TLR7 agonist SM-360320 and 
IFNα. * indicate significant increase of cytokine production over untreated.  
 
Figure 3: Plasma from SM-360320 (10µM and 1µM) treated PBMCs significantly 
inhibited replication of HCV replicons in Huh-7 cells (p=<0.05).The antiviral potential 
of plasma from IFNα treated blood was less effective. 
 
Figure 4:  SM360320 enhanced NK-cell activation in all 3 groups in a dose 
dependant manner with greater effects seen in NHD than CHC-patients. 
 
Figure 5: Effect of pDC depletion from PBMCs.  
A) Reduced  IFNα was observed in pDC depleted PBMCs in NHDs following SM-360320 
treatment but no significant change in 2’5’OAS expression.  B) In CHC-patients, 
untreated levels of IFNα in whole PBMCs were highly variable making interpretation 
on pDC-depletion difficult. However, reduced expression of 2’5’OAS was seen on 
depletion of pDCs. * indicate statistically significant enhancement or inhibition of IFNα 
















    247  Table 1. 
      CHC  NHDs 
      Naive (n=60)  NR (n=20)  n=80 
Age Median  46 45  42 
   Range  27-87 36-70  22-61 
Gender Male  46(77%) 16(80%)  54(68%) 
   Female  14(23%) 4(20%)  26(32%) 
Race Caucasian  57 17  Unknown
   Asian  1 3     
Genotype
a G1  28(47%) 14(70%)  N/A 
   G2/3  28(47%) 5(25%)     
   G4  1(1%) 1(5%)     
   Unknown  3(5%) 0(0%)     
Viral load
b Median  7.91E+05 5.52E+06  N/A 
   Range  (7.02E+02-2.32E+07) (7.25E+05-2.06E+07)     
Disease Severity
c Mild  19(32%) 5(25%)  N/A 
   Moderate  14(23%) 1(5%)     
   Severe  14(23%) 7(35%)     
   No Biopsy  13(22%) 7(35%)     
ALT (IU/L) (10-40)  Median  62 58.5  N/A 
   Range  10-169 22-252     
Risk for HCV  IVDU  33 7  N/A 
   Blood Product  14 9     
   Other  11 4     
Alcohol intake
d Low  33(55%) 16(80%)  N/A 
   Moderate  11(18%) 3(15%)     
   Heavy  16(27%) 1(5%)     
 
  
a HCV genotype determined using CPA accredited PCR-based ‘Genotyping for Treatment Assay’ (iQur Ltd, 
UK). 
b Viral load determined by quantitative PCR (Cobas Amplicor HCV Monitor test, Roche Molecular Systems, 
USA) quoted as copies/ml. 
c Based on histological analysis of biopsies for inflammation and fibrosis. In the absence of histological 
evidence, disease status was determined by clinical criteria including physical examination, diagnostic 
imaging and laboratory indices. 
d Low, <7 units/week; Moderate, 7-14 units/week; Heavy, >14 units/week 
 















IP-10  NHD Untreated  10.4  -  -  - 
     SM   1803.0  <0.001  174.2  (148.3-204.6) 
      IFNα  529.7 <0.001 51.2  (43.6,  60.1) 
   Naïve  Untreated  83.6  -  -  - 
      SM   4036.5  <0.001  48.3  (37.4, 62.4) 
      IFNα  1749.8 <0.001  20.9  (16.2,  27.0) 
   NR  Untreated  66.5  -  -  - 
      SM   3372.9  <0.001  50.7  (33.2, 77.4) 
      IFNα  1566.8 <0.001  23.6  (15.4,  36.0) 
IFNα (2a)  NHD Untreated  1.7  -  -  - 
     SM   94.4  <0.001  54.5  (43.6, 68.0) 
      IFNα  81.1 <0.001 46.8  (37.5,  58.4) 
   Naïve  Untreated  12.0  -  -  - 
      SM   338.8  <0.001  28.2  (19.8, 40.3) 
      IFNα  241.0 <0.001 20.1  (14.1,  28.7) 
   NR  Untreated  6.0  -  -  - 
      SM  269.2  <0.001  45.2  (25.0, 81.5) 
       IFNα  205.1 <0.001 34.4  (19.1,  62.1) 
TNFα  NHD Untreated  1.9  -  -  - 
     SM  185.8  <0.001  99.8  (86.9, 114.6) 
      IFNα  1.5 <0.01 0.8  (0.7,  0.9) 
   Naïve  Untreated  13.4  -  -  - 
      SM  179.5  <0.001  13.4  (10.5, 17.2) 
      IFNα  12.1 NS 0.9  (0.7,  1.2) 
   NR  Untreated  10.4  -  -  - 
      SM  141.3  <0.001  13.5  (9.0, 20.4) 
      IFNα  8.8 NS 0.8 (0.6,  1.3) 
IL-12p70  NHD Untreated  2.8  -  -  - 
     SM  7.2  <0.001  2.6  (2.2, 3.0) 
      IFNα  2.3 <0.05 0.8  (0.7,  0.9) 
   Naïve  Untreated  27.2  -  -  - 
      SM  357.3  <0.001  13.2  (10.1, 17.2) 
      IFNα  161.4 <0.001  5.9  (4.5,  7.8) 
    249     NR  Untreated  15.7  -  -  - 
      SM  311.9  <0.001  19.8  (12.7, 30.8) 
      IFNα  125.3 <0.001  8.0  (5.1,  12.4) 
IL-1β  NHD Untreated  0.5  -  -  - 
     SM  43.8  <0.001  96.7  (81.6, 114.6) 
      IFNα  0.3 <0.001 0.7  (0.6,  0.8) 
   Naïve  Untreated  5.6  -  -  - 
      SM  86.9  <0.001  15.5  (11.2, 21.3) 
      IFNα  6.2 NS 1.1 (0.8,  1.5) 
   NR  Untreated  4.8  -  -  - 
      SM  45.7  <0.001  9.5  (5.5, 16.5) 
      IFNα  4.0 NS 0.8 (0.5,  1.4) 
IL-4  NHD Untreated  1.2  -  -  - 
     SM  2.4  <0.001  2.1  (1.8, 2.4) 
      IFNα  0.6 <0.001 0.5  (0.5,  0.6) 
   Naïve  Untreated  8.2  -  -  - 
      SM  31.8  <0.001  3.9  (2.9, 5.2) 
      IFNα  8.3 NS 1.0 (0.8,  1.3) 
   NR  Untreated  4.7  -  -  - 
      SM  23.7  <0.001  5.0  (3.1, 8.2) 
      IFNα  5.8 NS 1.2 (0.8,  2.0) 
IL-6  NHD Untreated  4.5  -  -  - 
     SM  1419.1  <0.001  317.0  (257.5, 390.1) 
      IFNα  13.6 <0.001 3.0  (2.5,  3.8) 
   Naïve  Untreated  32.5  -  -  - 
      SM  1306.2  <0.001  40.2  (28.5, 56.7) 
      IFNα  61.2 <0.001 1.9  (1.3,  2.7) 
   NR  Untreated  17.3  -  -  - 
      SM  1137.6  <0.001  65.8  (37.3, 116.1) 
      IFNα  35.5 <0.001 2.1  (1.2,  3.6) 
IL-8  NHD Untreated  9.8  -  -  - 
     SM  40.7  <0.001  4.2  (3.6, 4.8) 
      IFNα  3.2 <0.001 0.3  (0.3,  0.4) 
   Naïve  Untreated  55.8  -  -  - 
      SM  87.5  <0.001  1.6  (1.2, 2.0) 
      IFNα  17.2 <0.001 0.3  (0.2,  0.4) 
   NR  Untreated  39.0  -  -  - 
    250        SM  43.9  NS  1.1  (0.7, 1.7) 
      IFNα  11.4 <0.001 0.3  (0.2,  0.4) 
IL-10  NHD Untreated  0.9  -  -  - 
     SM  1.6  <0.001  1.7  (1.5, 2.0) 
      IFNα  0.6 <0.001 0.6  (0.6,  0.7) 
   Naïve  Untreated  17.1  -  -  - 
      SM  46.3  <0.001  2.7  (2.2, 3.3) 
      IFNα  16.5 NS 1.0  (0.8,  1.2) 
   NR  Untreated  13.6  -  -  - 
      SM  33.7  <0.001  2.5  (1.8, 3.5) 
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